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ABSTRACT
The e f f e c t  of  some drugs on n u t r i t i o n a l  status has been 
studied in the guinea p ig ,  ra t  and man.
The chronic adm in is t ra t ion  o f  chlordiazepoxide (Librium)  
to the guinea pig increases the d ie ta r y  requirements of  
ascorbic a c id .  The possible underlying mechanisms and 
implicat ions of  th is  observation are discussed.
The chronic adm in is tra t ion  o f  prednisone to the guinea 
pig causes only an i n i t i a l  increase in the d ie ta r y  
requirements of  ascorbic a c id .  Evidence is presented 
pe r ta in ing  to the induction o f  de novo synthesis o f  the 
vitamin by the drug.
Pat ients  su f fe r ing  from rheumatoid a r t h r i t i s  and trea ted  
with antirheumatic  drugs have lower plasma tryptophan  
and excrete  increased q u a n t i t i e s  o f  kynurenine,  3"hydroxy-  
a n t h r a n i l i c  acid and xanthurenic acid in the u r in e .  The 
s ig n i f ic a n c e  of  these f ind ings  is discussed in r e la t i o n  to 
the n u t r i t i o n a l  requirements of  these p a t ie n ts .
The prolonged adm in is tra t ion  of  anticonvulsants  and pheno- 
th iaz ines  in man may lead to f o l a t e  d e f ic ie n cy .  Evidence 
is presented to the e f f e c t  tha t  f o l a t e  de f ic iency  may be 
the re s u l t  of  the increased a c t i v i t y  of  the hepatic  
microsomal drug-metabolising enzymes brought about by the 
potent inducing propert ies  of  these drugs.
When ant iconvulsants ,  s in g ly  or in combination,  or the 
t r i c y c l i c  drug, imipramine, are administered fo r  12 weeks 
to rats fed on d ie ts  containing d i f f e r e n t  concentrat ions  
of  f o l i c  a c id ,  they exacerbate,  induce, or have no e f f e c t  
on f o l i c  acid status depending on the d ie ta ry  intake  of  
the v i tam in .  Furthermore,  a de f ic iency  of  f o l i c  acid  
impairs or diminishes the extent o f  induction of  cytochrome 
enzymes by these drugs.
The combined adm in is t ra t ion  o f  phenobarbitone and d i l a n t i n  
fo r  12 weeks to female rats fed on d ie ts  o f  d i f f e r e n t  
f o l a t e  content increases the frequency of c e r ta in  
congenital abnormal i t ies  in the o f f s p r in g .  The 
impl icat ions  are  discussed.
"Science is the knowledge of consequences 
and dependence of one fa c t  upon another .
Thomas Hobbes
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INTRODUCTION
P r in c ip les  of  Drug Metabolism 
N u t r i t io n a l  Status and Drug Metabolism 
Drug Metabolism and N u t r i t io n a l  Status
1
Introduct ion
Section A -  P r in c ip les  o f  Drug Metabolism
Apart from i ts  n u t r ie n t  content ,  food contains substances which 
have no primary functions  in the overa l l  metabolism of the animal body. 
These substances are c o l l e c t i v e l y  known as a n u t r ie n ts ,  xenobiotics  or  
fo re ign  compounds. They include various food a dd i t ives  and n a t u r a l l y -  
occurring substances wi th  no known n u t r i t i o n a l  value.  Furthermore,  
other a n u t r ie n ts ,  such as medicines and p e s t ic id e s ,  may be ingested 
under c er ta in  condi t ions.  The accumulation o f  these chemicals in the 
body may induce metabolic derangements and produce poisoning or even 
death.
Although the animal is unable to defend i t s e l f  by s e le c t i v e  
ingest ion,  i t  can e l im in a te  these 'undes irab le '  substances by the process 
of ' d e t o x i c a t i o n ' .  In th is  process a non-polar l i p id  soluble  compound 
is transformed into  a more po lar  w ater -so lub le  d e r iv a t i v e  which resu l ts  
in the reduct ion,  or possibly  augmentation,  of  the pharmacologic act ion  
of  the compound and i t s  subsequent rapid excre t ion .
Sequence of  drug metabolism
Detoxication takes place in two phases (Wil l?ams, ■ 1 9 6 7 )s Phase I ,  
metabolic transformat ion (b iotransformation) and Phase I I ,  conjugat ion .  
Both processes give r is e  to the in troduction of  new funct iona l  groups 
in to  the molecule,  thus transforming a non-polar l i p i d - s o l u b l e  compound 
to a more polar  less l i p id - s o l u b l e  molecule,  which is then re a d i l y  
excreted.  I f  a compound already possesses a functional  group i t  may 
undergo only conjugat ion,  e .g .  benzoic acid is mainly conjugated with  
glyc ine  and glucuronic acid to form h ippur ic  acid and benzoylg1ucuronide  
resp e c t ive ly ,  the conjugates being excreted in the ur ine and b i l e .
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Phase I reactions may be ox id a t io n s ,  reductions or hydrolyses,  
and may be c la s s i f i e d  into  transformat ions catalysed by (a) 'microsomal
drug metabolising enzymes', (b) non-microsomal mammalian enzymes,present  
in the mitochondria,  lysosomes or cytoplasm of t issues or by enzymes of  
the blood plasma and (c) enzymes o f  the gut m ic ro f lo ra .
Phase I I  reactions are syntheses in which endogenous compounds, 
such as glucuronic  a c i d , g ly c in e ,  sulphate,  are added to the functional  
groups formed as a re s u l t  o f  Phase I reactions (Fig.V.Vl ) .  In many 
conjugations the t r a n s fe r  o f  endogenous substrates is mediated through 
coenzymes p a r t i c ip a t in g  in the intermediary metabolism of n u t r i e n t s ,  
but d i f f e r e n t  enzymes may be involved in cata lys ing  the t r a n s fe r  of  drugs.
(a) Phase I reactions  
Local isat ion  of  enzymes
The Phase I reactions take place p r i n c i p a l l y  in the l i v e r ,  although  
some also occur in the lung, sk in ,  g a s t r o in te s t in a l  t r a c t  and the kidney.  
Within the t issue  c e l l ,  the drug-metabolising enzymes, which ca ta lyse  
these react ions ,  have been shown to be mainly loca l ised  in the smooth 
endoplasmic ret iculum (Fouts,  1961; Remmer and Merker, 1965).
F i g . 1.1 Metabolism of drugs and fore ign compounds
Drug
Phase I ox idat ion
------------> reduction
asynthetic  and/or
Phase I I  conjugation
 ------^ products
synthet ic
react ions hydrolysi s products reactions
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Mechanism of microsomal oxygenation
Drug ox idat ion  occurs when ' a c t i v e  oxygen1 is t ra n s fe r re d  to 
the drug ( G i l l e t t e ,  1963)- Act ive  oxygen is formed through reaction  
of  molecular oxygen wi th  a component o f  microsomes reduced by NADPH, 
thus:
NADPH + A + H+  *  AH2 + NADP+
AH  ^ + 02  *  'Active  oxygen'
'A c t ive  oxygen' + Drug -----------------}  Oxidised drug + A + H20
NADPH + 02 + Drug  *  Oxidised drug + NADP+ + H20
where A is a microsomal component l a t e r  i d e n t i f i e d  w i th  cytochrome 
P-A50 in i ts  reduced form. NADPH-cytochrome c reductase is involved  
in the ox idat ion  of  NADPH, and NADPH-cytochrome-P-A50 reductase  
functions in the reduction of  oxidised cytochrome P-A5 0 . The enzyme 
system catalyses the consumption of  one molecule of  oxygen per 
molecule of  substrate  with  one oxygen atom appearing in the substra te  
and the other  undergoing two-equivalent reduct ion.  This system has 
been termed a 'mixed function oxidase'  (Mason, 1965) or  'mono­
oxygenase' (Hayashi, I 96A).  Subsequent to  the discovery of  the  
involvement o f  cytochrome P-A50 in drug metabolism, and of the 
a d d i t i v e  e f f e c t  o f  NADH and NADPH in increasing the ra te  o f  drug 
metabolism, Estabrook and Cohen, in 1969, proposed the fo l low ing  
overa l l  pathway fo r  the metabolism o f  drugs and other fo re ign  
compounds.
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Where S is the substrate ,  fp^ and fp-j. are the f lavop ro te ins  
cytochrome reductase and NADPH-cytochrome c reductase. The side  
pathway of  l i p id  peroxidation is lab e l led  LP to LPO. Major pathways 
are given in so l id  l in e s .  The fa c to r  "x" is an unknown in te rm edia te .
NADPH
NADH
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Mechanism of microsomal reductions
Microsomes can also re duct ive ly  cleave azo dyes and reduce 
nitro-compounds producing in both cases primary amines (Fouts e t  a l , 
1957)* Azo dyes are reduced by two mechanisms which involve (a) a 
pathway s e n s i t iv e  to carbon monoxide and s o lu b i l i s a t io n  which requires  
cytochrome P-A50, and (b) a carbon monoxide- insensit ive  pathway 
involving NADPH-cytochrome c reductase which is not destroyed by 
s o l u b i l i s a t io n  ( G i l l e t t e ,  1966). A t h i r d  pathway s en s i t iv e  to 
s o l u b i l i s a t io n  but in s en s i t iv e  to carbon monoxide has been reported in 
microsomes from animals t rea ted  with  3"methylcholanthrene (Hernandez 
et a l , 1967)•
Both NADH and NADPH can act as e lec tron  donors in the reduction  
of  nitro-compounds. Reduction is mediated through the formation of  
n i t roso  and hydroxylamino d e r iv a t iv e s  to give r i s e  to primary amines.  
N i t ro  reduction occurs only under anaerobic condi t ions,  and is mediated 
through cytochrome P-A50 ( G i l l e t t e  e t  a l , 1968).  The s e n s i t i v i t y  to  
oxygen may be in part  due to au to -ox ida t ion  of  the hydroxyl ami no 
d e r iv a t i v e s .  These workers have proposed an e lec tron  t ransport  system 
which would expla in  both ox id a t iv e  and reduct ive  functions of  the  
microsomal drug-metabol ising system.
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Some components of  the microsomal drug metabolis ing system
Occurrence and general p ropert ies  of  cytochrome P-450: Cytochrome
P-450 was f i r s t  reported by K1ingenberg, 1958 and G a r f in k e l ,  1958 
and was studied by Omura and Sato (1962,  196*0.  I t  is a haemoprotein 
found in a v a r i e t y  of  v e r teb ra te s ,  including probably a l l  mammals.
I t  is mainly found in the hepatic  endoplasmic re t icu lum,  but has 
also  been reported in a number of  other  t issues such as adrenals ,  
kidney and i n t e s t in a l  mucosa.
Orrenius and Ernster ,  in 1964, reported that carbon monoxide
y
forms a complex wi th  reduced P-450 and consequently in h ib i t s  i ts  
enzymic a c t i v i t y .  Substances that  i n h i b i t  drug metabolism, such 
as deoxycholate and snake venom, have been shown to convert cytochrome 
P-450 to P-420 , an in ac t iv e  form of the cytochrome (Omura and Sato,  
196*j) .  Furthermore,  substances th a t  a l t e r  drug metabolism often  
cause p a r a l l e l  changes in cytochrome P—**50 concentrat ion (Orrenius  
and Ernster ,  1964).
Binding o f  drugs to cytochrome P-450: Drugs and fo re ign  compounds
in te ra c t  w ith  cytochrome P—*f50 to produce two kinds o f  spectra l  
changes (Imai and Sato, 1966 ; Remmer e t  a l , 1966).
Type I spectral  changes are character ised by a peak a t  385_390 nm 
and a trough 'at 418-427 nm and represent the in te ra c t io n  o f  a substra te  
with mixed function oxidase to form a complex (Schenkman, e t  a l , 1967 ) -  
Type I spectra l  change has been shown to be a c h a r a c t e r i s t i c  o f  the  
protohaem and to be caused by an increase in the e l e c t r o n e g a t i v i t y  o f  
one l igand of the haem (Schenkman and Sato,  1968) .
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Type I I  spectra l  changes are characterised by a peak a t  ^25-^35 nm 
and a trough a t  390 nm-^05 nm. Type I I  spectra l  change is s im i la r  to the 
reaction between a basic amine and a ferr ihaemoprote in  and was shown to be 
a ferrihaemochrome spectra l  change (Schenkman e t  a l , 1967).
A modified type I I  spectrum, also known as an inverse type I 
spectrum has been described with  a peak a t  ^20 nm and a trough near 390 nm. 
Modified type I I  spectra were shown to be reverse type I spectra l  changes 
in both absolute and d i f fe re n c e  spectra ,  and i t  was suggested th a t  they 
were due to displacement from the enzyme of some compound previously  bound 
(Schenkman e t  a l , 1969)- This type of  spectrum involves in te ra c t io n  
between compounds and a non-haem part  of  the mixed function oxidase.  I t  
is possible  tha t  modified type I I  compounds may act a t  the same or  
d i f f e r e n t  s i t e  from type I compounds (Schenkman e t  a l , 1972).
(b) Phase I I  reactions
Conjugation takes place mainly in the l i v e r ,  but i t  has a lso been 
shown to occur in the kidney, g a s t r o in te s t in a l  mucosa and skin (Stevenson 
and Dutton,  I960 ,  1962).  The metabolic d e r iv a t iv e s  of  drugs and fo re ign  
compounds formed by phase I reactions are conjugated wi th endogenous 
metaboli tes ,  such as glucuronic ac id ,  sulphate,  g lyc in e ,  g lu ta th io n e  or  
undergo methylat ion or a c e ty la t io n .  Glucuronide conjugation is by f a r  
the most important reaction in view of the general a v a i l a b i l i t y  of  glucose 
in the b io log ica l  system (Dutton,  1966). Uridine-diphosphate g lucuronic  
acid (UDPGA), formed from UDP-glucose, is the coenzyme concerned in th is  
reac t ion ,  and in the presence of various glucuronyl  t ransferases can form 
glucuronides of  a lcohols ,  phenols,  carboxy l ic  acids ,  amines or t h i o l s .
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Factors a f f e c t in g  drug metabolism
Drug metabolism is a f fe c ted  by a number o f  fa c tors  which can be 
c l a s s i f i e d  as genet ic ,  ph y s io lo g ic a l ,  pharmacodynamic and environmental .  
These have been reviewed (Parke,  1968) and only the fac to rs  of  d i r e c t  
relevance to th is  thesis  w i l l  be b r i e f l y  discussed.
1. Environmental factors
A number o f  drugs and tox ic  chemicals can s t im ula te  or i n h i b i t  
the a c t i v i t i e s  of  drug metabolising enzymes.
Hepatic enzyme induct ion : More than two hundred drugs,
in sec t ic id e s ,  carcinogens and other  chemicals have been shown
to s t imulate  the a c t i v i t y  o f  drug-metabolising enzymes in
l i v e r  microsomes. The pharmacological act ion or s t ru c tu re
of the compounds bears no apparent r e la t io n s h ip  to t h e i r
a b i l i t y  to induce the enzymes. Inducers f a l l  in to  two c ategor ies :
(a) drugs and in s e c t ic id e s ,  which induce the metabolism o f  
a v a r i e t y  of  drugs, phenobarbitone being the  
representa t ive  of  th is  group, and
(b) large po lycy c l ic  hydrocarbons which have inductive  e f f e c t s  
on a smaller number of  microsomal enzymes, 3-methyl -  
cholanthrene and 3,^-benzpyrene being the major represent ­
a t ive s  o f  th is  second category.
The concomitant adm in is tra t ion  o f  phenobarbital  and 3 ,^-benzpyrene  
to rats in doses s u f f i c i e n t  fo r  t h e i r  maximal c h a r a c t e r i s t i c  
induction resulted in an a d d i t i v e  e f f e c t  of  the l i v e r  microsomes 
to metabolise drugs ( G i l l e t t e ,  1963a).  No such e f f e c t  could be
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demonstrated, however, when 3 ,^-benzpyrene and 3-methylcholanthrene  
were administered e i t h e r  alone or in combination.  This suggests 
tha t  the two categories  o f  inducer compounds p r e c i p i t a t e  t h e i r  
e f f e c t  in d i f f e r e n t  ways. These chemicals a lso d i f f e r  in the  
course and in te n s i t y  o f  induction.
Mechanisms of enzyme induct ion : The term 'enzyme in d u c t io n 1 is
s p e c i f i c a l l y  used to describe the process which increases the ra te  
of synthesis of  an enzyme r e l a t i v e  to i t s  normal ra te  o f  synthesis  
in the ind iv idual  organism. Enzyme induction by both 3- methyl-  
cholanthrene and phenobarbital  is independent of  the hormones of  
the t e s t i s  or ovar ies ,  of  adrenals ,  o f  p i t u i t a r y  and thyro id  
glands ( G i l l e t t e ,  1963a; Shimazu, 1965; Conney, 1967).
The induction of  drug-metabolising enzyme a c t i v i t y  by 3“methyl-  
cholanthrene or phenobarbital  is blocked by the i n h ib i t io n  of  
prote in  synthesis,  by e th ion ine  (Conney e t  a l ,  1956),  puromycin 
(Conney and Gilman, 1963) or act inomycin D (Orrenius e t  al , 1965).  
The a b i l i t y  of  act inomycin D to block the induction o f  drug-  
metabolising enzymes by 3_methylcholanthrene or phenobarbital  
suggests tha t  these enzyme inducers may acc e le ra te  the DNA- 
directed synthesis o f  RNA, which functions as a template fo r  the 
synthesis of  the drug-metabol ising enzymes.
The phenobarbital-mediated increase in to t a l  l i v e r  microsomal 
prote in  has been suggested to be due to e i t h e r  an increase in 
the ra te  of  i t s  synthesis and/or a decrease in the ra te  of  i t s  
breakdown. The molecular basis fo r  l i v e r  microsomal enzyme 
induction is s t i l l  not c le a r .  Phenobarbitone and 3 -m ethyl-
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cholanthrene induction o f  microsomal prote in  synthesis in vivo  
is p a r a l le le d  by increased incorporat ion o f  amino acids into  
microsomal prote?n in v l t r o  (Gelboin and Soko lo f f ,  1961). The 
in vivo incorporation o f  l l fC -leuc ine into  microsomes of  
phenobarb i ta l - t rea ted  rats is increased, al though other sub- 
c e l l u l a r  f ra c t io n s  are not a f fe c te d  (Kato e t a l , 1965).
The p r o l i f e r a t i o n  o f  the smooth membranes of the endoplasmic 
ret iculum is l i t t l e  or not a f fe c ted  in animals t rea ted  with  
3,^-benzpyrene or 3_methylcholanthrene (Fouts and Rogers, 1965).
In con tra st ,  treatment of  animals with  phenobarbital causes a 
marked p r o l i f e r a t i o n  o f  smooth endoplasmic reticulurn w i th  l i t t l e  
or no e f f e c t  on rough endoplasmic ret iculum (Fouts and Rogers,  
1965; Remmer and Merker, 1965).  The adm in is tra t ion  of  pheno- 
b a rb i ta l  to rats leads to an increased ra te  of  incorporat ion of  
inorganic phosphate into phospholipid of  both smooth and rough 
f ra c t io n s  of  the microsomes. This suggests tha t  enhanced 
phospholipid synthesis may be an e a r ly  step in the phenobarb i ta l -  
induced p r o l i f e r a t i o n  of  smooth endoplasmic re t iculum (Orrenius  
and Ericsson, 1966). These f in d in g s ,  however, have not been 
confirmed by other workers (Holtzman and G i l l e t t e ,  1966) who 
showed th a t  the increase in hepatic  microsomal phospholipid in 
response to phenobarbital  is due to the i n h ib i t io n  of  phospholipid  
catabo l i  sm.
2.  Pharmacodynamic factors
Prote in b ind ing: Most drugs and fore ign  compounds, whether
in jec ted  or ingested,  are u l t im a t e ly  d is t r ib u te d  to the body 
through the blood, bound, to a g reater  or lesser  e x te n t ,  to
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plasma pro te ins .  Drugs may bind to a v a r i e t y  o f  plasma p ro te in s ,  
p a r t i c u l a r l y  albumin,  which is genera l ly  assumed to  have a v a r i e t y  
o f  binding s i t e s .  Drugs and t h e i r  metaboli tes ,  n u t r ien ts  and 
endogenous substances compete d i r e c t l y  fo r  s p e c i f ic  binding s i t e s  
or i n d i r e c t l y  by imposing an a l t e re d  conformation that  impedes 
attachment of  substances elsewhere in the molecule.  Amounts of  
binding pro te in  are an important determinant o f  drug storage,  
a c c e s s i b i l i t y  to s i tes  o f  e l im in a t io n  and a c t io n ,  and may a lso  
c o r r e la te  with  shor t -  and long-term s id e - e f f e c t s .  Lewis and his 
co-workers in 1971, observed that  the incidence of prednisone 
s id e -e f f e c ts  doubled in pa t ien ts  wi th serum albumin leve ls  lower 
than 2 .5  gm. This was a t t r i b u t e d  to the fa c t  tha t  prednisone and 
i t s  metaboli te  prednisolone are bound to c o r t is o l - b in d in g  g lo b u l in ,  
but the capaci ty  of  th is  c a r r i e r  is exceeded a f t e r  repeated 
adm in is tra t ion  and the excess drug is car r ie d  p a r t l y  by serum 
albumi n.
A number o f  drugs and fore ign compounds have higher a f f i n i t y  than 
endogenous metaboli tes and n u tr ien ts  fo r  binding to serum albumin.  
Tryptophan, an essentia l  amino acid and precursor o f  n i c o t i n i c  a c id ,  is 
the only amino acid found to be s i g n i f i c a n t l y  bound to plasma 
albumin. In f a c t ,  less than 20% of  to t a l  plasma tryptophan  
appears to be in a f r e e ly  d i f f u s i b l e  form in normal subjects  
(McArthur and Dawkins, 1969). Antirheumatic drugs notably  
s a l i c y l a t e s ,  phenylbutazone, prednisone and indomethacin, d isp lace  
tryptophan from i t s  binding s i t e s ,  thus leading to  a l t e re d  t r y p t o ­
phan metabolism. This in te ra c t io n  w i l l  be discussed in d e t a i l  
in chapter 3.
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3. Physiological  fac tors
Age, sex, disease,  pregnancy, hormones and n u t r i t i o n a l  status  
have been shown to a f f e c t  drug metabolism. Of these fa c tors  
only the e f f e c t  of  n u t r i t i o n a l  status w i l l  be discussed here in 
the fo l low ing  section of  the In troduction .
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Section B -  The E f fe c t  o f  N u t r i t io n a l  Status on Drug Metabolism
In view o f  the widespread occurrence of  primary m a ln u t r i t io n  in 
the developing countr ies ,  and secondary m a ln u t r i t io n  a r is in g  from 
c er ta in  disease s ta te s ,  even in a f f l u e n t  s o c ie t ie s ,  the i n t e r r e l a t i o n s h ip  
of  n u t r i t i o n a l  status and the a b i l i t y  of  an ind iv idual  to metabolise drugs 
may have important repercussions in both the w e l fa re  and the response of  
the indiv idua l  to drugs. N u t r i t io n  can a f f e c t  the metabolism of drugs 
in at  least two ways. F i r s t l y ,  i f  the d ie ta r y  intake of  c a lo r ie s  is 
low, prote in  w i l l  be catabol ised and used as a source of  energy, thus 
reducing the a v a i l a b i l i t y  of  amino acids fo r  p ro te in  synthesis .  This  
may reduce the amounts of  d i f f e r e n t  enzymes including those involved in 
the metabolism of drugs in the t issues.  On th is  basis one could argue 
that  drug dose leve ls  fo r  malnourished pa t ien ts  should be lower than f o r  
those who are w e l1-nourished. Secondly, the substrates used fo r  the  
conjugation o f  drugs are derived from n u t r ie n ts .  Sulphate,  fo r  example,  
is derived from metabolism of sulphur -conta ining amino acids of  the d ie t  
and glucose is required fo r  synthesis of  UDPGA necessary fo r  glucuronide  
formation (Dutton,  1966). In malnourished ind iv idua ls  there  would,  
th e re fo re ,  be competit ion fo r  essent ia l  n u t r ie n ts .  Hence, i f  one 
supposes that conjugation mechanisms have a p r i o r i t y ,  sulphate would be 
made a v a i l a b le  by the catabolism of t issue  prote ins and glucose by 
gluconeogenesis (Roe, 1967).
Much o f  the evidence f o r  the e f fe c ts  o f  n u t r i t i o n  on the metabolism 
of  drugs has been derived from animal experiments.  I f  these data are to  
give us information which might be e x t rap o la te d ,  w ith  caut ion ,  to man i t  
seems p e r t in en t  to  e s tab l ish  that the same kind of  mechanisms e x is t  in man
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fo r  metabolising drugs as in,  say, the r a t .  Data obtained with  human 
l i v e r  (Nelson, P r i t h v i  Raj ,  B e l f i  and Masters,  1971) in d ica te  tha t  the 
mean values fo r  c e r t a in  drug-metabolising enzymes are lower than those 
found in the ra t  and pig l i v e r .  Although the authors showed wide 
indiv idual  v a r i a t i o n ,  th is  may be due to the lapse of  t ime between 
death and autopsy.
(a) Acute s ta rva t io n  and drug metabolism
The a c t i v i t y  o f  the drug-metabol ising enzymes involved in the 
oxidat ion  o f  h e x o b a rb i ta l , N -d ea lky la t  ion o f  pyramidon, hydroxy-  
l a t io n  of  a c e t a n i l id e  is depressed both in vivo and in v i t r o  in
male mice starved fo r  36 hours (Dixon, Shu l t ice  and Fouts, 1960).
Electron microscopy of l i v e r  sections revealed s t ru c tu ra l  changes 
in the endoplasmic ret iculum of the starved animals,  such as 
reduction in the amount of  ergastoplasm with changes in microsome 
sub-uni ts ,  which may account fo r  the depression o f  drug-metabol ising  
enzyme a c t i v i t y  (Fawcett ,  1955; Jones and Fawcett,  1965).
Sex dependency of  the e f fe c ts  of  s ta rv a t io n  on drug metabolism in
the ra t  were reported by Kato and G i l l e t t e ,  in 1965. They
reported that  the ra te  of  hydroxylat ion  o f  pentobarbita l  and hexo- 
b a r b i t a l ,  in w e l l - f e d  ra ts ,  was three  times greater  in males than in 
females,  whereas 72 hour s ta rva t io n  increased the enzyme a c t i v i t i e s  
by more than 50 per cent in females but decreased them by 50 per 
cent in males. The authors a t t r ib u t e d  the sex dependent e f f e c t  of  
sta rva t ion  to the inf luence o f  androgenic hormones on the enzyme 
a c t i v i t i e s .  To that  e f f e c t ,  they showed that  castra ted  ra ts  
metabolised hexobarbital  slowly both when w e l l - f e d  and when s tarved.
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Administrat ion  of  methyl testosterone  increased the ra te  of  
metabolism of  hexobarbital  and e l i c i t e d  the d i f fe ren ces  in drug 
metabolism seen between w e l l - f e d  and starved animals.
The re - feed ing of  female rats fo r  2k  and kS hours fo l low ing  a 
s ta rva t io n  period of  72 hours e l i c i t e d  a decrease in the 
a c t i v i t y  of  the enzymes th a t  metabolise aminopyrine and hexo­
b a rb i ta l  to approximately 35 and 52 per cent of  control  values  
respect ive ly  (Kato,  1967). This observation,  however, is a t  
variance with that o f  Dixon e t  a 1, in 1960, who showed th a t  in 
male mice fasted fo r  36 hours the a c t i v i t y  of  the microsomal 
drug-metabolising enzymes returns to normal w i th in  2k  hours 
a f t e r  food. The underlying mechanism for  these observations  
is not c le a r .
Enzymes involved in phase 2 o f  drug metabolism have a lso  been 
shown to be influenced by s ta rv a t io n .  Rats fasted fo r  72 hours 
have been shown to have s i g n i f i c a n t l y  lower a c t i v i t y  o f  UDPG- 
dehydrogenase, a s p e c i f ic  dehydrogenase involved in ox idat ion  
of UDPG to UDPGA (M ie t t inen  and Leskinen, 1963),  the glucuronide  
donor in the g lucuronidat ion o f  fore ign  compounds and endogenous 
metaboli tes .  The same authors have also shown tha t  the  
a c t i v i t y  o f  3-glucuronidase,  an enzyme important in the hydrolysis  
of glucuronides , is s ig n i f i c a n t l y  increased in the l i v e r s  of  
rats fasted fo r  72 hours. Thus, starved ra ts  produce smal ler  
amounts of  glucuronide conjugates not only because glucuronide  
formation is d e f i c i e n t  but also because the ra te  o f  hepatic  
glucuronide breakdown is increased.
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(b) Prote in nutr i  t ion  and drug metaboli  sm
Kato, Oshima and Tomizawe, in 1968, showed that  the ra te  of  
drug metabolism and the a c t i v i t y  o f  drug-metabolising enzymes 
in the l i v e r  is c lo se ly  re la ted  to the amount of  pro te in  in the 
d i e t .  Furthermore,  feeding adu l t  male rats a 3 per cent casein  
d i e t  fo r  14 days resul ted in a reduction in the concentrat ion of  
cytochrome P-450 per l i v e r  un i t  weight to about 33 per cent o f  
control  va lues.  Adminis trat ion o f  phenobarbital  to  these ra ts  
e l i c i t e d  a much smaller increase in hepatic cytochrome P-450 than 
th a t  observed in w e l l - f e d  control  ra ts  (Marshall  and McLean, 1962).  
Other workers have shown that p ro te in  d e f i c ie n t  d ie ts  increase the  
t o x i c i t y  of  endosulphan (Boyd and Dubos, 1969),  of  d iazinon (Boyd 
and Carsky, 1969) and of  d i e l d r i n  in rats (Krishnamurthy,  Subramanya, 
and J a y a r a j , 1965).  High m o r t a l i t y  w i th  marked h is to lo g ic  changes 
have also been reported in rats  on low d ie t a r y  casein fed d i e l d r i n  
(Lee, Harr is  and Trowbridge,  1964).
In contrast to the concept above that pro te in  de f ic iency  can 
increase the t o x i c i t y  of  some fore ign  compounds, i t  can also  
reduce the t o x i c i t y  of  o thers .  To th is  e f f e c t  Campbell and 
C o s t e r l i t z  in 1948, and McLean and McLean in 1966 have shown that  
young male ra ts  fed d ie ts  low in pro te in  but adequate in minera ls ,  
vitamins and l ip o t r o p ic  fac to rs  are re s is ta n t  to the to x ic  e f f e c t s  
of  CCl^ whether measured by m o r t a l i t y  or by indices of  l i v e r  damage. 
This has been p a r t l y  explained by some workers,  who assume th a t  
CCl^ may be metabolised,  probably to a f re e  r a d ic a l ,  which may 
i n i t i a t e  autoxidat ion in microsomal and mitochondrial  membrane 
l i p i d s ,  re su l t in g  in c e l l u l a r  necrosis and f a t t y  i n f i 11ra t  ion of  
the l i v e r  (Recknagel, Ghoshal, 1966 ; S l a t e r ,  1966).  Rats fed
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p r o t e i n - d e f i c ie n t  d ie ts  are less able to e f f e c t  th is  conversion  
due to the decreased a c t i v i t y  of  hepatic  drug-metabolising enzymes. 
The protection  th a t  a low-prote in  d ie t  a f fords  against CCl^ 
t o x i c i t y  is reversed by adm in is tra t ion  o f  drugs such as pheno- 
barbitone or DDT, tha t  induce the a c t i v i t y  of  the drug-metabol ising  
enzymes (McLean et  a 1, 1966). This has led to the suggestion 
tha t  a close c o r re la t io n  ex is ts  between CCl^ t o x i c i t y  and the 
a c t i v i t y  of  the drug-metabolising enzymes in the l i v e r .  I t  is ,  
however, u n l ik e ly  tha t  the low a c t i v i t y  o f  the drug-metabol ising  
enzymes is the sole fa c to r  in protecting  rats  on pro te in  d e f i c i e n t  
d ie ts  from the CCl^ t o x i c i t y  since s ta rv a t io n ,  which also reduces 
the a c t i v i t y  of  drug-metabolising enzymes (Kato and G i l l e t t e ,  1965),  
augments the t o x i c i t y  of  th is  compound.
Many an t i -o x id a n ts  are  known to protect against  hepatic  necrosis  
(McLean, McLean and Judah, 1965) and some, such as ethoxyquin and 
buty la ted hydroxytoluene, not only prevent CCl^ t o x i c i t y  in ra ts  
but a lso reverse the p o te n t ia t in g  e f f e c t  of  DDT (Cawthorne e t  a l , 
1970).  Furthermore, an t i -o x id a n ts  are known to induce the  
a c t i v i t y  of  drug-metabolising enzymes in the l i v e r  (Cawthorne e t  a l ,
1970; G i lb e r t  and Golberg, 1965).  I t  is ,  th e r e fo r e ,  possible  th a t  
a n t i -o x id a n ts  e l im in a te  the formation o f  an a c t iv e  in termediate  
or i f  such an intermediate  is formed i t s  l i fe -s p a n  is considerably  
shortened by fu r t h e r  metabolism in the presence of  a n t i -o x id a n t s  
(Cawthorne, Palmer and Green, 1973).
I t  has recently  been shown (Saurez,  Carlson and F u l l e r ,  1971; S t r ip p ,  
Hamrick and G i l l e t t e ,  1972) tha t  pretreatment of  ra ts  with  3 -m e thy l -  
cholanthrene p a r t i a l l y  n u l l i f i e s  the h ep a to to x ic i ty  o f  CCl^ and 
bromobenzene. I t  has been f u r t h e r  suggested that  a d m in is t ra t io n  of
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3-methylcholanthrene leads to an increase in the o v e ra l l  ra te  of  
[l l fC] bromobenzene metabolism in rats but reduces the metabolic  
pathway leading to the formation o f  a tox ic  m etabo l i te .  The 
p o s s i b i l i t y  th a t  an t iox idants  and 3- methylcholanthrene act  through 
a s im i la r  mechanism in reducing CCl^ t o x i c i t y  cannot be excluded.
Low pro te in  d ie ts  appear to induce an adaptive  response o f  drug-  
metabolising enzymes in the l i v e r .  Thus, in the r a t ,  the capac i ty  
of  l i v e r  s l ic e s  to conjugate and excrete  b i l i r u b i n  has been shown 
to be unchanged a f t e r  k  days feeding of  a p r o t e i n - f r e e  d i e t  (Adlard,  
Lester ,  Lathe,  1969)• Increased rates of  conjugation of  p - n i t r o -  
phenol and o-aminophenol per gm l i v e r ,  o f  about 70 per cent ,  have 
also been reported in the l i v e r s  o f  immature male rats fed a p r o te in -  
f re e  d ie t  fo r  7 days (Woodcock and Wood, 1971).  S i m i l a r l y ,
Dickerson, Basu and Parke,  in 1971, demonstrated a r i s e  in the con­
centra t ions  of  biphenyl -A-hydroxylase,  A-methyl umbel 1i fe rone  glucuronyl  
t rans fe rase  and p-n i trobenzoate  reductase in male weanling ra ts  fed 
a d ie t  containing 7 per cent p ro te in  f o r  1h and 28 days.
The mechanism underlying th is  adaptive  response o f  the l i v e r  to  
d e f i c i e n t  intake of  prote in  in rats is not c le a r .  I t  has, however, 
been proposed tha t  i t  is mediated through c o r t ico s te ro n e ,  fo r  there  
is a c o r re la t io n  between the increase of  biphenyl -4 -hydroxylase  and 
the leve ls  o f  plasma cor t icosterone  in the ra t  (Basu, Dickerson and 
Parke, 1971). This is fu r t h e r  supported by the work of  the same 
authors,  who have shown a r ise  in the leve ls  of  b iphenyl-A-hydroxylase  
in wel l  fed animals in response to cor t icos te rone  a d m in is t ra t io n .
The fa c t  tha t  s tero ids  can inf luence drug metabolism has a lso been 
demonstrated in another study (D r ie ver ,  Bousquet and Miya,  1966),  
in which the blood leve ls  of  hexobarbital  and p e n to b a rb i ta l ,
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a t  15 and b$  minutes resp ec t ive ly  fo l lowing t h e i r  ad m in is t ra t io n ,  
were s i g n i f i c a n t l y  lower in p h ys ica l ly  stressed than non-stressed  
control  ra ts .  The authors f u r t h e r  showed that  both ACTH and 
cort icosterone  could mediate the stress induction of  drug 
metabolism in hypophysectomised ra ts ,  whereas only cor t icos te rone  
could produce th is  e f f e c t  in adrenalectomised animals,  thus 
ind ica t ing  tha t  the mechanism of s t ress - induct ion  o f  drug 
metabolism required an in ta c t  p i t u i ta r y -a d re n a l  a x is .
I t  appears,  th e re fo re ,  tha t  apart  from enzymic depression in 
response to n u t r i t i o n a l  d e f ic ie n c y ,  there e x is ts  a compensatory 
mechanism by which drug metabolism in the l i v e r  o f  n u t r i t i o n a l l y -  
deprived or stress-induced animals can be regulated through s te ro id  
hormones.
(c) Mineral  de f ic iency  and drug metabolism
Weanling rats  maintained on a ca lc ium -free  d i e t  fo r  kO days were 
shown to have depressed a c t i v i t i e s  o f  drug-metabolising enzymes 
(D in g e l l ,  Joiner  and Hurwitz ,  1966). The authors have a lso  shown 
tha t  the rats  on the ca lc ium -free  d ie t  were metabolising hexo- 
ba rb i ta l  a t  a much slower ra te  and had 80 per cent longer hexo- 
b a rb i ta l  sleeping time than control  animals.  The hypothesis was 
put forward that  the observed depression o f  drug metabolism in 
calcium d e f i c i e n t  rats  may be due to the in a c t iv a t io n  o f  drug-  
metabolising enzymes e i t h e r  by s t ru c tu ra l  changes in the enzyme 
prote in  or by a s p e c i f i c  in h ib i t io n  of  prote in  synthes is .  Calcium,  
however, has been associated with membrane pore s t ru c tu re  and may 
be involved in transport  mechanisms. I t  i s ,  th e re fo re ,  possible  
tha t  the depressed drug metabolism is due to a lack per se o f  
d ie ta r y  calcium.
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Dietary  d e f ic ie n c ie s  of  zinc (Becking and Morrison, 1970) and 
magnesium (Becking and Morrison, 1970a) have been shown to depress 
the metabolism of a number of  drugs in the ra t  both in vivo and 
in v i t r o . The hepatic  microsomal cytochrome P-450 content is 
decreased in both z inc and magnesium de f ic ie n c ie s  in the r a t .
The decrease in cytochrome P-450 has been shown to occur at  
approximately the same time as the decrease in the ra te  of  drug 
metabolism in the d e f i c i e n t  animals.  A decreased a c t i v i t y  of  
the e lec tron  transport  system required fo r  the metabolism of drugs,  
due to decreased cytochrome P-450 l e v e ls ,  may thus lead to an 
a l t e r a t i o n  in the b iotransformat ion o f  drugs.
(d) V?tamin de f ic iency  and drug metabolism 
Ascorb^c_acj_d
In te res t  in the ro le  of  ascorbic acid in the metabolism of drugs 
has evolved from the observation that drugs such as phenobarbitone,  
which cause induction of  hepat ic  microsomal drug-metabolising  
enzymes, can s t imulate  the ur inary  excre t ion  of  the vitamin in the  
ra t  (Longenecker, Fr icke and King, 1940) and also th a t  ascorbate-  
d e f ic ie n t  guinea pigs were more responsive to zoxazolamine, ,a  
muscle re laxant drug, than were normal guinea pigs (Conney e t  al , 
1961). The increased s u s c e p t i b i l i t y  of  as c o rb a te -d e f ic ie n t  guinea 
pigs to zoxazolamine was explained by a decrease in i t s  ox idat ion  
in vi t r o  in microsomes prepared from v itamin C -d e f ic ie n t  guinea pig 
1i ver .
More recent studies with  hepatic microsomes prepared from v itamin C- 
d e f i c i e n t  animals show a s ig n i f ic a n t  decrease in the p -hydroxyla t ion
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of a c e t a n i l id e  (Degkwitz and Standinger,  1965) hydroxyla t ion of  
coumarin (Degkwitz,  L u f t ,  P f e i f f e r  and Standinger,  1968 ) and amino- 
pyr ine-N-demethylat ion (Leber,  Degkwitz and Standinger,  1969).  
Furthermore,  Leber e t  al (1969) have demonstrated th a t  microsomes 
from a sc o rb a te -d e f ic ie n t  guinea pigs show a s ig n i f i c a n t  decrease  
in content of  cytochrome P-450 but not o f  cytochrome bc . A decrease  
in microsomal cytochrome P-450 content has also been reported in 
another study (Avenia,  1972) in which i t  was f u r t h e r  shown that  
th is  was accompanied by an increase in cytochrome P-420,  the 
in a c t ive  form of  cytochrome P-450.
In 1969 Kato, Takanaka and Oshima maintained guinea pigs on an 
ascorbic a c id - f r e e  d ie t  fo r  12 days and studied the "in vi t ro  
metabolism of a number of  drugs. They reported,  contrary  to e a r l i e r  
studies,  tha t  although the hydroxylat ion of  a n i l i n e ,  hexobarbita l  
and zoxazolamine was decreased the metabolism of aminopyrine,  
meperidine, p - n i t r o a n i s o l , p-dimethyl  aminoazobenzene and p - n i t r o -  
benzoic acid was not a l t e r e d .  Moreover, there  was n e i th e r  any change 
in the content of  microsomal cytochrome P-450 and cytochrome b^ nor 
in the a c t i v i t y  of  NADPH cytochrome-c reductase.  They concluded 
tha t  vi tamin C def ic iency  s p e c i f i c a l l y  a f fec ted  hydroxy la t ion  
reactions and involved the terminal  oxidase component of  the e lec t ro n  
transport  system.
The importance of  the c h ro n ic i ty  of  ascorbic acid d e f ic ie n c y ,  a 
fa c to r  ignored in many studies,  was demonstrated by Zannoni, Flynn 
and Lynch, in 1972. They showed that  i t  was not u n t i l  the hepat ic  
microsomal ascorbic acid was approximately 30 per cent o f  normal,  
and animals had lost 5 per cent o f  t h e i r  body weight ,  th a t  there  
was any s ig n i f i c a n t  decrease in the a c t i v i t i e s  o f  a n i l i n e  hydroxylase,
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aminopyrine-N-demethylase,  or p-nitrc^-O-demethylase and the
concentrat ions of  microsomal e lec tron  transport  components.
Their, f ind ing  is f u r t h e r  v a l id a ted  by.  the fa c t  tha t  moderately
severe c a l o r i c  r e s t r i c t i o n  a f fe c ted  ne i th e r  drug metabolism a c t i v i t i e s ,
nor microsomal e lec tron  transport  components, in the way th a t  vi tamin
C d e f ic iency  d id .  Enzyme k in e t ic s  studies (Zannoni e t  a l . 1972)
/
showed that K values obtained with  microsomes from normal and m
ascorbic a c id - d e f i c i e n t  guinea pigs indicated no obvious c o r r e la t io n  
in apparent a f f i n i t y  o f  drug substrates wi th decreased drug enzyme 
a c t i v i t y .  There was, however, a consis tent  a ty p ica l  type I I  
substrate-cytochrome P-450 binding spectrum in vitamin C -d e f ic ie n t  
animals, which was concominant with  the reduction o f  microsomal 
cytochrome P-450 content .  The authors postulated th a t  the a ty p ic a l  
spectrum may be in d ic a t iv e  of  a change in the s t ruc ture  of  the 
microsomal phospholipid membrane associated with  cytochrome P-450 
and suggested tha t  v i tamin C may be required fo r  the maintenance of  
i t s  i n t e g r i t y .  The adm in is tra t ion  of  vi tamin C to d e f i c i e n t  animals 
e l i c i t e d  a return o f  drug-metabolising enzyme a c t i v i t y ,  o f  the  
q uant i ty  and q u a l i t y  of  e lec tron  transport  components, and o f  the 
a l te re d  type I I  cytochrome binding spectrum to normal l e v e ls .  The 
t ime required fo r  th is  reversal  has been a t t r ib u t e d  to  the time 
needed possibly fo r  the resynthesis of  hepatic microsomal p r o te in .
Vitamin E
Hydroxylat ion and demethylat ion of  drugs by the l i v e r  has been 
reported to be increased fo l lowing the oral  or in t ra p er i to n ea l  
admin is tra t ion  of  a-tocopherol  to the ra t  (Carpenter,  1967 ,1968 ,1972) .
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The increase in drug hydroxylat ion has been shown to be prevented 
by actinomycin D administered 15 minutes p r io r  to feeding the  
animals a - to c o p h e ro l . This observation indicates tha t  the e f f e c t  
of  the v itamin on the microsomal drug hydroxylat ion may be mediated 
via  a mechanism dependent on RNA and pro te in  synthes is .  The 
vitamin has, however, been reported to be involved in the regu la t ion  
of  haem synthesis .  Vitamin E de f ic iency  has been shown 
(Carpenter,  1972) to decrease the bone marrow a c t i v i t y  o f  6-amino-  
l e v u l i n i c  acid synthetase,  and of  hepatic 6 -am ino levu l in ic  acid  
dehydratase.  I t  has f u r t h e r  been shown to lower,  by about 50 per 
cent ,  the leve ls  of  cytochromes b^ and P-450, and i t  may well  be 
th a t  v i tamin E exerts  i t s  regu lat ion  of  drug metabolism through i t s  
e f f e c t  on cytochrome P-450.
R |b o f la v m
The importance o f  f l a v in s  in the reduct ive pathway was f i r s t  shown 
by Kensler,  in 1948, who found a d i r e c t  c o r re la t io n  between hepatic  
f l a v i n  leve ls  and the a b i l i t y  o f  ra t  l i v e r  s l ic e s  to reduce a 
carcinogenic azo dye, dimethylaminoazobenzene. Furthermore,  the  
add i t ion  o f  f l a v i n s ,  in v i t r o , has been shown to s t im ula te  the  
reduction of  n i t r o  compounds (Fouts and Brodie,  1955) and azo 
compounds (Fouts,  Kamm and Brodie,  1957; Shargel ,  1967).
More re ce n t ly ,  (Shargel and Mazel, 1973) the e f f e c t  o f  r i b o f l a v i n  
def ic iency  on drug metabolism has been studied.  The authors  
showed, tha t  in ra t  a decrease in microsomal f l a v i n  leve ls  of  56 
per cent,  was associated with  a decrease in NADPH-cytochrome-c 
reductase (52 per cent)^ azo reductase (71 per cent) and benzpyrene
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hydroxylase (74 per c e n t ) .  F lavin d e f ic iency  had no s ig n i f ic a n t  
e f f e c t  on microsomal cytochrome P-450 content and aminopyrine  
demethylase. They f u r t h e r  showed th a t  the CO-sensit ive pathway,
i . e .  cytochrome P-450 mediated,  o f  azoreductase was unaffected by 
f l a v i n  d e f ic ie n c y ,  fo r  pretreatment of  d e f i c i e n t  animals wi th  
phenobarbital  s i g n i f i c a n t l y  increased cytochrome c reductase,  
cytochrome P-450 content ,  aminopyrine demethylase and azoreductase  
a c t i v i t y .  Furthermore,  although pretreatment o f  f l a v i n - d e f i c i e n t  
animals wi th  3-methylcholanthrene increased microsomal cytochrome 
P-450 content and benzpyrene hydroxylase a c t i v i t y ,  i t  did not a f f e c t  
the normally induced, CO-insensi t ive  microsomal azoreductase pathway 
(non-cytochrome P-450 mediated).  Thus the induction of  azoreductase  
by 3”methylcholanthrene was shown to be f lavin-dependent and so was 
the induction of  benzpyrene hydroxylase, fo r  the a c t i v i t y  of  the 
l a t t e r  was increased with  increasing microsomal f l a v i n  le v e ls .  The 
authors put forward the concept tha t  part  of  the mechanism o f  azo­
reductase induction by 3-methylcholanthrene was due to an induced 
change in the s t ruc ture  or composition o f  microsomal f l a v o p r o t e in .
They supported t h e i r  i n te r p r e t a t io n  by f ind ings  th a t  ( i )  a minimal 
f l a v i n  level  was required fo r  the induction of  3-methylcholanthrene  
in f l a v i n - d e f i c i e n t  animals ( i i )  increased enzyme a c t i v i t y  was not 
compensated by an increase in microsomal f l a v i n  leve ls  and ( i i i )  
induction of  3-methylcholanthrene-augmented FMN-stimulation of  
microsomal azoreductase in v? t r o .
Other studies on the e f f e c t  of  vitamins on drug metabolism in d ic a te  
tha t  the de tox ica t ion  o f  cyanide to thiocyanate  may be v itamin  
dependent, and th a t  thiamine d e f ic iency  in mice increases the 
t o x i c i t y  of  chlord iazepoxide ,  morphine, phenobarbital  and p e n to b a r b i ta l .
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(e) D ie ta ry  l i p id s  and drug metabolism
The metabolism of various drugs has been shown to  be decreased in 
ra ts  fed a f a t - f r e e  d i e t  fo r  3 weeks thus ind ica t ing  a d ie t a r y  f a t  
requirement fo r  the synthesis o f  drug-metabolising enzymes (Norred 
and Wade, 1972). Furthermore,  enhanced phenobarbital  induction of  
drug-hydroxylat ing enzymes and cytochrome P-450 has been reported  
in r a t s ,  whose d ie ts  were supplemented wi th  polyunsaturated f a t t y  
acids (Century and Horwitt , 1968; Marshal l and McLean, 1971).  The 
p o s s i b i l i t y  ex is ts  tha t  the e f fe c ts  of  polyunsaturated f a t t y  acids  
on drug metabolism may be due to the added ant iox idants  (Parke,
Rahim and Walker, 1972) or to peroxidised l ip id s  and ste ro ids  (Brown, 
M i l l e r  and M i l l e r ,  195*0.  However, i t  is known th a t  polyunsaturated  
f a t t y  acids play a s ig n i f i c a n t  ro le  in the s t ru c tu re  o f  microsomal 
membrane phospholipids (Norred e t  a 1, 1972) and that  the maintenance 
of  an a c t iv e  form o f  cytochrome P-450 in drug metabolism is dependent 
on phospholipid.  Thus the observed change in drug metabolism in 
response to d ie ta r y  l i p i d  may be due to an a l t e r a t i o n  in the membrane 
environment o f  the cytochrome.
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Section C ~ Drug Metabolism and N u t r i t io n a l  Status
Drug therapy in the treatment o f  disease has expanded exp los ive ly  
in the l a s t  30 years and i t  is est imated that  thousands o f  agents are  in 
common use in modern medicine.  There is no doubt tha t  l iv e s  are saved 
or prolonged, th a t  incurable  condit ions are made more comfortable and 
th a t  many surgical  procedures are avoided by the use o f  drugs.
The extensive  use o f  th is  great range of  agents,  however, has 
brought along with  i t  a ser ies  o f  undesirable react ions ,  varying in 
s ev e r i ty  from the t r i v i a l  and t ra n s ie n t  to the i r r e v e r s i b l e  and f a t a l .  
Drug-nutr ien t  in te ra c t io n s ,  one of  the undesirable  e f fe c ts  o f  c e r t a in  
drugs, have been known to occur fo r  a long t ime. I t  is only r e ce n t ly ,  
however, that  th is  kind o f  in te rac t io n  is rece iv ing increasing a t t e n t i o n .
The d i f f e r e n t i a l  diagnosis of  n u t r ie n t  d e f ic iency  is a e t io lo g ic a l  
and the re fo re  requires understanding tha t  the f i v e  basic causes of  a l l  
n u t r ie n t  de f ic iency  include three inadequacies and two increases,  namely 
inadequate ingest ion,  absorption or u t i l i s a t i o n  and increased excre t ion  
or requirement.
A f u l l  discussioncof the many ways by which drugs a f f e c t  
n u t r i t io n a l  status would be beyond the scope of th is  th e s is ;  th e re fo re ,  
i t  is proposed th a t  discussion should be d irec ted  towards those drugs 
tha t  a f f e c t  the a v a i l a b i l i t y  of  m icronu tr ien ts ,  namely vitamins and 
minerals .  Thus, drugs may reduce absorption,  increase excre t ion  or  
i n t e r f e r e  with the u t i l i s a t i o n  of  vitamins and minerals and induce 
corresponding de f ic ie n c ie s  that  consequently necessi ta te  intakes g r e a t ly  
in excess of  recommended allowances.
F o l ic  acid and vitamin
Megaloblastosis ,  in genera l ,  may be considered as the morphologic 
re su l t  o f  any biochemical defect re s u l t in g  in a lower ra te  o f  DNA syn­
thesis  (Herbert ,  1965). The re su l t in g  'nuclear-cytoplasmic  d is s o c i a t io n 1, 
or asynchrony, is due to r e l a t i v e l y  slow DNA synthesis in r e la t io n  to  
r e l a t i v e l y  normal RNA synthesis and is morphological ly manifested in a l l  
p r o l i f e r a t i n g  t issues ,  such as bone marrow, by large c e l l s  conta in ing  
slowly maturing and d iv id ing  nuclear DNA surrounded by more normal-appearing  
cytoplasmic RNA. Some of the ways by which drugs can induce such
biochemical defects  is shown in F i g . 1 .2 .
Thus, drug-induced megaloblastosis is mediated mainly through an
impaired c e l l u l a r  a v a i l a b i 1 i t y  or u t i l i s a t i o n  o f  f o l a t e  or v i tamin  B ^ *
However, any drug capable of  delaying DNA synthesis is capable of  producing 
megablastosis regardless of  which DNA synthet ic  block i t  may i n h i b i t .
( i ) Drugs and f o l a t e  aVa? lab i1i t y
The a c t iv e  form of  f o l a t e  is te t r a h y d r o f o l i c  acid (THFA), which is the  
c a r r i e r  o f  one-carbon moiet ies .  One example of  i t s  c a r r i e r  function  
is the t r a n s fe r  o f  a methyl group to deoxyur idy la te  to form thym idyla te ,  
an important step in the synthesis o f  DNA ( F i g . 1 .2 ) .
Any drug which (1) decreases the i n t r a c e l l u l a r  concentrat ion o f  
f o l a t e  or (2) in h ib i ts  i ts  c yc l ic a l  in terconversions,  can p o t e n t i a l l y  
cause megaloblastosis.  Decreased i n t r a c e l l u l a r  f o l a t e  concentrat ion  
may be due to decreased ingest ion,  absorpt ion,  transport  and d e l iv e r y  
to c e l l s ,  c e l l u l a r  uptake and re te n t io n ,  or increased e x c r e t io n ,  
destruct ion  and requirements.  In te r fe rence  wi th  the c y c l ic a l  
interconversion or u t i l i s a t i o n  o f  the vitamin may be due e i t h e r  to  
u n a v a i l a b i l i t y  o f  vi tamin B ^  or in h ib i t io n  of  any f o l a t e  i n t e r ­
convert ing enzymes.
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De Novo pathway
Deoxyuridine DNA Thymine
± t
Deoxyuridyl ate Thymidylate
P te ro y l -  
glutamic acid
5“ 10 Methylene THFA
Dihydrofo la te
Di hydrofo la te  
y  reductaseGlyci ne
MethionineTHFA
|Pyr i doxal-P0
5-Methyl  THFA
Homocystei neSerine
F i g . 1.2 Some fac tors  a f f e c t in g  DNA-thymine synthesis:
1* D ihydrofo la te  reductase step -  s i t e  o f  a c t ion  of  
f o l a t e  antagonists .
2. Homocysteine transmethylat ion step -  s i t e  of  
act ion o f  drugs inducing vitamin d e f ic ie n c y .
3. Serine hydroxymethylation step -  s i t e  of  act ion  
of  drugs inducing pyridoxine d e f ic ien c y .
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(a) Folate  antagonists
r-*
Fol ic  acid antagonists such as methotrexate,  i n t e r f e r e  wi th  the 
conversion o f  d ih y d ro fo la te  (DHFA) to te t r a h y d r o fo la t e  (THFA), 
thus in te r ru p t in g  one of  the essentia l  c y c l ic  pathways in which 
the v itamin is involved.  The megaloblastosis which is induced 
by these drugs has been explained as being due to the accumulation 
of the v itamin in the DHFA form and subsequent u n a v a i l a b i l i t y  o f  
THFA, the carbon-donor form o f  the vitamin in purine and 
pyrimidine biosynthesis (Bert ino  and Johns, 1972).
Methotrexate and other  s t ru c tu ra l  analogues of  f o l i c  acid  have the  
common property of  binding i r r e v e r s i b l y  to d ih y d ro fo la te  
reductase,  the enzyme cata lys ing  the reduction o f  DHFA to  THFA 
(Condit,  1961; Werkheiser, 1963).  Thus, the a d m in is t ra t io n  of  
these drugs in h ib i ts  the enzyme's a c t i v i t y ,  which in turn in h ib i t s  
the production and recycl ing o f  the cofactor  (THFA), w i th  a 
re su l ta n t  a r r e s t  in the synthesis of  DNA ( S a r t o r e l l i  and Booth,
1962; S a r t o r e l l i ,  Upchurch and Booth, 1962); the de novo synthesis  
of DNA-thymine from deoxyur idy la te  requires a supply o f  reduced 
f o l a t e  (THFA) to form 5—10 methylene THFA, the co factor  which 
donates i t s  methyl group to deoxyuridyl a te  to form thymidyla te  
(F ig .  1 .2 ) .
Methotrexate has a lso been shown to a f f e c t  RNA and pro te in  synthesis  
in a s im i la r  way. Thus, the drug has been shown to markedly 
reduce 3H -u r id ine  incorporation into RNA and to a lesser  e x tent  
3H- leucine incorporat ion into  prote in  (Hryniuk, 1972).  Hypo- 
xanthine completely reverses both of  these e f fe c ts  and f u r t h e r
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appears to  enhance 3H -u r id ine  incorporat ion into RNA, e i t h e r  
in presence or absence of added methotrexate.  In view of the 
methotrexate- induced blockade of  de novo purine synthesis o f  
RNA, in h i b i t i o n  o f  DHFA-reductase may lead to a block in the  
formation o f  new DHFA-reductase, by preventing synthesis of  
RNA necessary to form th is  enzyme p ro te in ,  thus making r e p l i c a t io n  
impossible and leading to c e l l  death.  I t  is possible  tha t  f o l a t e  
antagonists may induce megaloblastosis by other mechanisms in view 
of t h e i r  s t ru c tu ra l  analogy to f o l i c  ac id .  Methotrexate has been 
shown to i n h i b i t  the absorption o f  p te ro y l -g lu tam ic  acid in ra t  
(Burgen, Goldberg, 1962; Hepner, 1969),  although th is  may not 
p er ta in  in man (Freedman, Weir ,  Brown 1973).  Methotrexate  appears 
n e i the r  to compete s i g n i f i c a n t l y  fo r  in te s t in a l  absorption in man 
nor to i n h i b i t  in t e s t in a l  absorption by in te r fe ren c e  w i th  the 
reduction of  PGA. I t  has, however, been postulated (Corcino,  
Waxman and Herbert ,  1971; De Veber,  V a le n t in e ,  1964; Nahas, Nixon 
and Bert ino,  1972) th a t  f o l a t e  antagonists and f o l a t e  may p a r t l y  
share a common c e l l u l a r  transport  system and the drugs may thus 
i n t e r f e r e  wi th  the a v a i l a b i 1i t y  of  the vitamin a t  the c e l l u l a r  
l e v e l .
(b) Anticonvulsants
I t  has been known since 1952 tha t  the prolonged a dm in is t ra t io n  
of  anticonvulsants is associated w i th  megaloblastosis .  Since 
then,  a number o f  studies (Reynolds, M i lner  and Matthews, 1966; 
Reynolds, 1968; Mantz, Tempe, Jaeger,  1970) have demonstrated 
low serum and red blood c e l l  f o l a t e  l e v e ls ,  and o ccas iona l ly  over t  
megaloblastic anaemia, in a m a jo r i ty  of  pa t ien ts  rece iv ing  long­
term anticonvulsant therapy.  Although diphenylhydantoin
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(D i l a n t in )  has been most studied,  f o l a t e  de f ic iency  and anaemia 
have nevertheless been reported with  phenobarbital  and primidone.
The mechanism by which anticonvulsants  induce f o l a t e  d e f ic iency  
is not wel l  understood.
In the search fo r  an explanation o f  the decreased f o l a t e  leve ls  
associated wi th anticonvulsant therapy many studies have centred  
on decreased in te s t in a l  absorption o f  f o l a t e .  Monoglutamate,  
derived from large  doses o f  reduced pteroylg lutamate  and a l l  
methyl THFA, is absorbed unchanged from the i n t e s t in e  (Whitehead 
and Cooper, 1967; Strum, Nixon and Bert ino,  1971),  and s i g n i f i c a n t  
amounts of  other reduced fo la te s  are  converted in the in t e s t in a l  
mucosa to methyl THFA before transport  to the l i v e r , ( P e r r y  and 
Chanarin,  1970; Whitehead, P ra t t  and V i a l l e t ,  1972).  Furthermore,  
in man, 1-5-methyl THFA is absorbed more re ad i ly  than i ts  
physicochemical ly iden t ica l  isomer d-5-methyl  THFA, in d ic a t in g  
tha t  an a c t iv e  transport  mechanism fo r  f o l a t e  may e x is t  in the 
human in te s t in a l  mucosa (Scot t ,  Freedman and Brown, 1972).  Contrary  
to the observation in man, i t  has been argued that  a c t iv e  t ranspor t  
of  f o l a t e  in the ra t  may not e x i s t ,  fo r  the uptake of  1-5-methyl  
THFA is d i r e c t l y  proport ional  to i t s  concentrat ion over a 1000-fo ld  
range (Strum et a l , 1971). I t  has a lso been demonstrated th a t  in 
man glucose enhances in te s t in a l  f o l a t e  absorption ,  possibly  due to  
solvent-drag action (Gerson, Cohen and Hepner, 1971).  The 
importance of  glucose enhancement in d i lan t in -m ed ia te d  f o l a t e  
absorption is not c le a r .
The l i m i t a t io n  o f  most f o l a t e  absorption studies is th a t  they 
have been c arr ied  out w ith  unreduced monoglutamate, although  
polyglutamyl f o l a t e  is found in approximately 80 per cent of
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the d ie t  and reduced forms of  f o l a t e  comprise approximately  
90 per cent o f  natural  monoglutamates (Rosenberg, 1972).  The 
knowledge about the e f f e c t  o f  D i l a n t in  on PGA absorpt ion must 
there fore  be t rea ted  with  caution when the nature o f  food f o l a t e  
is taken into  account.
Most of  the normal d ie ta ry  f o l a t e  is in the polyglutamyl form 
and before absorption a l l  but one of  the y-1inked glutamyl  
residues o f  polyglutamate must be removed by y-g lutamyl  carboxy-  
peptidase (conjugase),  an enzyme found in human in te s t in e  
(Butterworth ,  Baugh and Krumdieck, 1969). Diphenylhydantoin-  
induced malabsorption of  f o l a t e  polyglutamate in v ivo and 
i n h ib i t io n  of  human in te s t in a l  conjugase a c t i v i t y  in v i t r o  has 
been reported using a p a r t i a l  ly  p u r i f i e d  yeast prepara t ion  as 
the polyglutamate source (Hoffbrand and Necheles, 1968;
Rosenberg, S t r e i f f . a n d  Godwin, 1968).  However, f u r t h e r  studies  
in vivo (Houlihan,  Scott  and Boyle, 1972) and in v i t r o  (Baugh, 
Krumdieck, 1969; Bernstein,  Gutstein and Weiner, 1970) f a i l e d  
to v e r i f y  the above observat ions.  In p a r t i c u l a r ,  Baugh e t  al  
(1969) used a rad io ac t ive  assay fo r  the conjugase, which is 
much more accurate ,  but f a i l e d  to demonstrate any in v i t r o  
i n h ib i t io n  o f  conjugase a c t i v i t y  in response to  d iphenylhydantoin.  
Meynell (1966) and Dahlke and Mertens-Rosler (1967) suggested 
tha t  diphenylhydantoin in h ib i te d  the in t e s t in a l  absorpt ion o f  
PGA. However, t h e i r  method o f  assessing f o l a t e  malabsorption  
(e leva t ion  o f  serum f o l a t e  leve ls  a f t e r  an oral  dose o f  f o l a t e  
monoglutamate) was too uncerta in  for  any f i rm  conclus ions.  More
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rece n t ly ,  diphenylhydantoin has been shown to s i g n i f i c a n t l y  decrease 
the ra te  of  PGA absorption in man (Gerson, Hepner and Brown, 1972),  
but perhaps of  g reater  s ig n i f ic a n c e ,  th is  study a lso  demonstrated 
that  the in h ib i t io n  of  absorption was more marked wi th  glucose 
stimulated absorption.  This may ind ica te  that the drug exerts  
in h ib i t io n  on some general in t e s t in a l  absorption process such as 
solvent drag,  sodium exchange and in te s t in a l  ATPase (Hepner, A ledort  
and Gerson, 1970),  and hence i n d i r e c t l y  in h ib i ts  PGA absorpt ion.
Such an exp lanat ion ,  a l b e i t  u n sp ec i f ic ,  is in te re s t in g  fo r  i t  would 
p a r t l y  expla in  the s i m i l a r i t y  in the mode of act ion  of  chemical ly  
d is s im i la r  anticonvulsant drugs on f o l a t e  absorption .
I t  is ra ther  in t r ig u in g  that some pa t ien ts  never develop f o l i c  acid 
def ic iency  or anaemia despite  prolonged therapy wi th these drugs.
This may be explained by some excess capacity  o f  the in t e s t in e  to 
absorb f o l a t e ,  such as is seen in studies a f t e r  resection (Baker,  
Thompson and Feingold,  1969). I t  is thus possible  tha t  f o l a t e  
def ic iency  in the e p i l e p t i c  only ensues fo l lowing a decrease in 
f o l a t e  reserves,  e i t h e r  through poor d i e t ,  or diminished absorpt ion ,  
or pregnancy (Gatenby, 1960).
Changes in in te s t in a l  pH is another fa c to r  by which d i l a n t i n  may 
exer t  an in h ib i t io n  on f o l a t e  absorpt ion.  The optimal pH fo r  
conjugase a c t i v i t y  is 4 .6  and a t  a l k a l in e  pH the enzyme becomes 
in a c t ive  (Rosenberg e t  a l . 1968).  D i la n t in  is s trongly  a lk a l i n e  
in so lut ion (pH 12).  The absorption of  f o l i c  a c id ,  a weak a c id ,
is favoured by acid pH and in h ib i ted  by a lk a l in e  pH as produced by 
d i l a n t i n  in solut ion (Benn, Swan and Cooke, 1971). A lk a l in e  pH 
in chronic d i l a n t i n  users,  and in h ib i t io n  of  f o l a t e  absorption by 
bicarbonate have been demonstrated (Benn e t  a l , 1971; Elsborg,  1971),
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although d i l a n t i n  adm in is t ra t ion  to normal subjects did not change 
t h e i r  in te s t in a l  pH. Chronic adm in is tra t ion  must obviously be a 
fa c to r  accounting fo r  such d i f fe re n ce s .  Furthermore,  pH measure­
ments probably r e f l e c t  condit ions in the more rapid major stream of  
the in te s t in e  ra ther  than in the microenvironment o f  the mucosal 
surface (Schanker, Tocco and Brodie,  1953) tha t  c h i e f l y  contro ls  
in t e s t in a l  f o l a t e  absorption.
Serum f o l a t e  transport  may be mediated through a c a r r i e r  pro te in  and 
evidence indicates th a t  a c e t y l s a l i c y l i c  acid may decrease f o l a t e  
binding to serum prote in  ( A l t e r ,  Z v a i f l e r  and Rath, 1971).  Thus, 
decreased binding would be another fa c to r  involved in reduced serum 
and t issue  f o l a t e  leve ls  seen in long-term d i l a n t i n  therapy.  In 
a d d i t io n ,  there  ex is ts  c e r ta in  s t ru c tu ra l  resemblance between a n t i ­
convulsants and f o l i c  acid and i t  has been suggested tha t  t h e i r  
pharmacological act ion  may be due to the a n t i f o l a t e  propert ies  o f  
these drugs (Girdwood and Cenman, 1956; Herbert and Tisman, 1973).  
Supporting evidence for  th is  act ion  o f  anticonvulsants  is derived  
from the fa c t  th a t  f o l a t e  adm in is t ra t ion  to s t a b i l i s e d  pa t ien ts  
rece iv ing ant iconvulsants may lead to an increase in the frequency  
and s ev e r i ty  of  se izures .  Although th is  has been contested,  i t  
may well  be th a t  enhancement o f  se izure  control  may only be achieved  
in low f o l a t e  sta tes (Reynolds e t  a l , 1966) .  Furthermore,  f o l a t e  
adm in is t ra t ion  reverses the mental slowness and apathy seen in 
pat ien ts  on long term anticonvulsant therapy (Reynolds, 1967).
Recently,  an a l t e r n a t i v e  hypothesis has been advanced (Maxwell 
et  a l , 1972) ,  which is s im i la r  to the mechanism by which a n t i ­
convulsant drugs p r e c ip i t a t e  osteomalacia (see l a t e r ) .  The basis 
of  the hypothesis is the powerful enzyme inducing p roper t ies  o f
these drugs in man and other  species.  Thus, ant iconvulsant  
drugs by inducing the hepatic  drug-metabolising enzymes a lso  
increase f o l a t e  demands which,  on a chronic basis ,  would lead 
to decreased c e l l u l a r  f o l a t e  and, u l t i m a t e l y ,  megaloblastosis.
Oral contracept ives
Decreased serum f o l a t e  concentrat ions among oral  contracept ive  
users have been reported in several  studies (Necheles,  Snyder,  
1970; Ryser, Farquet and P e t i t e ,  1971; Shojania,  Hornady and 
Barnes, 1969; Shojania,  Hornady and Barnes, 1968 ; S t r e i f f ,  1970) 
but have been contested in another study (Spray, 1968).
In h ib i t io n  o f  in te s t in a l  absorption of  f o l a t e  polyglutamate by 
oral  contraceptives has been suggested as the causative fa c to r  
( S t r e i f f ,  1970) although occul t  malabsorption may have been 
present in some cases (Holmes, 1970; Shojania e t  a 1, 1969;
Toghi l l  and Smith, 1971).  In one study ( S t r e i f f ,  1969),  i t  
was shown tha t  f i v e  women who developed megaloblast ic anaemia 
w hi le  tak ing oral  contracept ives  did not respond to d ie t a r y  f o l a t e  
but did respond to oral  f o l a t e  ad m in is t ra t io n ;  the same author in 
1970 demonstrated decreased absorption o f  yeast polyglutamate ,  
but normal monoglutamate absorpt ion,  in women taking oral  c o n t ra ­
cept ives .  There have been reports of  abnormal i n t e s t in a l  biopsy 
and xylose malabsorption,  which did not f u l l y  resolve a f t e r  
discont inuat ion  o f  oral  contracept ives ,  in one p a t ie n t  (Togh il l  
et  a l , 1971),  and abnormal in t e s t in a l  biopsies during ora l  
contraceptive  therapy in others (Shojania e t  a l , 1969 ) •  In view 
of  the normal serum f o l a t e  leve ls  in the m a jor i ty  o f  ora l  
contraceptive  users i t  may well  be th a t  ora l  c o n trace p t iv e -  
induced malabsorption of  f o l a t e  polyglutamate a t t a in s  c l i n i c a l  
s ig n i f ic a n c e  only when superimposed on another absorption de fect
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or on marginal d ie ta r y  f o l a t e  in take .
Despite lack of  in vi t ro  evidence,  the concept of  oral  contra ­
cept ive  mediated conjugase i n h ib i t io n  in the in te s t in e  ( S t r e i f f ,
1969),  as the mechanism by which ora l  contraceptives p r e c i p i t a t e  
f o l a t e  d e f ic ie n c y ,  is ra ther  s im i la r  to tha t  of  diphenylhydantoin  
(Hoffbrand e t  a l , 1968 ; Rosenberg e t  a l , 1968). This mechanism, 
however, must be viewed wi th caut ion f o r  (a) a l l  these studies  
assessed f o l a t e  absorption by serum f o l a t e  e le va t ion  a f t e r  a te s t  
dose of sem i-pur i f ied  yeast f o l a t e  polyglutamate and (b) improved 
methodology has indeed cast considerable doubt on the 'drug-  
induced conjugase i n h i b i t i o n '  concept in the case of  diphenylhydantoin.
( i i ) Drugs and vitamin  ^ a v a i l a b i 1i t y
The use of  oral  contraceptives has been associated w i th  decreased serum 
vitamin B ^  concentrat ions ,  wi thout anaemia (W e r ta l ik ,  Metz and LoBuglio,  
1972). Fola te de f ic iency  was also present in some p a t i e n ts ,  which could 
be corrected by ora l  pteroyl  glutamic acid a d m in is t ra t io n ,  but had no 
e f f e c t  on serum vitamin B ^  concentrat ions .  The s ig n i f ic a n c e  of  
decreased vitamin B ^  concentrations fo l lowing oral  contracept ive  therapy  
is not known. The p o s s i b i l i t y ,  however, ex is ts  tha t  ora l  co n tra ­
ceptives may reduce vitamin B ^  binding to serum p ro te in ,  f o r ,  despi te  
reduced serum le v e ls ,  the t issue  stores of  the vitamin are normal as 
judged by normal levels  of  serum vitamin B ^ -b in d in g  p r o t e in ,  e ry th ro cy te  
vitamin B ^ ,  normal S c h i l l in g  t e s t ,  and no in h ib i t io n  of  the v itamin  assay.
Metformin,  a biguanide ora l  hypoglycaemic agent used to  t r e a t  mild 
obese d ia b e t ic s ,  has been reported to cause vitamin B ^  malabsorption  
in 30 per cent of  71 d ia b e t ic  pa t ien ts  on long term therapy (Tomkin e t  al  ,
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1971)* The B.J2 malabsorption was not found to be due to lack of  
i n t r i n s i c  fa c to r  or to  small bowel co lon isa t ion  with  b a c t e r ia ,  which 
is occas ional ly  found in d ia b e t ic  p a t ie n ts .  Biguanides have been 
shown to i n h i b i t  the a c t iv e  t ransport  of  a number o f  n u t r ie n ts  
including glucose (Caspary, 1971)* Whether the malabsorption of  
vitamin B ^  is due to competit ive  in h ib i t io n  of  metformin or in a c t iv a t io n  
of the enzyme systems involved in the a c t iv e  t ransport  of  B ^  remains to  
be e luc ida ted .
Pyridoxine (B^)
Hydrazides,  such as is o n ic o t in ic  hydrazine ( INH) or isoniaz id  and 
th ioacetazone,  have been found in some pa t ien ts  to produce a n e u r i t i s  which 
is cured by pyridoxine a d m in is t ra t io n .  The act ion  o f  these drugs appears 
to be tw o - fo ld ,  fo r  they increase the ur inary  excret ion o f  B^  and also form 
hydrazone complexes with  pyridoxal  phosphate, thus in a c t iv a t in g  the coenzyme 
(Yoneda and Asano, 1953).
P e n ic i l la m ine ,  a che la t ing  agent used in the treatment of  Wi lson's  
disease,  can also p r e c i p i t a t e  symptoms o f  B^  d e f ic ie n c y ,  probably due to  
complex formation with  pyridoxal  phosphate (Aposhian, 1971).  I t  has re cen t ly  
been demonstrated that  the long-term use of  the combination-type o f  ora l  
contraceptives is accompanied by an increased ur inary  excre t ion  of  such 
tryptophan metaboli tes as xanthurenic ac id ,  kynurenine, 3“hydroxykynurenine,  
and an elevated 3"hydroxykynurenine:3"hydroxyanthrani1 ic acid r a t i o ,  fo l low ing  
an oral  tryptophan load (Rose, 1966; P r ic e ,  Thornton and M u e l le r ,  1967;
Brown e t  a l , 1969; Rose et  a l . 1972).  This excretory  p a t te rn  of  tryptophan  
metaboli tes resembles that of  n u t r i t i o n a l  v i tamin B^  de f ic ie ncy  (Yess e t  a l , 
1964; Rose e t  a l , 1972) and can be corrected by the ora l  adm in is t ra t io n  o f
-  39 -
the vitamin p r io r  to the tryptophan loading te s t  (Rose, 1966; Pr ice  e t  a l , 
1967; Rose and Adams, 1972). I t  would appear,  th e re fo re ,  th a t  the use 
of ora l  contracept ives  may p r e c i p i t a t e  pyridoxine d e f ic ie n cy .
" , Although the mechanism by which oral  contracept ives  increase  
tryptophan metabolism through the t ryptophan-n iac in  pathway has not been 
estab l ished ,  evidence from studies on laboratory  animals points to  three  
p o s s ib i1i t i e s :
( i )  Oestrogenic s te ro ids  induce hepat ic  tryptophan oxygenase, an 
e f f e c t  mediated by the adrenals (Braidman and Rose, 1971).
Hepatic c o r t is o l  a c t i v i t y  is increased by oestrogen ( K e l l e r ,  
Richardson and Yates,  1969) anc* hepatic  tryptophan oxygenase 
levels  are g re a t ly  increased by hydrocort isone a dm in is t ra t io n  
(Braidman e t  a l , 1971; Greengard, 1971). This resu l ts  in 
increased divers ion of  tryptophan through the tryp tophan-n iac in  
pathway, thereby s t ra in in g  the capacity  of  pyridoxal  phosphate-  
dependent enzymes o f  the pathway, e s p e c ia l ly  a f t e r  a tryptophan  
load (Green, Joseph and Curzon, 1970; Br in ,  1971).
( i i )  There may e x is t  a reduced a v a i l a b i l i t y  o f  cofactor  fo r  the  
pyridoxal-phosphate-dependent enzymes of the tryp tophan-n iac in  
pathway, because o f  increased a c t i v i t y  o f  pyridoxal  phosphate-  
dependent amino transferases (Br in ,  1971) and
( i i i )  Oestrogen sulphate esters formed in the l i v e r  may i n h i b i t  the  
enzymes kynureninase and kynurenine aminotransferase by competing 
with  pyridoxal  phosphate fo r  the binding s i te s  on apoproteins  
(Mason and Manning, 1971; Mason, Ford and Wu, 1969) .  This 
p o s s i b i l i t y ,  however, cannot expla in  the increased e xcre t ion  o f  
N-methyl-n icotinamide in pregnant women (Rose, 1966).
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I t  has been suggested (Green et  a l , 1970) th a t  the induction of  
tryptophan oxygenase may decrease the a v a i l a b i l i t y  o f  ( i )  tryptophan and
( i i )  the coenzyme fo r  serotonin synthes is ,  in view o f  the increased demand 
fo r  both in the t ryptophan-n iac in  pathway. Decreased leve ls  of  bra in  
serotonin may in fa c t  be responsible fo r  the depression and behavioural  
changes seen in ora l  contraceptive  users.  Furthermore,  i t  has been shown 
tha t  kynurenine and 3-hydroxykynurenine i n h i b i t  the uptake o f  tryptophan 
by the brain  (Curzon, 1971).
Niaci  n
P e l l a g r a - l i k e  symptoms have been described in pa t ien ts  on ison iaz id  
treatment fo r  tubercu los is .  The symptoms disappeared fo l low ing  combined 
therapy with  n iac in  and pyr idoxine .  I t  has been postulated tha t  n iac in  
def ic iency  in p a t ien ts  on th is  drug is only secondary to pyr idoxine d e f ic ie n c y  
since the l a t t e r  is essentia l  in the conversion o f  tryptophan to  n iac in  
(Di Lorenzo, 1967).  Thus, i t  would appear th a t  the combination o f  poor 
niacin  intake and isoniaz id  medication may, and indeed can, lead to  c l i n i c a l  
p e l la g ra .
Ascorbic acid
Low leve ls  of  plasma and leucocyte ascorbic acid have been reported  
many times in studies on old people (Burr e t  al  , 1974).  This by no means 
m inor i ty  group o f  the populat ion,  is susceptib le  to fa c tors  that would 
increase the excret ion of  ascorbic acid and Oswald (1959) has suggested 
tha t  the need fo r  ascorbic acid increases wi th  age. The a n t i b i o t i c  t e t r a ­
cyc l in e  has been shown to decrease the ascorbic acid content o f  leucocytes  
(Shah, Barbhaiya and Skrinwasan, 1968) and in old people,  a f a l l  in leucocyte
ascorbic acid leve ls  is accompanied by increased ur inary  excre t ion  of  
the vitamin (Windsor et  a l , 1972). The mechanism by which t e t r a ­
cyc l ine  induces ascorbic acid deplet ion is not known but the drug may 
i n t e r f e r e  with  the tubular  reabsorption of  the v itam in .  Furthermore,  
t e t r a c y c l in e  has been shown to enhance the conversion o f  ascorbic  
acid to  dehydroascorbic acid (Dudani and K r is h n a n u r t i , 195*0 and may 
thus inf luence the a v a i l a b i l i t y  o f  the v i tamin .
The use of  oral  contraceptives has been associated wi th  depressed 
plasma ascorbic acid and to t a l  ascorbic acid concentrat ions (Rivers and 
Devine, 1972) and also wi th  preventing the sharp increase in plasma 
ascorbic acid a t  the time of ov u la t io n .  The authors o f fe re d  no 
explanat ion for  t h e i r  observation.  However, they reported th a t  ora l  
contraceptive  users had lower fa s t in g  plasma ascorbic acid l e v e ls ,  an 
observation which may be in d ic a t iv e  of  reduced tubular  reabsorption  
of  the vitamin in response to oral  contracept ives .  Other s te ro id  
drugs have also been implicated in in t e r f e r in g  with  the metabolism of  
ascorbic a c id .  Thus, prednisone has been reported (Bartholomew, 1972) 
to have been the causative fa c to r  in p r e c ip i t a t in g  f rank  c l i n i c a l  
scurvy in a woman s u f fe r in g  from rheumatoid a r t h r i t i s .  However, i t  
is not known a t  present how these drugs a f f e c t  ascorbic acid metabolism.
Vitamin D and calcium
Biochemical and occasiona11y c l i n i c a 1, osteomalacia has been 
reported in pa t ien ts  on long-term anticonvulsant therapy (Dent e t  al ,
1970; Richens and Rowe, 1970; Hunter et  a l , 1971),  and on s im i la r  
therapy with g lu te th im ide ,  a hypnotic (Greenwood, Prunty and S i l v e r ,  1973)*  
The adm in is tra t ion  of  vi tamin D leads to amel iorat ion  of  the c o n d i t io n .
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C ho leca lc i fe ro l  is converted to i t s  b i o l o g i c a l l y  a c t iv e  forms by 
double hydroxylat ion in the 25 pos i t ion  (25"hydroxycholeca lc i fe ro l)  and 
subsequently in the 1 -p os i t ion  ( 1 ,25 -d ih y d ro x y c h o le c a lc i fe ro l ) in the 
l i v e r  and kidney re sp e c t ive ly .  The lat . te r  is the most a c t iv e  in 
promoting in te s t in a l  calcium absorption (Lawson e t  a l , 1971). I t  has 
been suggested that  anticonvulsant drugs induce accelerated hepatic  
microsomal metabolism of the vitamin to polar metaboli tes  other  than 
25- h y d ro x y c h o le c a lc i fe ro l , which are apparent ly  b i o l o g i c a l l y  in ac t iv e  
(Hahn, Birge and Scharp, 1972). The authors supported t h e i r  hypothesis 
by demonstrating tha t  ( i )  3H-choleca1c i f e r o l  is ra p id ly  converted to more 
polar m etaboli tes ,  some of  which are  b i o l o g i c a l l y  in a c t iv e ,  by pa t ien ts  
on long-term phenobarbital  treatment ( i i )  tha t  such conversion can be 
induced by a conventional  dose of  phenobarbitone and ( i i i )  th a t  pheno- 
b a rb i ta l  adm in is t ra t ion  to rats induces an increase in hepat ic  conversion  
of  3H -c h o le ca lc i fe ro l  and 3H-25~hydroxycholecalci ferol  to  more polar  
metabol i tes in v i t r o , an e f f e c t  mediated through increased hepatic  
microsomal hydroxylase a c t i v i t y .
In conclusion,  among the many side e f f e c t s  o f  drugs,  th e r e fo r e ,  the  
p o s s i b i l i t y  of  crea ting  a n u t r i t i o n a l  d e f ic iency  must always be borne in mind.
P ro p o s e d  scheme o f  s t u d i e s
Many invest iga tors  have shown tha t  ascorbic acid can in f luence  drug-  
metabolism and that drugs can a f f e c t  the metabolism of ascorbic a c id .  The 
mechanism of these phenomena, however, are not known, and the e f f e c t  o f  
drug admin is t ra t ion  on the metabolism of ascorbic acid in a species th a t  
cannot normally synthesise ascorbic acid has been invest iga ted .
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Defect ive  tryptophan metabolism has been known to occur in 
pat ien ts  su f fe r in g  from rheumatoid a r t h r i t i s ,  due to t h e i r  drug intake .  
Therefore ,  the importance of th is  defect in r e la t io n  to the tryptophan-  
niacin  i n t e r r e la t io n s h ip  and n iac in  requirements in man has been 
considered.
I t  is now well  known that there e x is ts  an impairment of  f o l i c  
acid metabolism fo l low ing  chronic adm in is t ra t ion  o f  ant iconvulsant  drugs.  
The t e n t a t i v e  hypothesis that impairment is due to the potent enzyme- 
inducing propert ies  of  these drugs has been tested by c o r r e la t io n  of  
parameters of  drug metabolism, f o l a t e  def ic iency  and d ie ta r y  f o l a t e  
intake and requirements,  in man and in the r a t .
The hypothesis tha t  the anticonvulsant - induced f o l a t e  de f ic ien cy  
may be a fa c to r  predisposing the o f fsp r in g  o f  female e p i l e p t i c s  to  
te ratogenesis  has been proposed (Parke, personal communication) and i t  
has been examined in the ra t .
C h a p t e r  Two
THE EFFECT OF DRUGS ON ASCORBIC A CID  METABOLISM
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The scurvy f lew through the schooner's crew 
As they sa i led  on the a r c t i c  sea.
They were f a r  from land and t h e i r  food was canned 
So they got no vitamin C.
For D e v i l 's  the use of  orange ju ic e
the skipper 'ad said ,  said he.
They were v ic t u a l l e d  wi th pickled pork,  my dears,  
Those Mariners bold and f r e e ,
Yet l i f e  is b r i e f  on the best corn beef 
I f  you don't  get vi tamin C.
(ACH, 1928)
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I ntroduct ion
The a c t i v i t y  of  the hepat ic  drug metabolising enzymes is 
known to be influenced by such fa c tors  as sex, age, species and 
s t r a in ,  s t ress ,  hormones, admin is tra t ion  of  drugs and other  
chemicals and n u t r i t i o n a l  s ta tus .  With respect to n u t r i t i o n ,  
ascorbic acid is one of  the n u tr ie n ts  essent ia l  in the 
maintenance of drug metabolism.
A number of  in v ivo invest iga t ions  have shown tha t  the 
metabolism of  a number of  drugs is decreased in ascorbic a c id -  
d e f ic ie n t  animals. Thus, Richards,e t  al (1941) showed a prolonged 
pentobarbita l  sleeping time in vitamin C d e f i c i e n t  guinea p igs ,  an 
e f f e c t  which could be reversed by the admin is tra t ion  of  the v i tam in .  
Axelrod,  e t  al (1954) found a s ig n i f i c a n t  increase in plasma h a l f -  
l i f e  of  a c e t a n i l id e ,  a n i l i n e ,  and a n t ip y r in e  in scorbut ic  guinea 
pigs.  These authors concluded that vi tamin C is essent ia l  fo r  
the optimal metabolism of these drugs.
In 1961, Conney, e t  a l , studied the i n t e r r e la t io n s h ip  
between the metabolism of ascorbic acid and drugs with  re ference  
to the a b i l i t y  of  ascorbic acid to inf luence the metabolism of  
drugs and v ice  versa . They demonstrated that  vi tamin C -d e f i c ie n t  
guinea pigs were more se n s i t iv e  to the muscle -re laxant drug 
zoxazolamine than were normal control  guinea pigs.  They a t t r i b u t e d  
the increased s e n s i t i v i t y  towards the drug to impaired a c t i v i t y  of  
the enzyme system in l i v e r  microsomes that  metabolises the drug.
The same authors,  among o thers ,  also demonstrated that a great  
v a r ie t y  of  drugs, a l b e i t  chemically and pharmacological ly u n re la te d ,
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could markedly s t imulate  the ur inary  excre t ion  of  ascorbic acid in 
the r a t .  The drugs included were a v a r i e t y  of  hypnotics,  
ana lgesics ,  m uscle -re laxan ts , an t i  rheumatics,  ant ih istamines and 
carcinogenic hydrocarbons, a l 1 of  which shared a common property ,  
namely tha t  o f  potent hepatic  enzyme induct ion.  Furthermore,
Conney and his co-workers showed that ( i )  the turnover ra te  of  
vitamin C was increased 5 and 10 times in rats pretreated  wi th  
pentobarbita l  and chloretone respect ive ly  and ( i i )  tha t  the 
adm in is tra t ion  o f  these drugs not only led to an augmented ur inary  
ascorbic acid excret ion but also to  a corresponding marked increase  
in i ts  metabolic breakdown. The increased metabolic breakdown 
may be assumed to r e f l e c t  increased metabolic requirements o f  the  
v i tamin ,  which in the ra t  are met by increased synthesis of  ascorbic  
ac i d .
Most animals can convert D-glucose to ascorbic acid as they  
possess the necessary enzyme, L-gulonolactone oxidoreductase,  in 
t h e i r  system. Man, the higher apes, guinea pigs and f r u i t  bats ,  
however, are m etab o l ica l ly  anomalous in tha t  they cannot e f f e c t  the  
conversion,  due to lack of  the enzyme. For man and the l a t t e r  
animals, th e re fo re ,  an adequate exogenous source of  the v itamin  
is essentia l  fo r  the maintenance o f  good heal th  and optimal  
metabolism.
In view of the increased metabolic breakdown of ascorbic  
acid in response to drugs in the ra t  and, f u r t h e r ,  the gen era l ly  
chronic adm in is t ra t ion  o f  drugs, i t  was considered of  in te r e s t  to  
inves t iga te  the e f f e c t  o f  drugs on ascorbic acid metabolism in a 
species unable to synthesise ascorbic ac id .  The drugs
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chlordiazepoxide (Librium) and prednisone were chosen fo r  
study.
Chlordiazepoxide (L ibr ium) ,  a member o f  the ch lord iazepine  
group of  drugs, is an hypnotic,  non-addict ive  with  high le tha l  
dose, r e l a t i v e l y  f r e e  from s id e -e f f e c ts  and a mild inducing agent  
of  the hepatic  drug-metabolising enzymes. I t  is mainly these 
prop e r t ies ,  along w i th  i t s  pharmacological advantages, th a t  have 
gained the drug such wide d is t r i b u t i o n  and human usage. I t  was 
selected fo r  study p a r t i c u l a r l y  because o f  i t s  chronic use in old  
people,  e i t h e r  alone or in combination wi th  other drugs. This 
p a r t i c u l a r  populat ion group is known g e nera l ly  to have suboptimal  
intakes of ascorbic ac id .  I t  is th e re fo re  possible tha t  the drug,  
might,  in view of  the suboptimal intake of  vi tamin C by these  
ind iv iduals  and the possible increase in the metabolism of  the 
v i tamin ,  lead to impairment of  these old peoples1 heal th .
Cor t icos te ro id  adm in is tra t ion  is accompanied by c e r t a in  
undesirable haemorrhagic skin mani festat ions  such as purpura,  
petechiae,  ecchymoses and ease of  b ru is ing .  With cor t isone ,  
cort  i cotrophi n and hydrocort isone the incidence of these f ind ings  
was reported to be between 2-5 per cent (Hench e t  a l , 1954).
The authors o f fe red  no explanat ion fo r  :the phenomena. Complications  
of  the same nature have been recorded wi th  the adm in is t ra t ion  of  
prednisone and prednisolone (Dordick e t  a l , 1956).  The incidence  
here,  however, was considerably higher varying from 18 to 34 per 
cent in a group of rheumatoid a r t h r i t i c  pa t ien ts  (Boland, 1956).
In 1958, Dordick e t  al reported the occurrence o f  haemorrhagic 
skin mani festat ions  in 23.3  per cent of  a group o f  pa t ien ts
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s u f fe r ing  from rheumatoid disorders and t rea ted  wi th prednisone or  
prednisolone. The authors reported that  the lesions disappeared 
completely when the dosage o f  the stero ids  was e i t h e r  lowered or  
discont inued, or when ascorbic acid supplement (1OOmgBfcwice d a i ly )  
was used concominantly.  They concluded that  these phenomena were 
re la ted  to some derangement o f  ascorbic acid metabolism. Possib ly ,  
even more convincing evidence to th is  e f f e c t  is a report  o f  massive 
g a s t ro in te s t in a l  haemorrhage as a complicat ion of  overt  c l i n i c a l  
scurvy which developed 8 days a f t e r  prednisone therapy fo r  rheumatoid 
a r t h r i t i s  (Bartholomew, 1972).
MATERIALS AND METHODS
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A. Mater ia ls  
Substrates
Phenolphthalein glucuronic acid was obtained from Sigma,
London.
Standards
Bovine serum albumin was obtained from BDH Chemicals, 
England. Saccharo 1-4 lactone was purchased from Cal-Biochem,  
London.
Cofactors
Reduced nicotinamide adenine d inuc leot ide  (NADH) was 
obtained from Boehringer,  West Germany.
Other chemicals
Chlordiazepoxide (Librium) was provided by Dr. Long,
Hoffman La-Roche L t d . ,  England. 1-4 Pregnadien-17,21 d i o l —3 ,1 1 ,  
20 t r io n e -2 1 - a c e ta te  (prednisone) was purchased from S tera lo ids  
I n c . ,  New York. 2 ,6  Dichlorophenolindophenol was obtained from 
Sigma, London. L-gulonic  acid-y -1actone was obtained from 
Fluka A .G . , England.
All  other chemicals used were of  Analar grade and were 
purchased from BDH Chemicals, England.
M ater ia ls  fo r  d ie ts
The broad bran and broad oats were purchased from Atkinsons  
& Co. L t d . ,  Gu i ld ford ,  Surrey, England and the dr ied f u l l  cream
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and dried skimmed mi 1k were bought from Unigate L td . ,  Gu i ld ford ,  
Surrey,  England. The s a l t  mixture fo r  the ascorbic a c id - f r e e  
d ie t  was obtained from Glaxo Laborator ies ,  Greenford,  Middlesex,  
England. The dr ied yeast was obtained from DCL L t d . ,  Mitcham, 
Surrey,  England. The magnesium oxide (heavy) and 2-methyl 1-b  
naphthoquinone were purchased from Sigma, London.
B. Diets and Animals
(a) Diets
A s c o rb i^ a c jc H f  !!§£.. di§£
The scorbutogenic d ie t  was b a s ic a l ly  that described by 
Hughes and Hurley (1969) (Appendix I ) .
The ingredients  were mixed in a Hobart mixer fo r  15 minutes.  
Water was then added gradual ly  u n t i l  the mixture was j u s t  wet 
(300 ml/kg food) .  The wet mixture was fu r t h e r  mixed fo r  15 minutes 
and then passed through a Hobart mincer. Thus, the powdered d ie t  
was transformed into  a f a i r l y  hard p e l l e t  form, which was acceptable  
to the animals.  The p e l le ts  were dr ied at  75° overnight and fed 
to the animals.  No ascorbic acid could be detected by chemical 
analys is  in the d ie t  so prepared.
When th is  d i e t  was fed to f i v e  guinea pigs a l l  animals died  
w ith in  1h to 25 days.
(b) An imals 
Gu mea_pjgs
Pure s t r a in  Dunkin-Hart ley male guinea pigs (250-300 gm)
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were used throughout. The animals were purchased from Porcel lus  
Animal Breeding L t d . , H e a th f ie ld ,  Sussex, England. Animals were 
housed in d iv id u a l l y  in metabolic cages (Forth Tech Animal Services  
L t d . ,  M id lo th ian ,  Scot land) .  The cages had a wide wired base and 
separation of  ur ine  and faeces was s a t is f a c t o r y .  They were washed 
on the morning that ur ine  c o l le c t io n  was to commence so as to  
e l im in a te  any leaching of the faeces into the urine  c o l le c te d .  The 
cages were modified a f t e r  purchase so th a t  any water s p i l t  was 
c o l le c te d ,  v ia  a d i f f e r e n t  route from tha t  of  u r in e ,  in to  another  
vessel .  Thus the c o l le c t io n  of  ur ine  was s a t is f a c t o r y .  The 
guinea pigs were t ra ined  to dr ink  d i r e c t  from a fo rce - fe ed ing  needle 
through which the ascorbic acid and the drugs were administered at
10.00 a.m. d a i l y .
The animals were fed an ascorbic acid f r e e  d ie t  and water ad 
l i b . They were s ta b i l i s e d  on o r a l l y  administered ascorbic acid 
(10 mg/kg) fo r  two weeks p r io r  to the commencement of  the experiment.  
Animals tha t  did not perform well  on th is  regime were excluded from 
the study a t  th is  p o in t .  The guinea pigs were then randomly d iv ided  
into  two groups, A, the experimental  and, B, the control  group.
Animals in group A received d a i ly  ascorbic acid (10 mg/kg body weight)  
and prednisone (7 mg/kg body weight in 5% aqueous propylene g ly c o l )  
(section A) or Librium (50mg/kg body weight in s a l in e )  (sect ion B) 
by mouth. Animals in group B received the same amount of  ascorbic
acid per ki logram body weight and an equal volume of propylene  
glycol per ki logram body weight (sect ion A) or sa l ine  (sect ion B) 
as animals in group A without the drug. Both control  and experimental  
animals were weighed d a i ly  a t  10.00 a.m. ± 30 min p r io r  to the 
adm in is tra t ion  of  ascorbic acid and drugs.
Ascorbic acid was measured in the urine over 2h  hours and 
in the selected t issues ,  blood, spleen,  l i v e r  and adrenals ,  p r io r  to  
and fo l lowing the adm in is tra t ion  o f  the drugs, Hepatic cytochrome 
P-A50, cytochrome b,-, hepatic microsomal prote in  and g lu c a r ic  acid in 
the ur ine  were determined p r io r  to ,  and fo l lo w in g ,  the a dm in is tra t ion  
of the drugs as an index of  hepatic  microsomal enzyme induction.
C. Methods
Preparation o f  l i v e r  subfractions
Animals were randomly s a c r i f i c e d  e i t h e r  by cerv ica l  d is lo c a t io n
( ra ts )  or by decap i ta t ion  (guinea p ig s ) .  The l i v e r  was qu ick ly
excised and washed in ice-cold homogenising medium to remove blood.
I t  was gent ly  b lo t ted  on f i l t e r  paper, freed from adhering f a t  and
fibrous t issues ,  and weighed. I t  was then minced wi th  scissors and
homogenised in a glass homogeniser (s ize  C) using a loose f i t t i n g
Teflon pest le  (Pot ter  and Elvehjem, 1936).  For each homogenisation
two up and down strokes were used, the homogenising vessel being kept
in an ice-bath during the process. The volume of  the homogenate was
then adjusted so that  1 ml was equ iva lent  to 250 mg o f  l i v e r  ( r a t )  and
1 ml was equiva lent to 100 mg of l i v e r  (guinea p ig ) .  I t  was then
placed in 50 ml polycarbonate MSE cen t r i fu g e  tubes and centr i fuged
in an MSE 'High Speed 18' cen t r i fu g e  a t  10,000 x g (11,000 rpm) a tav
A0 fo r  20 minutes.  The supernatant was then centr i fuged in an MSE
'Superspeed 50' c en t r i fu g e  a t  105,000 x g (A0,000 rpm) a t  A0 fo ra v
one hour. The supernatant was discarded and the microsomal p e l l e t ,  
so obtained was washed wi th homogenising medium to remove any traces  
of  the supernatant f r a c t i o n .  The p e l l e t  was then resuspended in the 
a l iq u o t  volume taken, using one slow up and down stroke,  in a s iz e  B 
homogenising vessel .  This was the 'microsomal suspension'.
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Preparation o f  other  t issues
The spleen and the adrenals were exc ised,  washed, b lo t te d ,  
freed of any extraneous matte r ,  weighed and homogenised in the  
same way as the l i v e r  in t r i c h l o r o a c e t i c  acid (6% w / v ) . The 
volume of homogenate was adjusted so tha t  1 ml was equ iva lent  to 
19 mg o f  spleen and 1 ml was equiva lent to 25 mg of adrena l .  I t  
was placed in a 50 ml c e n t r i fu g e  polycarbonate tube and centr i fuged  
in an MSE 'M is t ra l  6L ' c en t r i fu g e  a t  2,500 rpm a t  A0 fo r  15 minutes.  
The supernatant was reta ined fo r  the appropr ia te  est imations.
For hepatic  ascorbic acid es t im at ions ,  l i v e r  homogenate 
(1 ml) was added, immediately fo l lowing homogenisation, to 6% (w/v)  
t r i c h lo r o a c e t i c  acid (A m l) ,  mixed and centr i fuged in an MSE 
'M is t ra l  6L ' c en t r i fu g e  a t  2,500 rpm a t  A0 fo r  15 minutes.  The 
supernatant was re ta ined.
Serum (1 ml) fo r  ascorbic acid determination was mixed wi th  
6% w/v t r i c h l o r o a c e t i c  acid (A ml) and allowed to stand a t  room 
temperature fo r  5 minutes.  I t  was then centr i fuged as previously  
out l ined  and the supernatant was re ta ined .
General experimental  conditions
The fo l lowing standard condit ions were observed fo r  
purposes of un i formity  and r e p r o d u c ib i l i t y  as well  as fo r  v a l id  
d i r e c t  comparison.
In order to avoid d i f fe rences  a r is in g  from diurna l  v a r i a t i o n s ,  
guinea pigs were k i l l e d  a t  6.00 a.m. ± 30 minutes and a l l  operat ions
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were complete w i th in  1.5 hours. A l l  ascorbic acid est imations  
were performed on the day of  e x t rac t io n  to avoid losses due to 
storage.
Microsomal preparat ions were prepared i n ' i s o t o n i c  KC1 (1.15%) 
in 0.01 M phosphate b u f fe r  pH 7 . A.
A l l  animals used were kept in a constant environment.  The 
temperature was maintained a t  22° ,  humidity a t  50 per cent and the  
l i g h t in g  was on a twelve-hour 1ight-darkness system. No insec t ic ides  
were used in the animal house.
Chemical determinations  
^l2r2§2!T§l_9Y£22!]r2!T®-£l^50_content
Cytochrome P-A 50 ,  the terminal  mixed function oxidase,  was 
measured by means of  i ts  CO-ligand binding reduced spectrum a t  
A50 nm as described by Sladek and Mannering, 1 966 .  An a l iq u o t  of  
the microsomal suspension d i lu te d  ( 1 : 3 )  with 0.1 M phosphate b u f fe r  
pH 7 . A was added to two 1 cm glass cuvettes .  A few granules of  
sodium d i t h i o n i t e  were added to both cuvettes and CO bubbled through 
one of the cuvettes fo r  about 30 seconds. The d i f fe re n c e  spectrum 
between 390 and 500 nm was measured in a Pye Unicam SP 1800 dual 
beam recording spectrophotometer, and the cytochrome P-A50  
expressed as the d i f fe re n c e  in opt ica l  density  between A50 and A90 nm, 
and converted to nmoles using an e x t in c t io n  c o e f f i c i e n t  o f  91 mM/cm 
(Omura and Sato, 196A) .
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t}i2r2§2!Il§l_9Y^ 29!]r2!Il?_^ 5-- - - - - - -
Cytochrome was measured as the d i f fe re n c e  spectrum of  
NADH reduced microsomes against oxidised microsomes by the method 
of  Schenkman, Remmer and Estabrook (1967).
Microsomal suspension was d i lu te d  (1 :3 )  w ith  0.1 M phosphate 
buf fe r  pH 7*4 and added into two 1 cm glass cuvettes .  In one 
cuvette  0.1 ml NADH (1 mg/ml) was added and a d i f fe re n c e  spectrum 
was obtained between 390 and 450 nm in a Pye Uni cam SP 1800 dual 
beam recording spectrophotometer. Cytochrome b^ was expressed as 
the d i f fe re n c e  in o p t ic a l  density  between the trough and the peak,  
namely 410 and 426 nm, and converted to nmoles using an e x t in c t io n  
c o e f f i c i e n t  of  185 mM/cm (Omura e t  a l , 1964).
l^2E2§2!T2l_2r2£2iD_22Di2D£
The method used was that described by Lowry e t  al (1951)•
An a l iq u o t  of  t issue  (0 .5  ml) in 0.5 M NaOH containing  
prote in  (<300 yg) was added to 0.5  M NaOH (0 .5  m l ) .  Copper 
reagent, f r e s h ly  prepared,  (5 .0  ml) was added. The mixture was 
thoroughly mixed and allowed to stand fo r  10 minutes a t  room 
temperature. Fo l in -C ioca l tea u  phenol reagent (d i lu te d  1:2 wi th  
d i s t i l l e d  water)  (0 .5  ml) was then added and the tube was 
immediately mixed. The blue colour was read a f t e r  30 minutes a t  
720 nm, in a Pye Unicam SP 500 semiautomatic spectrophotometer.
Su i tab le  t issue  blanks and standards (0-250 yg o f  bovine 
serum albumin) were c ar r ied  through the same procedure.
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The copper reagent was prepared by mixing 1 per cent CuSO^.
5H2O (1 .0  ml) w i th  2 per cent potassium t a r t r a t e  (1 .0  ml) and 2 per 
cent ^ 2 ^ 2  (100 ml) .
Il2§y2_2222r^ i£_§2i^ _^ 2i2I!IlD§£i2D
The method used was th a t  based on the coupling o f  the 
oxidat ion  product o f  ascorbic a c id ,  dehydroascorbic a c id ,  w i th  2-4  
din i t rophenylhydraz ine  forming an ozazone, which absorbs maximally 
at' 520 and 360 nm (Roe and Kuether,  1943).  The incubation period  
was shortened as described by Geschwind, Wil l iams and Li (1951).
To an a l iq u o t  o f  the t issue  supernatant (20 m l ) ,  obtained 
as previously  described,  acid washed n o r i t  (0 .75  gm) was added, 
thoroughly mixed and f i l t e r e d  (Whatman No.1, 11.0 cm paper) .
To an a l iq u o t  o f  the f i l t r a t e  (4 ml) two drops, from a 
Pasteur p ip e t te  (50 drops/ml) ,  of  th iourea (10% w/v in 50% v /v  
aqueous ethyl  alcohol)  and 2% w/v 2 - 4 , d in i trophenyl  hydrazine in 
9N (1 ml) was added. The mixture was incubated a t  57° f o r
45 minutes in a water bath.  The mixture was cooled in ice water  and, 
whi le  in the ice water ,  85% sulphur ic  acid (5 ml) was slowly added 
and mixed. The mixture was allowed to stand a t  room temperature  
fo r  f o r t y - f i v e  minutes before reading the op t ic a l  density  in a 
Uni cam SP 500 spectrophotometer a t  520 nm.
Appropriate t issue  blanks,  which were not h e a t - t r e a t e d ,  and 
standards (0 -1 .6  mg ascorbic acid)  were set up and car r ied  through 
the same procedure.
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The method is h ighly  s p e c i f ic  fo r  ascorbic a c id ,  and 
substances such as hexoses, pentoses and glucuronic acid do not 
i n t e r f e r e  at  t h e i r  normal physiological  t issue  lev e ls .  L-Gulonic  
a c id -y - la c to n e  did not in t e r f e r e  with  the method over a range of  
0-500 mg/100 ml. Recovery of  added ascorbic acid ranged from 92 
to 101 per cent.
yElQ 3EY..§scgrbi.c_ac|d_determ im at i^n
The animals were kept in indiv idual  metabolic cages and 
ur in e ,  fo r  ascorbic acid determination was co l lec ted  fo r  24 hours.  
Metaphosphoric acid (20% w/v) was used as the p reservat ive  agent.
The method used fo r  ascorbic acid determinat ion was the one 
based on the reduction of  an a c id ic  so lu t ion  of  the redox dye, 2 ,6  
dichlorophenol indophenol, by ascorbic acid .
The ur ine was centr i fuged at  2,000 rpm fo r  ten minutes and 
passed through a cat ion exchange resin (Zeo-Carb 225, mesh s ize  
52-100) to e l im in a te  compounds i n t e r f e r in g  wi th  ascorbic acid 
determination (Hughes, 1964). The glass column was 30 cm in 
length,  1.2 cm in diameter and 10 cm was packed. A c t iv a t io n  was 
carr ied  out by washing f i r s t  with 2N-NaOH (30 ml) and then water  
u n t i l  washings were no longer a l k a l in e .  The column was then 
washed with  2N-HCL (30 ml) and then water u n t i l  the e lu a te  was no 
longer ac id .  The resin was reac t iva ted  a f t e r  s ix  ur ine samples 
were run through and fresh resin was used a f t e r  three re a c t i v a t io n s .
Urine a l iq u o ts  (6 .0  ml) in metaphosphoric acid (2% w/v)  were 
added to the column through a p ip e t te  and e lu ate  co l le c ted  in a 
graduated c y l in d e r  containing 20% w/v metaphosphoric acid (2 m l ) .
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The column was washed with  water u n t i l  the e lu a te  was no longer  
acid .  The f i n a l  volume ranged from 28-30 ml. A l iquots  of  the 
e lu a te  (3 ml) and phosphate b u f fe r  pH 2 .3  (2 ml) were added to  
glass cuvettes (2 cm opt ica l  path) and mixed thoroughly.  The 
dye (2 ml) was added and quick ly  mixed. The opt ica l  densi ty  a t  
520 nm was noted,  15 seconds fo l lowing mixing,  in an Evans 
Electroselenium pho to e lec t r ic  co lo r im ete r .
Appropriate blanks and standards (0 -0 .4  mg ascorbic acid)  
were c arr ie d  through the same procedure. Recovery of  added 
ascorbic acid to the ur ine ranged from 88-97 per cent.
Ur inary D-g lucar ic  acid est imation
Pr me i_pl_e
D-Glucaric acid is converted to saccharo-1 ,4 - 1 actone in 
acid pH on b o i l in g .  The l a t t e r  in h ib i t s  the a c t i v i t y  of  8“ 
glucuronidase,  the in h ib i t io n  being re la ted  to the concentrat ion  
of the lactone,  (Marsh, 1963).
^E2E§E§^l2G_2f _E§£_l^vei^§-g jucuronj dase
Rat l i v e r  was homogenised in 0.02 M aceta te  b u f fe r  pH 5 .2
(1 ml equiva lent to 100 mg l i v e r ) ,  centr i fuged a t  3,000 x g atav
4° fo r  15 minutes in a 'High Speed 18' MSE c e n t r i f u g e ,  and the 
supernatant kept a t  4 ° .  A d i l u t i o n  (1 :7 )  o f  the supernatant was 
used fo r  the assay. A fresh preparat ion was made fo r  each assay.
l E 2§tment_of_the_urme
One of the two ur ine a l iquots  (5 ml) was adjusted to pH 2 .0  
with 3N HC1 (a) and the other to pH 8 .0  with  0.5 N NaOH ( b ) . Both
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a l iq u o ts  were placed in a b o i l in g  water bath fo r  40 minutes,  cooled 
and the pH o f  (a) was adjusted to 4 .0  with  0.5  N NaOH and of (b) to
6 .0  wi th 3 N HC1. The volume of both ur ine a l iquots  was made up 
to 10 ml with  water.  This const i tu ted  the ur ine  f r a c t i o n .
incubation
The incubation mixture consisted o f :
Acetate buf fer  pH 5 .2  (100 ymol) 0 .5  ml
Phenolphthalein glucuronide sodium s a l t  0.25 ml
(2 .5  ymol, cinchonidine f ree )
Urine f r a c t io n  (a) and (b) separate ly  or 1.0 ml
saccharo-1 ,4 - lacto ne
Di luted 6-glucuronidase preparat ion 0.25 ml
The mixture was incubated a t  37° fo r  60 minutes,
and glycine  b u f fe r  pH 10.7 (800 ymol) 2 .0  ml
was added, mixed, and the op t ica l  densi ty  
read at  440 nm in Uni cam SP 500 semi­
automatic spectrophotometer.
A p lo t  of  per cent i n h ib i t io n  vs concentrat ion of  saccharo-  
1 , 4 - lac tone  was constructed and the concentrat ion of  saccharo-1 ,4 -  
lactone in ur ine  a l iquo ts  (a) and (b) was read o f f  the curve.  The 
actual  u r inary  g lu c a r ic  acid concentrat ion was the d i f fe re n c e  
between the two values.  The conversion of  D-g lucar ic  acid to  
saccharo-1 ,4 - lacto ne was only 1/3 complete under the experimental  
condit ions employed.
Appropriate blanks and standards (0 .4  ymol saccharo-1 ,4 -  
lactone) were set up and carr ied  through the same procedure, except  
tha t  the standards were not bo i led .
-  62 -
The method suf fe rs  from the serious disadvantage in tha t  
the standards were not c ar r ie d  through the same procedure as the 
t e s t  u r ine .  However, i t  has been proved consistent enough and 
c e r t a i n l y  s u f f i c i e n t l y  accurate  f o r  comparison of  the excre tory  
values in control  and t rea ted  animals.
S t a t i s t  ics
The resul ts  in th is  thesis are expressed as the a r i t h m e t ic a l  
means ± S.E.M. and the means were compared by the s tudent 's  t  t e s t .  
To obta in  the value o f  P a degree of  freedom o f  ^  -  1 was
assumed in a l l  c a lc u la t io n s .
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SECTION A
The E f fe c t  of  Prednisone on Ascorbic Acid Metabolism 
Results
The 24 hour excret ion pattern  of  ur inary  ascorbic acid  
showed no d i f fe re n c e  between control and t rea ted  animals during  
the f i r s t  10 days fo l low ing  adm in is t ra t ion  of  the drug. On 
the 26th and 35th day of  medication,  however, the trea ted  animals  
excreted s i g n i f i c a n t l y  less ascorbic acid than contro ls  (Table 2 .1 )  
and they continued to excrete  less on the 46th and 55th day o f  
medication although the d i f fe re n ce  was not s ig n i f i c a n t  on these  
days. The ascorbic acid excre t ion  of  t rea ted  animals returned  
to control  leve ls  on the 78th day of  the study.  Thus, a t ra n s ie n t  
decrease in excretory  leve ls  of  ascorbic acid was seen which 
returned to normal a f t e r  78 days of  drug a d m in is t ra t ion .
A f te r  t h i r t y  days of  prednisone ad m in is t ra t io n ,  3 o f  the 8 
t rea ted  animals developed open, d i f fu s e d ,  skin lesions around the  
neck and back, along the spinal  column. The lesions were haemor­
rhagic.  They were slow to heal and spontaneously disappeared .on 
the 60th day o f  medication.
There was no d i f fe re n c e  in the concentrat ion of  ascorbic  
acid in the t issues of  contro l  and t rea ted  animals a f t e r  35 and 
85 days of  medication (Table 2 . 2 ) .
There was no evidence of  hepat ic  enzyme induction in the  
t rea ted  animals as judged by the leve ls  o f  P-450, b^, microsomal 
prote in  (Table 2 .3 )  and ur inary  D -g lucar ic  acid excret ion  
(Table 2 . 4 ) .
The decrease in u r inary  ascorbic acid excre t ion in the 
t rea ted  animal and the subsequent return to normal control  leve ls  
of  excre t ion  was thought to be in d ic a t iv e  of  e i t h e r  adaptat ion or  
t issue  ascorbate re d is t r ib u t io n  or de novo synthesis o f  ascorbic  
acid in response to the drug. In view of the f ixed  d a i ly  intake  
of ascorbic acid of  these animals the p o s s i b i l i t y  of  de novo 
synthesis was thought more l i k e l y  and the experiment was repeated 
to inves t iga te  th is  p o s s i b i l i t y .  The animals were in jec ted  
subcutaneously with  L-gulono-y-1actone (330 mg/kg),  the immediate 
precursor of  ascorbic ac id ,  a f t e r  79 days of  drug adm in is t ra t ion  
and the same parameters were studied as previously  described.
The synthesis of  ascorbic acid from L-gulono-y-1actone  
was tested in the r a t .  Table 2 .5  shows the marked increase in 
ur inary  ascorbic acid excret ion in male W is ta r -a lb in o  ra ts  fo l low ing  
the subcutaneous in je c t io n  of  L-gulono-y-1actone (330 mg/kg body 
weight) fo r  5 days.
Table 2 .6  shows a s im i la r  pa ttern  of  ur inary  ascorbic  
excre t ion to tha t  of  Table 2 .1 .  The s ig n i f i c a n t  decrease in the 
excre t ion occurred,  however, on the 34th and 44th day fo l low ing  
the admin is tra t ion  of  prednisone.  I t  can also be seen th a t  there  
is a n o n -s ig n i f i c a n t  increase in the excret ion of  ascorbic acid  
during the f i r s t  ten days fo l lowing medication.  Furthermore,  the 
excre tory  pattern  of  ascorbic acid did not change in response to  
the in je c t io n  of  L-gulono-y-1actone on the 79th day of 
exper imentat ion.
The ascorbic acid leve ls  in the t issues of  both control  and 
experimental  animals were not s i g n i f i c a n t l y  d i f f e r e n t  a f t e r  56 days
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of medication (Table 2 . 7 ) .  Fol lowing the in jec t ions  of  L-gulono-  
y - la c to n e  on the 79th day, however, the levels  of  ascorbic acid in 
the adrena ls ,  l i v e r  and spleen o f  the t rea ted  animals on the 85th 
day of medication is s i g n i f i c a n t l y  higher than the control le v e ls .  
In con trast ,  the blood ascorbate levels  of  the t rea ted  animals is 
s i g n i f i c a n t l y  lower than the control  lev e ls .
There was again no evidence of induction in the t rea ted
animals (Tables2.8 and 2 . 9 ) .
Contrary to the observation in the o r ig in a l  experiment,  none
of the animals developed skin lesions throughout the period of
th is  study.
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Table 2.1 Ur inary  excret ion  of  ascorbic acid in guinea 
pigs (± SEM) p r io r  to and fo l lowing the oral  
adm in is t ra t ion  of  prednisone (7 mg/kg).
Time (days)
Ur inary excre t ion  of  ascorbic acid  
(mg/24 hr)
Control Prednisone
Premedication 0 . 3 2  ± 0 . 0 4 (10 ) 0 . 3 5  ± 0 . 0 2 (10 )
Premed i cat  ion 0 . 2 8  ± 0 . 0 5 (10 ) 0 . 3 2  ± 0 . 0 5 (10 )
Days of  
treatment
1 0 . 2 7  ± 0 . 0 5 ( 8) 0 . 3 2  ± 0 . 0 5 ( 8)
10 0 . 2 9  ± 0 . 0 7 ( 8) 0 . 3 0  ± 0 . 0 3 ( 8)
26 0.31  ± 0 . 0 4 * ( 8) 0 . 1 8  ± 0 . 0 6 * ( 8 )
35 0.31  ±
o
•
O
( 8) 0 . 1 7  ±
+
0 . 0 5 ( 8)
46 0 . 2 0  ± 0 . 0 4 ( 4) 0 . 1 7  ± 0 . 0 2 ( 4)
55 0 . 2 6  ± 0 . 0 4 ( 4) 0 .21  ± 0 . 0 6 ( 4)
78 0 . 2 3  ± 0 . 0 6 ( 4) 0 . 2 4  ± 0 . 0 3 ( 4)
S t a t i s t i c a l  s ig n i f ic an ce  as compared wi th controls  
*p <0.05  
t p  <0.025
Numbers in parentheses ind ica te  the number of  animals 
in each group and a t  each point of  the period of  drug 
treatment.
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Table 2 .4  Urinary  g lu c a r ic  acid excret ion (± SEM) p r io r  to 
and fo l lowing the oral  adm in is tra t ion  of  
prednisone (7 mg/kg body weight)
Time (days)
Glucar ic acid excret ion  
(ymol/24 hr ur ine)
Control Predni sone
Premedication  
Day o f  treatment  
10 
40 
60
0.30 ± 0.07 (10)
0.30 ± 0.10 ( 8) 
0.31 ± 0.06 ( 4) 
0.32 ± 0.07 ( 4)
0.28 ± 0.05 (10)
0.27 ± 0.05 ( 8) 
0.35 ± 0.14 ( 4) 
0.28 ± 0.06 ( 4)
D if ferences not s ig n i f i c a n t
Numbers in parentheses ind ica te  the number of  animals 
in each group and a t  each point of  the period o f  drug 
treatment.
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Table 2 .5  Ur inary excre t ion of  ascorbic acid (± SEM) in 
ra ts  p r io r  to and fo l lowing the subcutaneous 
i n je c t io n  o f  L -gu lono-y- lactone (330 mg/kg 
body weight)  fo r  6 days.
Time (days)
Urinary excre t ion  of  ascorbic acid 
(mg/24 hr)
Control L-Gulono-y- lactone
Premedication 0.20 ± 0.03 (6) 0.20 ± 0.03 (6)
0.19 ± 0.02 (6) 0.21 ± 0.002 (6)
Day of treatment  
1 0.22 ± 0 .0 1 * (6) 0.46 ± 0 .11* (6)
3 0.21 ± 0 . 02§ (6) 0.57 ± 0.09§ (6)
5 0.25 ± 0.03 (6) 0.68 ± 0.10 (6)
6 0.26 ±
(NOo (6) 0.72 ± 0.1 Of (6)
8 0.21 ± 0 . 0 1§ (6) 0.49 ± 0.07§ (6)
10 0.28 ± 0.03 (6) 0.35 ± '0.09 (6)
12 0.24 ± 0.01 (6) 0.24 ± 0.02 (6)
S t a t i s t i c a l  s ig n i f ic a n c e  as compared with  controls
*p <0.05  
t p  <0.0025  
^p <0.0005
Numbers in parentheses ind ica te  the number of  animals 
in each group and a t  each point o f  the period of  
treatment.
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Table 2 .6  Ur inary  ascorbic acid excre t ion  (± SEM) in 
guinea pigs p r io r  to and fo l lowing the oral  
adm in is t ra t ion  of  prednisone (7 mg/kg) and 
then subcutaneous in je c t io n  o f  L-gulono-y-  
lactone (330 mg/kg) on the 79th day of  
exper imentat ion.
Time (days)
Ur inary excre t ion  o f  ascorbic acid 
(mg/24 hr)
Control Predn i sone
Premed ica t  ion 0.31 + 0 .02 (12) 0.32 + 0 .05 12)
Premedication 0.35 + 0 .04 (12) 0.30 + 0 .06 12)
Premedication 0.28 ± 0 .04 (12) 0.31 + 0 .03 12)
Day of treatment
1 0.32 ± 0 .04 (10) 0.43 + 0 .01 10)
3 0.29 ± 0 .02 (10) 0.43 + 0 .07 10)
6 0.30 i 0 .01 (10) 0.39 + 0 .01 10)
10 0.27 + 0 .05 d o ) 0.32 + 0 .07 10)
20 0.29 i 0 .03 (10) 0.26 ± 0 .07 10)
27 0.29 + 0 .03 (10) 0.23 + 0 .05 10)
34 0.30 i 0 .03’v d o ) 0.18 + 0 .04* 10)
44
<i) 0.31
+ 0 . 02§ (10) 0.16 + 0 .03§ 10)
55 cO4_J 0.28
+ 0 .03 (10) 0.20 + 0 .03 10)
74 o(0 0.28 ± 0 .02 ( 6) 0.29 + 0 .03 6)
79
1>-1 0.29 + 0 .02 ( 6) 0.31 + 0 .05 6)
80 oco 0.32
+ 0 .05 ( 6) 0.30 + 0 .03 6)
82 D 0.30 + 0 .05 ( 6) 0.32 + 0 .05 6)
84 1
. _ ___ (
0.31 0 .05 ( 6 ) 0.32 + 0 .06 6)
S t a t i s t i c a l  s ig n i f ic a n c e  as compared wi th  controls  
*p <0.025  
§ p <0.0005
Numbers in parentheses ind ica te  the number of  animals in 
each group and a t  each point of  the period of  drug t rea tment .
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Table 2 .9  Ur inary  D-g lucar ic  acid excret ion (± SEM) p r io r
to and fo l low ing  the a dm in is tra t ion  o f  prednisone  
(7 mg/kg) and the subcutaneous in je c t io n  o f  L- 
gulono-y - lactone (330 mg/kg) on the 79th day of  
experimentat ion.
Time (days)
Ur inary excre t ion  of  D -g lucar ic  acid  
(ymol/24 hr)
Control Prednisone
Premed ica t  ion 
Day of  treatment  
25 
85
0.31 ± 0 . 0 k  (12)
0 .29 ± O.O^ f (10)
0 .28 ± 0 . 0 k  ( 6)
0.29 ± 0.07 (12)
0.31 ± 0 .06  (10) 
0.21 ± 0.03 ( 6)
Differences not s i g n i f i c a n t
\
Numbers in parentheses ind ica te  the number of  animals in 
each group and a t  each point of  the period of  drug 
treatment .
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Pi scuss ion
The ora l  adm in is t ra t ion  of  prednisone to  guinea pigs has 
been shown to a l t e r  the pa t te rn  o f  u r inary  excret ion of  ascorbic  
acid w i th  no apparent e f f e c t  on the t issue  leve ls  of  the v i tam in .
The subcutaneous adm in is tra t ion  of  L -gulono-y- lac tone ,  an ascorbic  
acid precursor,  in prednisone-t reated and non-t reated animals indicated  
de novo synthesis o f  v i tamin C in the prednisone-t reated guinea pigs .
Increased ur inary  ascorbic acid excre t ion in response to  
acute adm in is tra t ion  of  drugs has been reported in the ra t  and has 
been a t t r ib u t e d  to increased synthesis of  the vitamin (Conney e t  a 1 , 
1961).  The mechanism, however, by which prednisone p r e c ip i t a t e s  
a s im i la r  e f f e c t  fo r  the f i r s t  ten days of  a prolonged a dm in is tra t ion  
period (Table 2 .6 )  in guinea p igs,  a species unable to synthesise  
ascorbic ac id ,  is not c le a r .  Increased ur inary  ascorbic acid 
excret ion over the same ten day period has also been reported in man 
in response to acute adm in is t ra t ion  of  t e t r a c y c l in e  (Windsor, Hobbs, 
Treby £ Cowper, 1972) and diphenylhydantoin (Loh, 1973)* I t  is 
possible tha t  the metabolism of these drugs e n t a i l s  an increase in 
the excret ion of  ascorbic acid or a l t e r s  i ts  t issue  a v a i l a b i l i t y  or  
both. With respect to the l a t t e r ,  i t  has recent ly  been shown tha t  
the presence of alcohol in the perfus ion medium of  a ra t  l i v e r  
perfusion system, s i g n i f i c a n t l y  increased the release of  ascorbic  
acid and other vitamins from the l i v e r  ( S o r r e l l ,  Baker, Barak £
Frank, 197*0. Furthermore,  a s p i r in  has been shown to i n h i b i t  the  
uptake of  ascorbic acid in to  leucocytes (Loh, Waters £ Wilson, 1973)•
I f  any of  these p o s s i b i l i t i e s  occurs with  prednisone,  then a 
temporary increase in plasma ascorbic acid would lead to  increased
-  76 -
loss of  ascorbic acid in the urine because the renal threshold may 
be exceeded, although a t rue  renal e f f e c t  of  the drug cannot be 
excluded.
Most o f  the studies reported in the l i t e r a t u r e  are concerned 
with the e f fe c ts  of  acute drug ad m in is t ra t io n ,  the e f f e c t s  of  
chronic drug a dm in is tra t ion  having been e i t h e r  ignored or a t  the  
best received very l i t t l e  a t t e n t io n .  The importance o f  the l a t t e r  
assumes even g reater  proport ions,  i f  one considers th a t  many drugs 
are administered c h ro n ic a l ly  and that  t h e i r  e f f e c t s ,  adverse or  
otherwise,  are  o f  g reater  relevance to the l i v i n g  organism than 
any t ra n s ie n t  e f fe c ts  re su l t in g  from the acute adm in is tra t ion  of  
drugs.
Prolonged a dm in is tra t ion  o f  prednisone reduces the excre t ion  
of ur inary  ascorbic acid (Tables 2.1 and 2 . 6 ) ,  an e f f e c t  opposi te  
to that observed over the f i r s t  ten days o f  drug a d m in is t ra t io n .  
Reduction of  the ur inary  leve ls  of  the vitamin may be viewed as 
evidence o f  biochemical ascorbic acid d e f ic ie n c y ,  ind ica t ing  tha t  
prednisone induces increased catabolism of  the v i tamin ,  which on a 
long-term basis and in the absence o f  supplementation or synthesis  
leads to a de f ic iency  s ta te .  In support of  the exis tence o f  a 
def ic iency  s ta te  is the f ind ing  t h a t  decreased ur inary  e xcre t ion  
of ascorbic acid is accompanied by haemorrhages of  the skin an 
observation compatible wi th  de f ic ie nc y  sta tes  in the guinea p ig .
I t  is not re a d i ly  understood, however, why these skin lesions did 
not appear when the experiment was repeated,  despite  the fa c t  th a t  
necessary steps were taken to ensure re produc ib i1i t y  of  condi t ions  
as c lo se ly  as possible .  In studies on humans, skin lesions
-  77 -
fo l lowing prednisone adm in is t ra t ion  occur in only a proport ion  
(23 per cent)  o f  the pa t ien ts  studied (Dordick,  e t  a l , 1958).
This may, a t  leas t  p a r t l y ,  expla in  the discrepancy observed.
The maintenance o f  normal t issue  ascorbate leve ls  by the 
trea ted  animals (Tables 2 .2  and 2 .7 )  is of  special i n t e r e s t ,  
p a r t i c u l a r l y  in the face of  decreased ur inary  ascorbic acid e xc re t io n .  
The r a p id i t y  wi th  which a de f ic ie ncy  disease appears in animals in 
response to a d ie t  containing suboptimal concentrat ion of  an 
essentia l  n u t r i e n t ,  or to  increased requirements fo r  the n u t r i e n t ,  
w i l l ,  in p a r t ,  depend upon the a b i l i t y  of  the t issues to re t a in  the 
n u t r i e n t .  Ascorbic acid is ra p id ly  lost  from the t issues o f  guinea 
pigs rece iv ing suboptimal intakes of  the vitamins and t h i s ,  no doubt,  
has a determinant ro le  in the rapid onset of  de f ic iency  in the  
species (Penney £ Z i l v a ,  19**6). I t  has been shown that in guinea 
pigs rece iv ing suboptimal intakes of  ascorbic a c id ,  the t issues which 
have high requirements fo r  ascorbic a c id ,  e .g .  eye lens,  b ra in ,  
develop a greater - than-average  re ten t ion  o f  the vitamin (G in te r ,
Bobek £ Gerbelova,  1965). Moreover, when dr ied skim-milk is fed 
as the primary source of  p ro te in ,  and a t  low ascorbic acid in take ,  
two c r i t e r i a  met in th is  ser ies  of  experiments,  the a s c o rb a te - re ten t io n  
by guinea pig t issues ,  e .g .  adrena l ,  spleen,  is s i g n i f i c a n t l y  
enhanced (Rhiannon, Wil l iams £ Hughes, 1972). I t  may the re fo re  
be that an enhanced t issue  re tent ion  reduces the ra te  of  dep le t ion  
and masks any e f f e c t  th a t  the drug might have had on t issue  
ascorbate.  The f u r t h e r  p o s s i b i l i t y  tha t  an in c ip ie n t  slow ra te  
of  biosynthesis o f  ascorbic acid may help maintain the t issue  
ascorbate of  the treated animals at  control  leve ls  w i l l  be discussed 
l a t e r .
There was no evidence of  hepatic microsomal enzyme induction  
under the experimental  condit ions employed, as judged by the micro­
somal leve ls  of  cytochrome P-**50, cytochrome b^, prote in  (Tables 
2 .3  and 2 .8 )  and u r inary  D-g lucar ic  acid excre t ion  (Tables 2 . k  
and 2 . 9 ) , fo l lowing the adm in is tra t ion  of  prednisone.  The drug,  
however, is known to be a potent enzyme inducer in the r a t  (Tredger,  
Chakraborty S Parke,  197*0 • I t  is possible  tha t  the absence of  
induction in the guinea pig is a species d i f fe re n c e  or tha t  is due 
to low ascorbic acid intakes.  With respect to the l a t t e r ,  i t  has 
recently  been shown that  suboptimal intakes o f  ascorbic acid lead 
to ( i )  a decrease in the hepatic  microsomal cytochrome P-*f50 
concentrat ion and the amount of  cytochrome bj. (Degkwitz,  Kaufmann, 
Luff  & Standinger,  1972),  ( i i )  to an a l t e r a t i o n  of  the s u b st ra te -  
binding propert ies  o f  cytochrome P-*t50 (Gundermann, Degkwitz & 
Standinger,  1973) and ( i i i )  a decrease in the a c t i v i t i e s  o f  several  
drug-metabol iz ing enzymes, e .g .  a n i l i n e  hydroxylat ion and aminopyrine 
N-demethylat ion,  when microsomal ascorbic acid is reduced to about 
30 per cent of  normal values (Zannoni, e t  a l , 1972).
The progressive increase in ur inary  ascorbic acid excre t ion  
from about the ***fth day onwards fo l lowing the adm in is t ra t ion  of  
prednisone (Tables 2.1 and 2 .6 )  was in te rpre ted  as in d ic a t iv e  of  
ascorbic acid biosynthesis in view of ( i )  the f ixed  d a i ly  intake  
of the v i tam in ,  ( i i )  the rapid r e d is t r ib u t io n  c h a r a c t e r is t i c s  of  
ascorbate in r e la t io n  to intake (t'£ = k days) and ( i i i )  the ra ther  
l a te  onset o f  the increase in ur inary  e xc re t io n .  I f  indeed b io ­
synthesis was the explanation then increased provision of  an 
ascorbic acid precursor should enhance such synthesis.
The e f fec t iveness  o f  L-gulono-y- lactone as a precursor of  
ascorbic acid was demonstrated in the ra t  (Table 2 . 5 ) .  I t  is 
seen tha t  subcutaneous adm in is t ra t ion  led to a marked increase  
in the u r inary  output of  the v i tam in ,  in agreement with  previous  
data (Isherwood, Chen, Mapson, 195**). Rat t issues are known to
be saturated with  regard to ascorbic acid and any surplus ascorbic  
acid synthesised would appear in the ur ine .
The adm in is tra t ion  of  L -gulono-y- lactone v ia  the same route  
and over the same period of  time did not e l i c i t  any increase in 
the ur inary  output of  ascorbic acid in the guinea pig (Table 2 . 6 ) .
There was, however, an increase in the concentrat ion of  ascorbic  
acid in the adrenals ,  spleen and l i v e r ,  and a decrease in the plasma 
leve ls  (Table 2 .7 )  ind ica t ing  biosynthesis o f  ascorbic acid from 
L-gulono-y- lactone.  The low c i r c u la t in g  plasma ascorbic acid  
leve ls  may r e f l e c t  enhanced uptake of  the vitamin by the t issues  
in view of t h e i r  r e l a t i v e l y  d e f i c ie n t  s ta te .  The gulono-y-1actone  
at  0-500 mg/100 ml : did not i n t e r f e r e  w i th  the est imation o f  
ascorbic acid when added d i r e c t l y  to the t issue  f i l t r a t e  or homogenate.
Controversy concerning whether or not the guinea pig can syn­
thesise ascorbic acid has been much revived (Odumosu & Wilson, 1973; 
Barnes, Constable,  Impey S Kodicek, 1973)•  The controversy centres  
around the presence or absence in the guinea pig of  the enzyme 
gulono-y- lactone oxidoreductase ( F i g . 2 . 1 ) ,  and the present f ind ings  
add to the corpus o f  a v a i l a b le  knowledge.
- so -
UDP-G1ucose
UDP-Glucose
dehydrogenase
UDP-a-D-Glucuronic Acid
V
a-D-Glucuronic  Acid
L-GuIonic Acid D-Glucuronolactone
o+A*'L-Gulonolactone Vy
D-g1ucu ronolactone  
dehydrogenase
/ > ! >
D -g lu ca r ic  acid
Gulonolactone 
oxidoreductase  
(microsomal)
L-Ascorbic Acid
F i g . 2.1 Pathway o f  ascorbic acid biosynthesis
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C e r ta in ly ,  ascorbic acid is synthesised from L-gulono-y- lac tone  
in the ra t  (Burns, Peyser S Ho l tz ,  1956; Hussan & Lehuninger,  1956) and 
L-gulono-y- lactone oxidoreductase is present in the ra t  p r i n c i p a l l y  in 
l i v e r  microsomes (Horowitz S King, 1953; Isherwood, Mapson & Chen, 1960; 
Cohen, 1961).  This enzyme has been demonstrated in the microsomal 
f r a c t io n  o f  embryonic guinea pig l i v e r  but was absent from microsomal 
preparations from adul t  animals (De Fabro, 1968). This has been 
a t t r i b u t e d  to to t a l  or p a r t i a l  suppression o f  synthes is ,  or production o f  
an in ac t ive  enzyme form, the re s u l t  o f  a gene-contro l led  enzyme 
dysfunction (Snyder, 1959)•
Biochemical in d i v i d u a l i t y  wi th regard to the need of exogenous 
ascorbic acid has been demonstrated in the guinea pig (Wil l iams S Deason, 
1967) and s im i la r  v a r i a b i l i t y  has recent ly  been documented in man 
(Ashida, Funahashi, Aoyama e t  a l , 1972).  Whether th is  is due to 
n u t r i t i o n a l  a d a p t a b i l i t y  by re ta rd ing the ra te  of  breakdown of ascorbic  
acid and the ra te  o f  i t s  u r inary  excre t ion ,  or to v a r i a b i l i t y  in rates  
of  synthesis o f  ascorbic ac id ,  by a lesser or greater  dominance of  the  
gene-controMed enzyme dysfunct ion,  is not c le a r .
Perhaps the most important l i m i t a t io n  of  a l l  previous studies  
concerning ascorbate synthesis in guinea pig is the lack of  information  
regarding the s ta te  o f  t issue  s a tura t ion  with  the v i tam in .  There are  
innumerable po te n t ia l  in te rac t ions  between genetic  d is p o s i t io n  and 
environmental inf luences (Snyder, 1959),  and pathological  consequences 
may be overcome by environmental fac tors  such as stress and prolonged 
exposure to new chemical substrates .  On th is  basis ,  one may exp la in  
the biochemical in d i v i d u a l i t y  observed with  regard to ascorbic acid  
requirements, and in th is  respect the d e f i n i t i o n  o f  the n u t r i t i o n a l  
status with regard to ascorbic acid is of  utmost importance. Indeed,
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the evidence of Odumosu e t  a l , 1973), suggests th a t  a s i g n i f i c a n t  
proport ion (17 out of  AO; h i  per cent)  o f  female guinea pigs on an 
ascorbic a c i d - f r e e  d ie t  were capable of  prolonged survival  due to  
endogenous synthesis o f  the vitamin as judged by the presence o f  
the enzyme gulonolactone oxidoreductase in the l i v e r s  of  these 
guinea pigs.  Barnes e t  a l , 1973, however, were unable to confirm  
these f in d in g s ,  but they used guinea pigs o f  a d i f f e r e n t  s t r a i n ,  
fed a d i f f e r e n t  d i e t .  These fa c tors  must be of  a t  least  some 
importance in the confirmat ion o f  any e f f e c t .
I t  is possib le ,  th e re fo re ,  tha t  in th is  series  of  experiments  
the ra te  of  synthesis of  ascorbic acid in the guinea pig may have 
been apprec iably  enhanced, due to one or more -environmental cond i t ions,  
such as prolonged vitamin C d e f ic ie n c y ,  increased demand due to drug 
adm in is t ra t io n ,  increased substrate (gulono-y- lactone) a v a i l a b i l i t y ,  
and possib ly ,  substrate  a c t iv a t io n  of  the enzyme. However, since  
L-gulono-y- lactone had no apparent e f f e c t  in the control  animals i t  
would appear tha t  the enhancement of  ascorbic acid biosynthesis is 
e i t h e r  due to the a dm in is tra t ion  of  prednisone or to a possible  
substrate a c t iv a t io n  in the presence of the drug.
The biosynthesis of  ascorbic acid  in the guinea pig e n t a i l s  
the presence of  gulonolactone oxidoreductase in the l i v e r  and i t  
would be of  in te re s t  to demonstrate and determine the enzyme under 
these c o n d i t io n s .
In conclusion,  i t  has been shown tha t  the prolonged a d m in is t ra t io n  
of  prednisone to guinea pigs i n i t i a l l y  increases the metabolic  
requirements of  ascorbic acid and subsequently induces the synthesis  
of the vitamin in the l i v e r .
SECTION B
THE EFFECT OF CHLORDIAZEPOXIDE ON ASCORBIC ACID
METABOLISM
Results
There was a s ig n i f i c a n t  increase in the ur inary  excre t ion  of  
ascorbic acid in the t rea ted  animals as compared to contro ls  fo r  
e ig ht  days fo l lowing the adm in is tra t ion  of  Librium (Table 2 . 1 0 ) .  The 
excre tory  leve ls  returned to control  values on the 15th day of  
medication.  On the AAth day, fo l lowing the a dm in is tra t ion  of  the 
drug, the t reated animals excreted s ig n i f i c a n t l y  less ascorbic acid 
in the ur ine as compared to c o n tro ls ,  a pattern  which persis ted u n t i l  
the 117th day o f  exper imentat ion.
The leve ls  of  ascorbic acid in the t issues of  the t reated  
animals were s i g n i f i c a n t l y  lower than control  leve ls  in the spleen 
cn the 50th,  90th and 123rd day, in adrenals on the 90th day,  and in 
blood on the 123rd day fo l lowing the adm in is tra t ion  of  the drug 
(Table 2 .1 1 ) .
There was no evidence of  hepatic microsomal induction,  as
indicated by the leve ls  of  cytochrome P-A50, cytochrome bc , and
b
prote in  in the l i v e r  (Table 2 .1 2 ) ,  and the u r inary  leve ls  of
g lu c a r ic  acid (Table 2 .1 3 ) .  However, on the 123rd day of  medication
trea ted  animals exhib i ted  s i g n i f i c a n t l y  elevated leve ls  of  cytochrome
bc as compared to contro ls  (Table 2 . 1 2 ) .  b
Animals t rea ted  wi th  the drug exh ib i ted  a s i g n i f i c a n t l y  lower 
ra te  o f  body weight gain than contro ls  (Table 2.1 A) and there was a
highly s ig n i f i c a n t  d i f fe re n c e  (about 200 gm) in the body weight of  
control  and experimental  animals on the 90th and 123rd day of  
med i cat  ion .
The p o s s i b i l i t y  tha t  the incidence of lower than control  
t i ssue  ascorbic leve ls  in the t rea ted  animals might be due to the 
i n i t i a l  increase in u r inary  excret ion of  ascorbic acid was 
investigated .  The experiment was repeated and the animals were 
s ac r i f ic e d  a f t e r  10 days o f  medication.  I t  can be seen (Table 2 .16)  
tha t  the increased ur inary  excret ion of  ascorbic acid is accompanied 
by s i g n i f i c a n t l y  lower than control  c i r c u l a t i n g  levels  o f  the 
vitamin in the serum and lower leve ls  in the spleen.
Table 2.10 Ur inary ascorbic acid excret ion in guinea pigs 
(t SEM) p r i o r  to and fo l low ing  the oral  
a dm in is tra t ion  o f  Librium (50 mg/kg)
Time (days)
Urinary  excret ion o f  ascorbic acid  
(mg/24 hrs)
Control Li bri  urn
Premed i cat  ion
+i<ro 0.01 14) 0.13 ± 0.02 14)
Premedication 0.13 ± 0.01 14) 0.13  ± 0.02 14)
Day of  medication
1 0.12 ± 0 .0 1 * 12) 0.16 ± 0 .01 * 12)
2 0.13 i 0 . 02+ 12) 0 .18 ± 0 . 02+ 12)
3 0.13 ± 0 .0 2 * 12) 0 .17 ± o o
+ 12)
8 0.13 ± 0 . 02+ 12) 0 .17 ± 0 .0 1 * 12)
15 0.12  ± 0.02 12) 0.13 ± 0.02 12)
44 0.12  ± 0.02§ 12) 0.07 ± 0.01§ 12)
46 0.13  ± 0 . 02§ 12) 0.09 ± 0.01§ 12)
87 0.12 ±
C
\|
oo
8) 0 .06 ± 0 .0 0 4 * * 8)
117 0.14 ± 0 .05 * 4) 0.05 ± 0 .0 06* 4)
S t a t i s t i c a l  s ig n i f ic a n ce  as compared with  contro ls
*p <0.025  
+p <0.05  
§ p <0.005
**p  <0.01
Numbers in parentheses ind ica te  the number of  animals in 
each group and a t  each po int of  the period o f  drug 
treatment.
4-J
(0 E , —v -c r -cr
L. ZJ -cr v—" ' —
•M •— s—/
to X—* + i  . +1 + i +•— 0) X •it CT\ LO
c -O D •— O  T— T— O OO O
. — •— tn CM O T— O T— O
E o tn • • • • • •
• o fD •— o  o o  o o  o
fD C
o
4->
<D
r— <1) •— 4-J *---..
(D X 0) ■— -cr \
L. Q . i_ 5 o s—- -c r
O CO o ■cr v—-
O cn 4-J + i  ^ +1 * + !  „ + 1 .a) tn \ c ' CO +
x fD cn o CO CM CO o r— CM CM
+j J E o CM O CM O t— o CM O
.  . • . • • .  •
cn o  o o  o o  o o  o
c
io -c r -cr -cr
E v—' ' —'
<— ---N ZJ + i + i  . +1 .
o CD «— CM CM CM
*4— "O CO o CM O -c r o
tn X o  o O  O o  o
- o o tn •— • • •  • • •
c fD •— _ l o  o o  o o  o
fD 4->
s_ o
O cd •— 4-1 ^ / —s ,---- /----.
4-J > X cd f— -cr -cr -cr -cr
•— L- 5 o N---^ v—' n—" ' —•
l_ _ i O 1_ +  | +1 + i +1 .
0 O cn 4-J CO OO -cr CM
tn s C I X  o X -  o c o  o LA  O
i_ fD cn o o  o o  o o  o O  O
Q . o • • •  • • • • •
o  o o  o o  o o  o
tn
CD
•— y—v
CL E , —s s—^ -cr
ZJ -cr -cr •—'
fD •— +1 + i  ^ + i  j .CD - o
C •—,—^ X CM i— c o cm
o r— •— CM O o T -  O
zj (D E • • » • • •
cn o  o o  o o  o
E O o
c ZJ o
. — 1—X T-- ---
<d J_ ^ N ,--- -c r ,-- -,—s CO o cn o -c r -cr '— -cr
s : o E +1 + i + l  ^ + !  ^UJ tn 4-J CO
t n fD c CM CM o  t— CTv O CO COo CM O CM o T— O CM O
+1 o • « • '  « • • • ’ •o  o o  o o  o o  o
tn
E _ _ ,---- y--V
fl) . ZJ -cr -cr -cr
> a) •— + i +1 ^ +1 ^a> Xf ZJ L-i— . •— tn X CO CM -cr c o cn cm„—N i— u tn •— CM O T— O CM o•o CD fD fD •— X • » • * • *
■— _y £Z 4-> o  o o  o o  o
um Nrr> Q) O i tiU U1
E -o X a)
o < s_ 2 r— x— s ^ — * -cr s
• — o o o -cr -c r '— ' -cr
X LTV O CD +1 + i  w + ' j . +1S_ tn \ 4-Jo fO CD fZ OO CM CO CO VO LO O  CO
o E E o CM O CM CO CM O CO o
tn ZJ s ^ o •  • « . •  • •  •
fD • — o  o o  o o  o o  o
L-
a) X
Z5 4-J
tn _ l C
tn cd
• — <4- E
f— O c 4-Jo fD
, — s •— (D
tn 4-1 1_
t— > - fD 4-J
.— fD o o o CO
• “O <4- LO cn CM
CM v ^ * a O r —a)
CD a) E tn
E CD > -
X I • — i_ fD
fD H Q . Q
h -
-O<1>
s_
fD
CL
EOo
tn
fD
<DOc
fDo
c
CD
4-JV)
+J(0
LO
CM
LO o
O o
. «
o o
V V
CL Q-
-!t + Nu
m
be
rs
 
in 
pa
re
nt
he
se
s 
in
di
ca
te
 
th
e 
nu
m
be
r 
of
 
an
im
al
s 
in 
ea
ch
 
gr
ou
p 
an
d 
ea
ch
 
po
in
t 
of 
th
e 
pe
ri
od
 
of 
dr
ug
 
tr
ea
tm
en
t.
LU
CO
>±l
TO
cn
o .
TO ____
cd 4-J
co JO•— cn3 •—
cn CD
5co•—
-otn o
JO
CD
> cn
CD
■— s
cn
C E
CD o4-J LA
O v—-
s_
D. E3
-o •—
c L-
TO JO
« —I
LA
JO 4-
O
CD
E C
O oL. ■—
JO 4->
CD TO
O L-
4-J 4-J
>- tn
o •—
co
o *ELA "O
-cri TO
Q_ ___
TO
CD L.
E o
Oi_ 0JO JO
o 4-1o4J cn
>- co
o •—
21— OTO i—
E •—
O o
tn 4—
Oi_ T3
o CO•— TOE
O
O 4-J
4-J L-
TO o
O - •—
CD s_
30 Q.
CM
T—
CM
CD
JO
CD
CD
>
CO —
CD +-> 
4-> CD O 2 
s_
o_ cn 
s
cn
E
c_ 
LTV CD 
JO >
CD —  
EO *-> 
i_  <D 
-C 5 o
O cn +j s  
> *  —  o  O 
E c
O  L- 
LA CD
-=r >i — 
O - —
CD 4J 
E CD 
0 2 s_
j o  cn 
o  \  
O — •m o 
>- E 
o  c
■M
coo
o
4-Jco
(_>
E
j o
coo
V)
> .
CD
■o
VO
o
+1
L A
CM
C A
O
+1
o
co
+1
C A
o
CM
co
4JTO
O
"O
CD
E
CD
vO
o
+1
o
CM
+1
o
vO
CM
\D
+1
1^.
LA
CA
CA
+1
O
CM
CM
CA
CA
+1
I-"-.
co
LA
+i
o
I-' -
CM
+J
c
CD
4-O
cn
>~TO
CO
O
L A
+1
C A
-3*
CM
CM
CA
+1
CO
L A  t— 
O  r -
CA
CA
+1
vO
CO
CM
+1
CM
-cr
CM
o
C A
CM
+1
L A
LA
CM
-cr -cr -cr
CM CM O
+1
CO
LA
CM
-cr
o
+i 
CA
vO
+i +i +i
O  LA CO
-cr c a  o
+ i
vO
CO
CM
CM
CM
+1
CM
-cr
CM
C A
CM
4->
c
O
o
"O
cd
L-TO
Q .
E
O
O
tnTO
CD
ocoTO
O
c
cn
+j
tn
TO
■M
< /)
LA
O
o
V
cn
13
L .
~a
4-o
“Oo
i_
(D
O -
a)
j o
+J
4 -o
4->
C
o
C L
JO
oTO
a>
~o
cTO
CL
3
o
s_
cn
cd
JO
E
3
CO
CD
JO
+J
CD
4->TO
O
* o
c
tn
CD
tn
CDJO
4-J
C
CD
1_TO
Q .
tn
L .
CD
JO
E
3
4-J
CO
CD
E
4-JTO
CD
-  88 -
Table 2.13 Ur inary g lu c ar ic  acid excre t ion  (fc SEM) p r io r  
to and fo l low ing  the oral  adm in is tra t ion  of  
Librium (50 mg/kg body weight)
Time (days)
Glucar ic  acid excret ion  
(ymoles/24 hrs)
Control Librium
Premedication 
Days o f  medication  
20 
55 
100
0.29 ± 0.06 (1*0
0.29 ± 0.03 (12) 
0.32 ± 0.10 ( 8) 
0.30 ± 0.05  ( *0
0.30 ± 0.02 (1*0 
0.30 ± 0.0*f (12)
0.31 ± 0.05  ( 8) 
0.33 ± 0 .07 ( *0
Dif ferences not s ig n i f i c a n t
Numbers in parentheses ind ica te  the number of  animals 
in each group and a t  each po int of  the period of  drug 
treatment .
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Table 2 .14  The body weight o f  guinea pigs (± SEM) p r io r  to  
and fo l lowing the ora l  adm in is tra t ion  of  Librium  
(50 mg/kg body weight)
Time (days)
Body weight (gm)
Control L i bri  urn
Premed ica t  ion 
Days of medication 
50 
90 
123
340.3 ± ' 9 .4  (14)
649.5 ± 2 4 .8 * (1 2 )
760.6 ± 3 0 .5+ (8) 
830.0 ± 19.1+ (4)
333.4 ± 1 3 . 8  (14)
546.0 ± 1 7 . 8 *  (12) 
572.8 ± 1 5 . 1+ (8)
602.5  ± 2 3 . 2+ (4)
S t a t i s t i c a l  s ig n i f ic an ce  as compared with  contro ls  
*p <0.0025  
+p <0.0005
Numbers in parentheses ind ica te  the number o f  animals in 
each group and a t  each point o f  the period of  drug 
treatment.
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Di scuss ion
The prolonged adm in is tra t ion  o f  ch lord iazepoxide (Librium) to  
guinea pigs on a low intake  of  ascorbic acid has been shown to a l t e r  
the ur inary  excret ion  of  the vitamin and induce deplet ion  in the t issues .
The changed ur inary  excret ion o f  ascorbate induced by Librium  
(Table 2 .10)  appears to be s im i la r  to th a t  induced by prednisone
(Tables 2.1 & 2 .6 ,  Section A) wi th  two exceptions,  ( i )  the i n i t i a l
increase in excre t ion  reached levels of  s ig n i f ic an ce  and ( i i )  once 
the decrease in excre t ion  had been estab l ished ,  i t  pers is ted u n t i l  the
117th day of  medication.  Whether the same mechanisms are o pera t ive
as fo r  prednisone is not c le a r .  I t  i s ,  however, in te re s t in g  tha t  
t e t r a c y c l in e  (Windsor e t  a 1 , 1972) and diphenylhydantoin (Loh, 1973) 
prednisone and Librium share a common pattern  in increasing the 
excret ion of  ascorbic a c id ,  in species unable to synthesise the 
v i tamin ,  despite  t h e i r  d is s im i la r  chemical s t ruc ture  and pharmacological  
mode of a c t io n .  The evidence,  so f a r ,  is i n s u f f i c i e n t  fo r  any genera l ­
isa t ion  to be made, but the p o s s i b i l i t y  tha t  these,  and other  drugs,  
p r e c i p i t a t e  t h e i r  e f f e c t  through a s im i la r  mechanism should not be 
overlooked a t  th is  stage.  The subsequent and continued decrease in 
ur inary  excret ion o f  ascorbic acid fo l lowing Librium (Table 2 .10 )  
fu r t h e r  supports the evidence regarding the s p e c i f i c i t y  o f  prednisone  
induction of  ascorbate biosynthesis discussed in the previous sec t ion .
Various drugs, carcinogens and tox ic  chemical compounds increase  
the turnover ra te  of  the vitamin by approximately t e n - f o ld  in the ra t  
(Conney et  a l , 1961). In th is  ser ies  of  experiments i t  has been shown 
tha t  Librium adm in is tra t ion  reduces the excret ion of  ascorbic acid by 
about 56 per cent in the guinea p ig ,  ind ica t ing  a g reater  u t i l i s a t i o n
of  the v i tamin .  S im i la r  f in d in g s ,  and o f  the same order of  
magnitude, have recent ly  been reported in response to phenobarbitone,  
chloretone and 3“methylchloranthrene in guinea pigs (Gupta, Choudhury 
S C h a t te r jee ,  1973).  I t  would appear,  th e re fo re ,  tha t  the re q u i re ­
ments fo r  ascorbic acid is increased fo l lowing the a dm in is tra t ion  o f  
these drugs.
In view of  the a b i l i t y  of  the ra t  and other  species to  
synthesise ascorbic a c id ,  Ft Is considered that  these species can 
adapt to the increased requirements by induced synthesis of  the  
v i tam in .  However, species that are unable to synthesise ascorbic  
acid are  dependent on increased exogenous v itamin to meet the 
increased requirements,  in the absence of which d e f ic ie n c y  symptoms 
appear.
The lower than control  t issue  ascorbic acid leve ls  in the  
Libr ium-treated  guinea pigs (Table 2 .11)  a t  various stages o f  treatment  
is fu r t h e r  evidence of  ascorbic acid d e f ic ie n c y .  The spleen is more 
severely  and con s is te n t ly  a f fe c ted  than other  t issues .  This is not 
r e a d i ly  exp l ic ab le  e s p e c ia l l y  when one considers tha t  the r a te  of  
deplet ion  of  ascorbic acid from the spleen is only s l i g h t l y  higher
than th a t  of  the adrenals (Hughes, Hurley & Jones, 1971).  The
deplet ion  occurs e a r ly  fo l lowing medication (Table 2 .15 )  and although  
serum leve ls  are s i m i l a r l y  a f fe c ted  they return to control  leve ls  on 
the 50th and 90th day. Possibly th is  is a s p e c i f ic  e f f e c t  of  the  
drug on the spleen.  Librium also resul ted in s i g n i f i c a n t  r e ta rd a t io n  
in the ra te  of  body weight gain and on the f i n a l  day o f  treatment the  
trea ted  animals were some 25% l i g h t e r  (Table 2 . 1 4 ) .  Guinea pigs on 
i n s u f f i c i e n t  ascorbic acid intakes have been shown to grow a t  slower
than normal rates and experimental  scurvy has been shown to  be
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associated with  rapid loss of  weight wi th  the onset of the 
scorbutic condi t ion  in the f i r s t  2-3 weeks (Holst  & F ro l ic h ,  1907).
I t  would seem t h a t ,  because of  the increased requirements for  the  
vitamin due to the drug, the animals are unable to grow normally  
since Librium does not reduce food in take ,  indeed the reverse is 
t rue  in the ra t  (Opitz & A k in la ja ,  1966).
There was no evidence o f  hepatic  microsomal enzyme induction  
as indicated by the leve ls  of  cytochrome P-A50, cytochrome b^, 
prote in  (Table 2 .12 )  and u r in a ry  g lu c a r ic  acid excret ion (Table 2 . 1 3 ) .  
I t  may be tha t  th is  is due to lack of  ascorbic a c id ,  fo r  reasons 
discussed under Section A, or is a species v a r i a t i o n ,  fo r  Librium 
is a moderate enzyme inducer, a t  doses of  AO mg/kg, in rat*and man 
(Orme, Breckenridge & Brooks, 1972).
I t  is concluded that  prolonged chlordiazepoxide  (Librium)  
a dm in is tra t ion  decreases the u r inary  excret ion and t is su e  leve ls  
of ascorbic acid by increasing the metabolic requirement fo r  the  
vitamin in the guinea p ig .
Chapter Three
TRYPTOPHAN-NICOTINIC ACID INTERRELATIONSHIP 
IN RHEUMATOID ARTHRITIS
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Introduction
Tryptophan, an essentia l  amino ac id ,  is the only amino acid  
found to be s i g n i f i c a n t l y  bound to plasma albumin.  In f a c t ,  less 
than 20 per cent of  the to ta l  plasma tryptophan appears to be in a 
f r e e l y  d i f f u s i b l e  form in normal subjects (McMenamy S Orcley,  1958).  
Ant i- rheumatic  drugs, notably s a l i c y l a t e s ,  phenylbutazone, prednisone,  
and indomethacin, d isplace tryptophan from i ts  albumin binding s i tes  
in man both in v i t r o  (McArthur S Dawkins, 1969) and in vivo (Smith & 
Lakatos,  1971). Furthermore,  the f re e  and to ta l  tryptophan con­
cen t ra t ion  has been shown to be decreased by 27.0  and 29.0  per cent  
re spe c t ive ly  in pa t ien ts  with rheumatoid a r t h r i t i s  rece iv ing one or  
more an t i - rheum at ic  drugs (McArthur, Dawkins & Smith, 1971).
Metabolic  abnormal i t ies  of  tryptophan occur in pa t ien ts  with  
rheumatoid a r t h r i t i s  and re su l t  in an increase in the ur inary  
excre t ion  of  kynurenine (Be t t ,  1962; P ina ls ,  1964; Beetham, Fischer  
& Schohenloher, 1964; J a f fe  & Altman, 1964),  3"hydroxykynurenine  
(P ina ls ,  -1964; F I ?nn et  a l , 1964),  3- hydroxyanthrani1 ic acid and 
xanthurenic acid (Spiera ,  1966).
Tryptophan is a precursor of  n i c o t i n ic  acid in man and many 
other animal species (S a r r e t t  & Goldsmith, 1947, 1949). Studies on 
the e f f i c i e n c y  of  tryptophan as a n i c o t i n ic  acid precursor have 
revealed that  in man 60 mg of tryptophan is equiva lent  to 1 mg o f  
n ic o t in ic  acid (Ho rw i t t ,  Harvey, Rothwell e t  a l , 1956),  a r a t i o  
taken into considerat ion in deciding the recommended allowances in 
humans. I t  might,  th e re fo re ,  be that the lowering o f  plasma 
tryptophan by ant i - rheum at ic  drugs may have some repercussions on 
the requirements of  n i c o t i n ic  acid in these p a t ie n ts .  The evidence  
regarding the excret ion of  n ic o t in ic  acid metaboli tes in pa t ien ts
suf fe r ing  from rheumatoid a r t h r i t i s  is c o n f l i c t in g .  Increased 
excret ion of  N1-methylnicot inamide and i ts  pyridone has been 
reported (Pasquar ie l lo  & Tenconi,  1964),  which was not subsequently 
confirmed (Spiera ,  1966). The d ie ta ry  intake in t h e i r  pa t ien ts  
was not,  however, considered in e i t h e r  study,  and blood n i c o t i n ic  
acid levels  were not measured.
The present study was undertaken to inves t iga te  the p o s s i b i l i t y  
tha t  n i c o t i n ic  acid requirements may be a l te re d  in pa t ien ts  s u f fe r in g  
from rheumatoid a r t h r i t i s .
M a te r ia ls  and Methods
A . . M ater ia ls  
Standards
N1-methylnicotinamide hydrochloride ,  3"hydroxyanthrani1ic 
ac id ,  kynurenine,  xanthurenic acid and tryptophan were purchased 
from Sigma, London.
A l l  other chemicals were of  Analar grade and were purchased 
from BDH Chemicals, Poole, Dorset,  England.
Solvents
A l l  solvents used were of  Analar grade and were purchased 
from BDH Chemicals, Poole, Dorset,  England.
B. Methods
Plasma_tryptophan_determination
Tryptophan condenses with  formaldehyde and acetaldehyde, the
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side chain being subsequently cyc l ised to form norharman and harman 
re sp e c t ive ly .  In th is  method tryptophan is condensed wi th  formalde­
hyde to form norharman, a f luorescent substance (Denckla & Dewey,
1967).
Plasma (0 .02  ml) was t rea ted  with  t r i c h l o r o a c e t i c - f e r r i c  
ch lor ide  reagent (1 .8  ml) mixed and centr i fuged a t  20,000 x g a t
0  V
4° fo r  10 minutes.  The t r i c h l o r o a c e t i c  a c i d - f e r r i c  ch lo r id e  reagent  
consisted of  10% w/v t r i c h l o r o a c e t i c  acid conta ining 3 x 10 ** M 
f e r r i c  ch lo r id e .
To the supernatant,  formaldehyde (0 .2  ml) was added and mixed.
The reagents were heated fo r  one hour in a b o i l in g  water bath kept a t  
between 99° and 101°,  cooled and the incubation volume (2 ml) made 
up wi th 10% w/v t r i c h l o r o a c e t i c  a c id .  The f luorescence of the  
reaction product is read in a Perkin-Elmer MPF2A spectrophotof1uoro-  
meter a t  373 nm and 452 nm a c t iv a t in g  and f luorescent wavelength 
re s p e c t ive ly .
Blanks and standards (0-50 nmoles) were set up wi th  each assay 
and c arr ied  through the same procedure.
P a r t ic u la r  a t te n t io n  was paid to maintain ing the temperature  
at  or above 99° as temperatures below 99° have been reported to decrease  
considerably the y ie ld  of  the end-product of  the reac t ion .
The pyr id ine  nucleotides NAD and NADP account fo r  most o f  the 
n ic o t i n ic  acid present in the blood. The a 1k a l i -a c e to n e  condensation 
reaction of  N1-methyl nicotinamide (NMn) y ie ld s  a highly  f luorescent  
product with  both the pyr id ine  nuc leot ides ,  the in te n s i t y  o f  which is
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h a l f  as g re a t ,  per e q u iva len t ,  as tha t  o f  NMN. Haematocrit values
were a lso measured and the values expressed in terms of  n i c o t i n i c  acid
per ml o f  e ry throcy tes ,  since p r a c t i c a l l y  a l l  n i c o t i n ic  acid d e r iv a t iv es  
are present in the red c e l l s  (Gyorgy, 1967)•
Whole blood was deprote in ised wi th  25% w/v t r i c h l o r o a c e t i c
ac id ,  allowed to stand a t  room temperature fo r  5 minutes,  centr i fuged  
a t  2,400 rpm a t  4°C for  10 minutes and f i l t e r e d  (Whatman No.30,  7.0  cm
paper) .  To an a l iq u o t  o f  blood f i l t r a t e  (0 .5  m l ) ,  water (0 .5  ml) and
r e d i s t i l l e d  acetone (0 .5  ml) was added and mixed thoroughly.  This 
was fol lowed by the add i t ion  of  6N-NaOH (0 .2  ml) and immediate mixing.  
A f t e r  standing a t  room temperature fo r  5 minutes 6N HC1 (0 .3  ml) was 
added and mixed a t  once. The reagents were heated in a b o i l in g  water  
bath fo r  2 minutes; 20% w/v potassium dihydrogen phosphate was added 
(1 .0  m l ) ,  mixed and d i lu te d  with  water to a f ixed  volume (10 m l ) .  The 
f luorescence was measured in a Perk in-Elmer MPF2A spectrophotof1uoro-  
meter a t  360 nm and 483 nm a c t iv a t in g  and f luorescent wavelength
resp e c t ive ly .  Blanks and standards (0-10 yg NMN) were c a r r ie d  through
the same procedure.  Recovery of  added NMN to blood f i l t r a t e  ranged 
from 87 to 101 per cent.
yriD§IY_!$YDyE®DlQ£_£!§£§r!IliD§£l2!3
The d iazot ised  product of  o-aminoacetophenone, which kynurenine  
is converted to on d i s t i l l a t i o n ,  absorbs maximally at  540 nm (Tompsett,  
1959).  This serves as the basis of  the determination o f  kynurenine.
An a l iq u o t  o f  acid-hydrolysed urine (10 ml) was d i s t i l l e d  w i th  
water (30 ml) and sodium hydroxide (5 gm) u n t i l  an adequate volume o f  
d i s t i l l a t e  (20 ml) was obtained.
-  99 -
An a l iq u o t  of  d i s t i l l a t e  (10 m l ) ,  10 N hydrochloric  acid (0 .2  ml) 
and 0.1% w/v sodium n i t r i t e  (1 .0  ml) were mixed thoroughly and allowed  
to stand a t  room temperature fo r  5 minutes.  Ammonium sulphamate 
0 .5 % w/v (1 ml) was added and mixed. A f te r  standing a t  room 
temperature fo r  a fu r t h e r  5 minutes 0.1% w/v N - (1 -n ap h th y l ) -e th y le n e -  
diamine dihydrochlor ide  was added and thoroughly mixed. The op t ica l  
densi ty  was read at  5^0 nm in a Unicam SP 500 semi-automatic spectro­
photometer a f t e r  standing at  room temperature fo r  2 hours, fo r  
maximum colour development.
A control  d i s t i l l a t i o n  was car r ied  out at  n e u t r a l i t y  to  
determine the presence, i f  any, of  non-spec if ic  v o l a t i l e  amines.  
Standards (0-100 yg kynurenine) were also set up a t  the same t ime,  
the whole procedure being used. Recovery of  added kynurenine to the  
urine ranged from 91 to 99 per cent.
Determmation of  xanthurenic acid
F e r r ic  ions combine wi th  xanthurenic acid to form a green 
f e r r i c - x a n th u r e n ic  acid complex s a l t  which once formed remains s ta b le .  
This observation was the basis fo r  the est imation of  xanthurenic acid  
(Rosen, Lowy, Sprince,  1951)•
c
A f r a c t io n  of  the 2k  hrs ur ine  was adjusted to pH 7 *3 ~ 7 *5 ? 
f i l t e r e d  and an a l iq u o t  (2 .0  ml) was d i lu te d  with  water to a f ixed  
volume (10 m l ) ,  sodium d i t h i o n i t e  (15 mg) was added, fol lowed by 1.7% 
w/v ammonium f e r r i c  sulphate (FeNH^ (SO^^.  I 2H2O) (0.1 ml) and 5% w/v 
f re s h ly  made sodium bicarbonate (1 .0  m l ) .  The reagents were thoroughly  
mixed to permit ox idat ion  u n t i l  the green fe r r i c - x a n th u r e n ic  acid  
complex s a l t  was formed and remained s ta b le .  The op t ica l  dens i ty  was 
read at  620 nm in a Unicam SP 500 spectrophotometer.
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Urine blanks, in which the iron was maintained in the reduced 
s t a te ,  and standards (0-50 yg xanthurenic acid)  were included in each 
assay and t rea ted  in the same way. Recovery of  added xanthurenic  
acid to the ur ine ranged from 73 to 105 per cent .
29££I!rlD^£l2D_2£_yri9§rY_2lhyd roxyanthram |_ic_ac|d__(3“HAA)
A paper chromatographic procedure was found to be the most 
r e l i a b l e  method fo r  determination o f  th is  metaboli te  of  tryptophan  
in ur ine .  The method is th a t  described by Spiera ,  (1963) •
To a ur ine a l iq u o t  (30 m l ) ,  12N hydrochloric  acid was added 
mixed and the ur ine extracted  three times wi th  e ther  (30 m l ) ,  
discarding the ether  layer  each t ime. The pH of  the ur ine  layer  
was adjusted to 3.0  wi th 5N NaOH and extracted four times with  
ether  (30 m l ) .  The e ther  port ions were pooled and the e ther  
evaporated to dryness.  The residue was dissolved in ethy l  alcohol  
(1 .0  ml) and a l iquots  (10 y l )  appl ied to chromatography paper 
(Whatman No.1,  30 x 50 cm). The chromatograms were developed fo r  
7 hours in a solvent system, consis t ing of  formic acid (1 m l ) ,  
sodium formate (10 gm) and water (200 m l ) ,  and dried a t  room temp­
e ra tu re .  The spots,  corresponding to 3HAA, were i d e n t i f i e d  under 
UV l i g h t ,  cut out and e lu ted overnight in 0.2M phosphate b u f fe r  
pH 7.0  ( k  m l ) .  Eluate f luorescence was measured in a Perkin-Elmer  
MPF2A spectrophotof1uorometer a t  an a c t iv a t in g  wavelength of  320 nm 
and f luorescent wavelength of  A15. The a c t iv a t in g  and f luorescent  
spectrum of  each e lu a te  was checked tha t  i t  corresponded to th a t  o f  
3-HAA. Blanks and standards (0-200 yg 3"HAA) were set up w i th  
each assay.  Recovery of  added 3"HAA to ur ine ranged from 77 to 90 
per cent .
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N1-methylnicotinamide (NMN), one of  the p r inc ipa l  ur inary  
metabol i tes o f  n ic o t i n ic  a c id ,  reacts with  ketones in a l k a l i n e  
aqueous solut ions to produce a green f luorescent  compound. The 
l a t t e r  can be converted,  in the presence of  excess ac id ,  to another  
more s tab le  substance with  a blue f luorescence tha t  may be measured 
q u a n t i t a t i v e l y  (Gyorgy, 1967a).
An a l iq u o t  of  centr i fuged ur ine (0 .2  ml) was d i lu te d  wi th  
water to a f ixed  volume (1 .0  m l ) .  Charcoal trea ted  methyl-ethyl  
ketone-manganese c h lo r ide  reagent (0 .5  ml) was added fol lowed by 
6N NaOH (0 .2  m l ) .  The reagents were thoroughly mixed. A f t e r  
standing a t  room temperature fo r  5 minutes 6N hydrochloric acid  
(0 .3  ml) was added, mixed and heated f o r  f i v e  minutes in a b o i l in g  
water bath and cooled.  This was fol lowed by the add i t ion  o f  20% 
w/v potassium dihydrogen phosphate (1 .0  ml) and water to a f ixed  
f in a l  volume (10 m l ) .  The f luorescence was read in a Perkin-Elmer  
MPF2A spectrophotof1uorometer a t  360 nm and 483 nm a c t iv a t in g  and 
f luorescent  wavelength resp ec t ive ly .
Blanks and standards (0-10 yg NMN) were car r ied  through the 
same procedure.  Recovery of  added NMN to ur ine ranged from 85"98 
per cent .
The methyl-e thyl  ketone-manganese ch lo r id e  reagent consisted  
of  0.1 M manganese ch lo r id e  (1 .0  ml) and charcoal  p u r i f i e d  methyl-  
ethyl  ketone (500 ml) .
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C. Pat ients
The pat ien ts  studied were long standing cases of  rheumatoid 
a r t h r i t i s .  They were selected from the A r t h r i t i s  C l in ic  and 
control  p a t ien ts  from other o u tp a t ien t  c l i n i c s  in St.  Luke's H o s p i ta l ,  
Guildford (Appendix 2 ) .
Blood samples were obtained by venepuncture and processed 
immediately f o r  the determination of  n ic o t i n ic  acid and tryptophan.  
Twenty-four hour ur ine c o l le c t io n s  were s ta r ted  the fo l lowing day 
and urine was c o l lec te d  in concentrated hydrochlor ic  ac id .  Urines  
were frozen i f  not analysed immediately.
A l l  pa t ien ts  were issued wi th a note-book in which they were 
requested to w r i t e  a l l  food and dr ink  they ate  or drank f o r  a week 
and return  i t  upon complet ion.  They were advised not to  de v ia te  from 
t h e i r  normal d ie ta r y  p a t te rn ,  or r e s t r i c t  t h e i r  normal in take .  The 
d a i ly  d ie ta r y  intake of  energy,  p ro te in ,  tryptophan, th iamine,  r ib o ­
f l a v i n ,  n ic o t i n ic  acid and pyridoxine was ca lcu la ted  from standard 
food tables (McCance £ Widdowson, I9 6 0 ) .
Results
There was no d i f fe r e n c e  between the haematocrit and plasma 
n ic o t in ic  acid leve ls  of  control  pa t ien ts  and those s u f fe r in g  from 
rheumatoid a r t h r i t i s .  However, the concentrat ion of  to t a l  plasma 
tryptophan was s i g n i f i c a n t l y  lower in the l a t t e r  group (Table 3 .1 ) •
Patients  with rheumatoid a r t h r i t i s  excreted s i g n i f i c a n t l y  
la rge r  q u a n t i t i e s  of  kynurenine, 3~hydroxyanthrani1ic acid and 
xanthurenic acid but not of  f^ -methyln icot inamide in t h e i r  u r ine
(Table 3 -2 ) .
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The d a i l y  d ie t a r y  intake of  p ro te in ,  tryptophan and n ic o t i n ic  
acid was s i g n i f i c a n t l y  lower in pa t ien ts  su f fe r in g  from rheumatoid 
a r t h r i t i s  but the intake of  energy,  th iamine,  r ib o f l a v i n  and p y r i -  
dixone was not d i f f e r e n t  from tha t  o f  the contro ls  (Table 3 * 3 ) .
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Table 3.1 The haem'atocrit, serum to t a l  tryptophan and whole
blood n ic o t i n ic  acid leve ls  in contro ls  and pa t ien ts  
t rea ted  with  a n t i - rheum at ic  drugs.  Values are  
means fo r  the number of  pa t ien ts  shown in parentheses 
± SEM.
Controls •••• Ant i-rheumat ic. _d  iuigs p
Haematocrit {%) 42.3  ± 1 . 9 41.7  ± 1 .1 NS
(7) (15)
Tryptophan 6 .5  ± 0 . 3 4 .4  ± 0 . 3 0.0005
(ymol/ml) (7) (15)
N ic o t in ic  acid 32.5 ± 1.8 34.1 ± 1 . 8 NS
(yg/ml e rythrocytes) (7) . (15) .
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Table 3.2 The ur inary  excre t ion  o f  kynurenine, 3- hydroxy-
a n t h r a n i l i c  a c id ,  xanthurenic acid and N ^ m e th y l -  
nicotinamide in contro ls  and patien ts  t rea ted  with  
ant i - rheum at ic  drugs. Values are means f o r  the
number of  pa t ien ts  shown in parentheses ± SEM.
Controls Ant i-rheumati  c drugs P
Kynurenine 
(mg/24 hrs)
1.7
(7)
± 0.3 3.6
(14)
± 0.8 0.05
3“ Hydroxyanthran i 1i c 
acid (mg/24 hrs)
0.15
(7)
± 0.01 0.6
(15)
± 0 .1 ; 0.005
Xanthurenic acid 
(mg/24 hrs)
20.0
(7)
± 4 .0 99.0
(15)
± 19.0 0.0005
N-^-Methylnicotin-  
amide (mg/24 hrs)
5 .9
(7)
± 0.6 5 .8
(15)
± 0.9 NS
- 1 0 6 -
Table 3*3 The d a i ly  d ie ta r y  intake of  energy,  p ro te in ,  
tryptophan, thiamine,  r i b o f l a v i n ,  n ic o t i n ic  
acid and pyridoxine in contro ls  and pat ien ts  
t rea ted  with  an t i - rheum at ic  drugs. The 
values are means fo r  the number of  pa tien ts  
shown in parentheses ± SEM.
N ut r ie n t Controls Ant i- rheumatic  drugs p
Energy 1524 ±180 1600 ±150 NS
(cals /day) (7) (13)
Protei n 76.0 ± 3.4 60.9  ± 3.3 0.005
(g/day) (7) (13)
Tryptophan 1.0  ± 0.07 0.8  ± 0.04 0.005
(g/day) (7) (13)
Thiamine 1.1 ± 0.05 0 .9  ± ' 0 .07 NS
(mg/day) (7) (13)
R ibof lav in 1.6 ± 0.2 1.3  ± 0.1 NS
(mg/day) (7) (13)
Ni cot in i c ac id 29.0 ± ' 1 . 2 23.6  ± ’ 1. 4 0.0125
(mg/day) (7) (13)
Pyridoxine 1.2 ± 0.1 1.1 ± 0 . 1 NS
(mg/day) (7) ( 13)
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Pi scuss ion
A s ig n i f i c a n t  reduction in serum to ta l  tryptophan concentrat ion  
and an, increase  in the ur inary  excret ion of  kynurenine ( 2 - f o l d ) ,  3” 
hydroxyanthani1ic acid (4 - f o ld )  and xanthurenic acid ( 5 ~ f o ld ) ,  but 
not in N1-methyln icot inamide,  has been shown to occur in pa t ien ts  
with rheumatoid a r t h r i t i s .  These pa t ien ts  have also been shown to  
have a s i g n i f i c a n t l y  lower d ie ta ry  intake of  protein^ tryptophan and 
n ic o t i n ic  a c id ,  but not of  energy.
The f ind ings  of the present ser ies  confirm e a r l i e r  observations  
of  reduced to t a l  serum tryptophan and increased ur inary  excre t ion  
of  kynurenine, 3"hydroxyanthrani1ic ac id ,  and xanthurenic acid in 
rheumatoid a r t h r i t i s .  There was no such increase,  however, in the  
excret ion of  N-^-methyl n ic o t i  namide. This is in agreement with  
Spiera 's  observation (Spiera ,  1966) but not w ith  tha t  of  P asquar ie l lo  
and his co-workers (Pasquariel  lo ejt aj_, 1964),  who showed an increased 
excret ion o f  th is  m etabo l i te .
I t  would appear tha t  pa t ien ts  wi th  rheumatoid a r t h r i t i s  
metabolise a g re a te r  than normal amount of  tryptophan v ia  the 
kynurenine pathway ( F i g . 3 . 1 ) ;  that  i s ,  there  is a p r e f e r e n t ia l  
shunting of  tryptophan through th is  pathway. The mechanism by which 
th is  abnormali ty is induced is not c le a r .  Since monoamine oxidase  
a c t i v i t y  has been shown to be normal in these pa t ien ts  (Sp iera ,  1966),  
i t  is possible tha t  such a shunt may develop as a re s u l t  of  increased  
a c t i v i t y  of  hepatic  tryptophan pyrro lase .  The enzyme cata lyses the  
i r r e v e r s i b l e  conversion of  tryptophan to N-formylkynurenine and i t s  
increased a c t i v i t y  has been shown to increase the ur inary  excre t ion
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Tryptophan
I ndole 
Der iva tives
Kynuren i nase 
(PLP)
A nthran i1i c 
acid
Tryptophan
Pyrrolase
(Thiamine)
N-Formyi kynuren i ne
Kynureni ne 
formami dase
Kyiu ren i ne
Kynuren i ne 
hydroxy1ase 
( R ib o f 1avin)
3-hydroxykynurenine
Kynuren i nase 
(PLP)
3 -hydroxyanthrani1ic acid
Qui no j n i c  acid 
Decarboxylase
Tryptophan
hydroxylase
5- hydroxy-tryptophan
Decarboxylase 
(PLP)
5-hydroxy-t ryptami ne
i
5-hydroxy-i  ndoleaceti  c 
acid
aminotransferase (PLP) 
xanthurenic  acid
N ic o t in ic  acid
F i g . 3.1 Tryptophan metabolism showing, in brackets,  the 
stages a t  which some vitamins may p a r t i c i p a t e .
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of  metaboli tes  o f  the kynurenine pathway in the rabb i t  (Spiera  
& Chri st  ia n , 196*0 .
Tryptophan pyrro lase  is an adaptive  enzyme and i t s  a c t i v i t y  
in the l i v e r  can be increased by the a dm in is tra t ion  of  tryptophan  
and g lucocor t ico ids .  Tryptophan produces a substrate or cofactor  
type enhancement involving  decreased degradation of  p re -e x is t in g  
apoenzyme in the presence of normal synthet ic  ra te s ,  whereas gluco­
co r t ic o id s  produce a hormonal-type induction involving synthesis of  
new apoenzyme (White,  Handler & Smith, 1968). Increased hepatic  
tryptophan pyrro lase  a c t i v i t y  fo l lowing treatment with  s a l i c y la te s  
has been shown in the ra t  (Badaway & Smith, 1972). The increase  
persis ted fo r  several  hours a f t e r  drug admin is t ra t ion  and was 
a t t r ib u t e d  to an increase in l i v e r  tryptophan e f fec ted  by the  
displacement of  the amino acid from i t s  albumin binding s i tes  by s a l i ­
c y la te s .  I t  is possib le ,  th e re fo re ,  tha t  an t i - in f lam m ato ry  drugs 
used in the treatment of  rheumatoid a r t h r i t i s  i n d i r e c t l y  enhance 
the a c t i v i t y  o f  hepatic tryptophan pyrro lase ,  and thus increase the 
o x id a t iv e  degradation of  tryptophan through the kynurenine pathway,  
although the involvement, i f  any, of  g lucocort ico ids  cannot be 
excluded at  th is  stage.  I t  is d i f f i c u l t  to assess,  however, whether  
the abnormali ty in tryptophan metabolism found in our pa t ien ts  and 
the abnormal i t ies  reported by other  authors is so le ly  due to drug 
therapy,  fo r  such assessment would e n t a i l  the study of  pa t ien ts  p r io r  
to and fo l lowing the i n s t i t u t i o n  of  such therapy.
The d a i l y  d ie ta r y  intake of  tryptophan and n i c o t i n ic  acid was 
s i g n i f i c a n t l y  lower in rheumatoid a r t h r i t i s  p a t ie n ts ,  probably a 
r e f l e c t i o n  of  t h e i r  bwer prote in  in take .  The l a t t e r  was not due to
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reduced food in take ,  as judged by the s im i la r  energy intake of  
controls  and pa t ien ts  s u f fe r in g  from rheumatoid a r t h r i t i s .  The 
s ig n i f ic a n ce  of  these f in d in g s ,  however, is d i f f i c u l t  to in t e r p r e t  
since only four o f  the 13 pa t ien ts  studied (see Appendix 2) had a 
lower prote in  intake than the one recommended (65 and 55 g p r o t e i n /  
day fo r  men and women re s p e c t i v e ly ) ,  and only one p a t ien t  had a 
lower than recommended n ic o t i n ic  acid intake (18 and 15 mg 
equivalents  fo r  men and women respec t ive ly )  fo r  the same age group.
In view o f  the increased excre t ion  of  kynurenine, 3"hydroxyanthrani1ic 
acid and xanthurenic acid without a corresponding increase in the end 
product of  the kynurenine pathway, N1-methyln icot inamide,  i t  is 
possible  tha t  in cases o f  marginal d ie ta ry  intake ,  n ic o t i n ic  acid 
requirements may be increased, fo r  the excess of  metaboli tes  may 
enter the glutamate pathway and be catabol ised to carbon diox ide  
(Nishizuka,  Ichiyama, Gholson S Hayaishi ,  1965) .
The abnormali ty of  tryptophan metabolism via  the kynurenine  
pathway is by no means confined to rheumatoid a r t h r i t i s .  I t  has 
been reported in such condit ions as congenital hypoplastic  anaemia 
(Pr ice  ert ajh, 1970),  carcinoma of the breast (Rose £ Randall ,  1973) 
and bladder (Bryan, 1969), Hodgkin's disease (Musajo & Benassi , 1964) 
in pa t ien ts  with  kynureninase de f ic iency  (Binazzi  & Calandra, 1971) 
and in women on oral  contraceptive  therapy (Adams, Rose, Folkard e t  
a l , 1973). While the mechanisms involved may be d i f f e r e n t ,  in a l l  
these condi t ions,  the ur inary  excret ion of  kynurenine,  3"hydroxykynurenine, 
3“hydroxyanthrani1ic a c id ,  xanthurenic acid and the r a t i o  of  3- hydroxy-  
kynurenine to 3"hydroxyanthrani1ic acid is s i g n i f i c a n t l y  increased.
Although 3” hydroxykynurenine was not measured, in the present ser ies  
o f  experiments,  the ur inary  excret ion o f  kynurenine, 3"hydroxyanthrani1ic
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acid and xanthurenic acid was increased in our p a t ie n ts .  The 
f indings in these condit ions have been in terpreted  as in d ic a t i v e  
of  a functional  de f ic ienc y  of  pyr idoxine.
The d ie ta r y  intake of  pyridoxine in our pa t ien ts  compares 
favourably with  tha t  recommended (1-2  mg/day).  However, in view of  
(1) the enhanced a c t i v i t y  of  the kynurenine pathway and (2) the  
involvement o f  pyr idoxine ,  and fo r  tha t  matter thiamine and r ib o ­
f l a v i n ,  in c e r t a in  in terconversions w i th in  the pathway ( F i g . 3 . 1 ) ,  
i t  is possible th a t  these pa t ien ts  may have an increased requirement  
fo r  pyr idoxine ,  which may not be compensated by the average intake  
of normal in d iv id u a ls .  Pyridoxine and combined pyridoxine and 
n ic o t i n ic  acid supplementation corrects  the abnormali ty in tryptophan 
metabolism in women on oral  contraceptives (Adams et_ aj_, 1973),  and 
in Hodgkin's disease ( A l l e g r i ,  Muggeo, DeAntoni, Costa, Crepa ld i ,
1972). Furthermore,  i t  has been postulated that  per ipheral  neuropathy,  
a complicat ion o f  rheumatoid a r t h r i t i s  (Pal l  is S Scot t ,  1965),  may be 
the re s u l t  of  a chronic functiona l  de f ic iency  of  pyr idoxine (Bruckner,  
Smith, Lakatos,  Chamberlain, 1972).  The authors showed that  although  
pyridoxine therapy p a r t i a l l y  corrected the increased excre t ion  of  
tryptophan metaboli tes there was no s i g n i f i c a n t  improvement from the 
neuropathy.  The pa t ien ts  studied,  however, were long-standing cases 
of neuropathy and i t  may be tha t  the changes were i r r e v e r s i b l e .  I t
would be of  in te re s t  to determine whether the correc t ion  of  the  
abnormali ty in tryptophan metabolism by pyr idoxine therapy can 
in f luence the pred ispos i t ion  to and course of  neuropathy in p a t ien ts  
with  rheumatoid a r t h r i t i s .
Chapter Four
THE EFFECT OF DRUG-MEDIATED INDUCTION ON FOLATE METABOLISM
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In troduction
The prolonged adm in is t ra t ion  of  ant iconvulsant drugs to  
pat ien ts  wi th epi lepsy has been shown to be associated wi th  low 
concentrat ion of  f o l i c  acid in the serum, red blood c e l l s  and 
cerebrospinal  f l u i d  in a s ig n i f i c a n t  proport ion o f  these p a t ien ts  
(Reynolds e t  a l , 1966a; Reynolds, 1968; Mantz e t  a l , 1970).
Several possible explanations of  these observations have 
been suggested, thus: (a) ant iconvulsants in t e r f e r e  w i th  the
biosynthesis of  f o l a t e  coenzyme forms or t h e i r  function (Hawkins 
& Meynel1, 1954),  (b) anticonvulsants i n t e r f e r e  wi th  the absorption  
of f o l i c  acid (Meynell ,  1966; Dahlke e t  a l , 1967(» (c) a n t i ­
convulsants i n h i b i t  in te s t in a l  conjugages leading to polyglutamate  
malabsorption (Hoffbrand e t  a l , 1968; Rosenberg e t  a l , 1968) and 
(d) ant iconvulsants increase the d ie ta ry  requirements fo r  f o l a t e  as 
a consequence of t h e i r  potent inducing propert ies  (Maxwell e t  a l , 1972).
Fo l ic  acid plays an important ro le  in the formation o f  cy to ­
chrome enzymes and is fu r t h e r  a cofactor  fo r  c e r ta in  hydroxylat ion  
reactions e f fe c ted  by hepatic  microsomal enzymes ( T i e t z ,  Lindberg 
& Kennedy, 1964; Hagerman, 1964),  the increased a c t i v i t y  of  which,  
due to t h e i r  induction by anticonvulsants ,  w i l l  increase the cofactor  
requirements. This would, th e re fo re ,  imply tha t any other  drug 
which is administered over a prolonged period and has potent enzyme 
inducing p rope r t ies ,  w i l l  a lso lead to increased cofactor  r e q u i re ­
ments. I f  the increased requirements were not compensated by a 
corresponding increase in d ie ta ry  intake of  f o l i c  a c id ,  symptoms 
of  de f ic iency  w i l l  ensue.
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On the above premise the re la t io n s h ip  of  f o l i c  acid and 
anticonvulsants ,  t r i c y c l i c  antidepressants and phenothiazines in 
man, and anticonvulsants  and t r i c y c l i c  antidepressants in the 
r a t ,  has been inves t iga ted .
M a te r ia ls  and Methods 
A. M ater ia ls  
Substrates
Urocanic acid was purchased from Sigma, London.
Standards
Fo l ic  acid and vitamin was obtained from Sigma, London.
Enzymes
(See Methods)
Qther_ChemicaI§
Chloramphenicol succinate was obtained from Parke-Davies , 
England, imipramine by courtesy of  Geigy Pharmaceuticals L imited,  
England, diphenylhydantoin sodium ( D i l a n t in )  by courtesy of  Parke-  
Davies,  England, and chloramphenicol base was purchased from Sigma, 
London.
The Bacto lac tobac i11i Broth AOAC, LoctobacJ11 us casei and 
Lactobaci l lus  leichmanii media were bought from Difco Laborator ies ,  
England.
Al l  other chemicals were of  Analar  grade and were purchased 
from BDH Chemicals, England.
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Chloramphenicol -resistant  Lactobaci l lus  casei and Lacto­
b a c i l lu s  leichmanii  were purchased from the Torrey Research S ta t io n ,  
Aberdeen, Scotland.
Q£h§E_MateiMa js
Chicken l i v e r s  were purchased from Baxter Frozen Foods L t d . ,  
Aldershot ,  Hampshire.
V i ta m in - f re e  casein was purchased from Cal-Biochem, London, 
England, and a l l  other m ater ia ls  fo r  d ie ts  from L i l i c o  £ Co. L t d . ,  
Ble tch ley ,  Sussex, England.
Pat jents
All  the pa t ien ts  were selected from the Brookwood P s y c h ia t r ic  
Hospital  in Surrey.  They were long-standing cases tha t  had been 
hospi ta l ised  fo r  an o vera l l  average of  18 years and on s p e c i f i c  drug 
treatment fo r  10 years (Appendix 3 ) .  None of  the pa t ien ts  was 
rece iv ing vitamin supplements.
Fasting blood samples were drawn by venepuncture a t  7 .00  a.m.  
± 10 min. Serum and red blood ce l l  (RBC) f o l a t e ,  serum white
blood c e l l  (WBC), d i f f e r e n t i a l  and RBC counts,  haemoglobin, packed 
c e l l  volume (PCV), mean corpuscular volume (MCV), mean corpuscular  
haemoglobin (MCH), mean corpuscular haemoglobin concentra t ion (MCHC) 
were determined and blood f i lm s  were made. With the exception of  
f o l a t e  and vitamin B ^  determinat ions,  a l l  others were c arr ied  
out in Farnham General Hosp i ta l ,  Surrey.
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Urine was c o l lec ted  fo r  2k  hours fo r  g lucar ic  acid est imations  
and fo r  9 hours fo l lowing the ingestion of  h is t id in e  hydrochloride  
(15 gm) fo r  formiminoglutamic acid (FIGLU) and urocanic acid 
determinations.
The d ie ta r y  intake of  each p a t ie n t  was recorded over four  
days during the c o l le c t io n s  of  samples. Food fo r  the main meals 
(b reakfas t ,  lunch, supper) and food l e f t  over was weighed. Any 
food eaten or beverage drunk between meals was recorded by the 
nursing s t a f f .  This usual ly  amounted to  cups of tea w i th  bread,  
butter  and marmalade or jam of standard amounts which were 
quant i ta ted  a t  the beginning of  the study.  The n u t r ie n t  intake  
was ca lcu la ted  fo r  each p a t ien t  from standard food tables  
(McCance & Widdowson, 1960).
To ensure complete ur ine  c o l le c t io n s  and d ie ta r y  records 
the p a t ien ts  were under close supervision during the duration of  
the study.  Th is ,  however, did not involve any s ig n i f i c a n t  
deviat ions from the d a i l y  routine of  each p a t i e n t .
B. Methods
Microbio log ica l  assays 
Pr mci^gle
The estimation of  a given n u t r ie n t  by a m icrobio logical  assay 
e n t a i l s  the growth o f  a s e le c t iv e  micro-organism in a medium t o t a l l y  
devoid o f  the n u t r ie n t  and in which a known amount of  the n u t r i e n t  
is added. Quant i ta t ion  is achieved by measuring the growth o f  the
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micro-organisms t u r b i d i m e t r i c a l l y  and r e la t in g  i t  to the amount 
o f  the n u t r ie n t  present in the assay medium.
The use of  a chloramphenicol re s is ta n t  s t r a in  o f  Lacto­
b a c i l lu s  casei (L. casei)  has considerably s im p l i f i e d  the micro­
b io log ica l  assay of  f o l i c  acid in serum and red blood c e l l s .
The inclusion of chroramphenicol in the assay medium makes the 
previous necessary s t e r i l e  precautions obsolete and the assay can. 
be set up by a s in g le  step add i t ion  of  serum or haemolysate d i r e c t l y  
to an inoculated medium (Chanarin,  Kyle,  Stacey,  1972).
F o l ic  acid was dr ied a t  100° fo r  two hours and stored in a 
desiccator  under phosphorous pentoxide in the dark.
The L a c to b a c i l l i  broth AOAC was made up to the manufacturer1s 
sp e c i f ic a t io n s  and chloramphenicol sodium succinate (10% w/v)  was 
added to the broth to give d i lu t io n s  o f  300 yg/ml and 100 yg /ml .  
Aliquots of  the broth (10 ml) were s t e r i l i s e d  a t  10 1bs /sq . in .  fo r  
10 minutes.  The stock cu l tu re  was stored in the 300 yg chloi— 
amphenicol/ml broth a t  4° and subcultured weekly.
L.casei  fo r  the assay was subcultured into the 100 yg chloi— 
amphenicol/ml broth,  grown at  37° f o r  2k  hours, subcultured again 
and grown for  8 hours. The l a t t e r  was subcultured,  grown overnight  
a t  37°,  and the cu l tu re  used fo r  inocula t ing the medium, having 
subcultured i t  f i r s t  in the 300 yg chloramphenicol /ml broth fo r  
storage fo r  fu tu re  assays.
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Single strength medium (medium) was made up as described  
by the manufacturer,  cooled and 0.1% chloramphenicol base BP in 
1.0% ethyl  alcohol (1 ml) and ascorbic acid (1 .0  gm) was added 
per l i t r e  of  the medium. The pH was adjusted to between 6 . 1 - 6 . 3  
with  3N KOH and any p r e c i p i t a t e  al lowed to  s e t t l e  and discarded.
An a l iq u o t  (5 ml) o f  the medium served as blank.  The L. casei  
cu l tu re  was washed three  times with  10 ml a l iquo ts  of  the medium 
and f i n a l l y  resuspended in 2 ml a l i q u o t .  This const i tu ted  the  
inoculum of which a l iq u o ts  ( 0 .1 - 0 .1 5  ml)were added per l i t r e  of  
the medium. The inoculated medium was kept a t  4°  and constant ly  
s t i r r e d  to keep the organism in suspension.
Sera were stored with  ascorbate (5 mg/ml serum) and red 
blood c e l l  haemolysates were prepared in 1% w/v ascorbic acid  
so lu t io n .  Haematocrit readings were noted and a l l  samples stored  
a t  - 2 0 ° .
Assay_procedure
Aliquots of  serum and haemolysates (0 .05  ml) were d i lu te d  
with  medium (4 .95 ml) using a Fisons a u t o d i lu t e r .  The samples 
were then incubated a t  37° fo r  22 hours and water (5 ml) was added 
and mixed thoroughly p r io r  to reading the t u r b i d i t y  a t  625 nm in 
a Unicam SP 500 semi-automatic spectrophotometer. Blanks and 
standards (0~ 18 ng f o l i c  acid)  were set up w i th  each assay and 
c arr ied  through the same procedure. Recovery of  added f o l i c  acid  
to serum and haemolysates ranged from 9^“ 101% and 98-104% 
re sp e c t ive ly .
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Safeguards against contamination included doubly washed 
glassware which was segregated from other laboratory  use, use o f  
the same vessel fo r  given f o l i c  acid concentrat ions ,  and p la t in g  
the inoculum on blood agar and incubating i t  w ith  the assay batch 
to check a irborne or any other microbial  contamination.  The 
automatic d i l u t e r  was kept clean by running through a t  leas t  1 l i t r e  
of  water p r io r  to each assay.
y|tamm_Bi £
Serum vitamin -B was estimated by the method in which 
Lactobaci l lus  leichmanii  (L. le ichmanii )  was used as the te s t  
organism (Matthews, 1962).  The values of  serum vitamin B ^  
obtained by the L. leichmanii  method c o r r e la te  wel l  w ith  those 
from the s l i g h t l y  more s p e c i f ic  Euglena g r a c i l i s  one (Baker,
Frank, Pasher, Sobotka, 1960).  The l a t t e r ,  however, requires
much more laborious and time consuming manipulations than the  
former.
EL?2§I§£l2G_2f _lG22ylyOL§D^ _Yi£§!I)i[L§i 2--~iyD
L. leichmanii was grown, subcultured f o r t n i g h t l y ,  and stored  
at  4° a s e p t i c a l l y  in the B ac to - la c to b ac i11i broth AOAC. The 
inoculum was a s e p t ic a l l y  prepared p r io r  to each assay as in the L. 
casei method, except tha t  a d i l u t i o n  (1:100) was made before adding 
1 drop of  the inoculum from a Pasteur p ip e t te  (50 drops/ml) to each 
assay tube.  The maker's ins truct ions  were fol lowed fo r  the 
rehydration of  the medium.
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Serum (2 .5  ml) was mixed with  0 .2  M sodium aceta te  b u f fe r  
pH k . 6  (2 .5  ml) conta in ing sodium cyanide (18 mg/1) and water  
(10 m l) .  I t  was placed in a b o i l in g  water bath fo r  30 minutes,  
cooled and f i l t e r e d  (Whatman No.5^1 f i l t e r  paper) .  The pH of  
an a l iq u o t  o f  the f i l t r a t e  (9 ml) was adjusted approximately to  
6 .8  with  0.1N NaoH (0 .8  ml) and water added to a f ixed  f in a l  
volume (15 m l ) .  This const i tu ted  the serum e x t r a c t .
Assay_Erocedure
To an a l iq u o t  o f  serum e x t r a c t  (2 ml) water (3 ml) and double 
strength assay medium (5 ml) was added, mixed, and the mixture  
autoclaved fo r  3 minutes at  15 p . s . i . ,  inoculated and incubated at  
37° fo r  2k  hours. The tubes were thoroughly mixed p r io r  to reading 
the density  of  b a c te r ia l  growth t u r b i d i m e t r i c a l l y  a t  720 nm in a 
Unicam SP 500 semi-automatic spectrophotometer.  Blanks and 
standards (0-200 pg vitamin B ^ )  were c ar r ie d  through the same 
procedure. Recovery of  added vitamin B ^  to serum ranged from 
Sk to 108 per cent.
The precautions taken against  contamination were the same 
as those in the f o l i c  acid assay.
The values of  serum vitamin B ^  obtained in d i f f e r e n t  
lab ora to r ies  appear to d i f f e r  w ide ly .  This is p a r t l y  due to 
the d i f f e r e n t  methods used, and also to  the presence or absence 
of  cyanide during the e x t ra c t io n  of  the v i tam in .  Cyanide has 
been used in th is  method in view of reports th a t  traces of  th is  
chemical in the e x t rac t io n  medium w i l l  pro tect  vi tamin B ^  from
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destruct ion  during au toc lav ing ,  w i l l  also a ss is t  in s p l i t t i n g  o f f  
the bound v itamin from prote ins (Denton & Kel logg, 1953) and 
improve recoveries of  added vitamin (Spray,  1955).
Enzyme assays
L!lliG§!IY_2^ilIl§£i2!]_2f _f2I!DiC?iD22iy£§!Ili2_§2i^_i£l§ty)
FIGLU is excreted in the ur ine in large amounts fo l low ing  
any impairment o f  the f o l i c  acid coenzyme functions.  I t  is 
estimated by employing a crude chicken l i v e r  enzyme preparation  
which f i r s t l y  reduces f o l i c  acid to i t s  a c t iv e  form, THFA, and 
secondly catalyses the t ra n s fe r  of  the formimino-group o f  FIGLU to  
THFA. The end-product o f  the react ion is converted to 5~10 
metheny1-THFA with  hydrochloric acid and is read s p ec tro p h o to m etr ic a l ly .
yEyy2_2D?Y!D2_BE22§I§^ i2D
Frozen chicken l i v e r s  were scissor-mineed and added to 0.1 M 
potassium phosphate b u f fe r  pH 6 .0  (1 :1 .3  volumes),  homogenised and 
centr i fuged a t  33,000 x g a t  4° fo r  10 minutes.  The supernatantcN/
was dialysed overnight against  d i s t i l l e d  w ater ,  the pH adjusted to  
6 .0  and any residue centr i fuged and discarded. The supernatant  
was kept a t  -2 0 °  in a l iquo ts  (10 m l ) .
§yy§£E§£2_§2 ! 2£ i 2D
Potassium dihydrogen orthophosphate 20 mmoles) 
)
Dissolved in d i s t i l l e d
C i t r i c  acid
)
2 mmoles) 
\
water (100 ml) and the
Magnesium sulphate heptahydrate
)
2 mmoles) 
\
pH adjusted to 6 . 0 .
NADP
)
12 ymoles) Prepared fresh before
Fo l ic  acid
)
55 ymoles) use.
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The incubation mixture consisted o f :
Liver  e x t r a c t 1 ml
Substrate solut ion 2 ml
Incubated a t  37° fo r  2 hours and added
Ur i ne 0 . 0 1 - 0 . k  ml (not to exceed 0 .2  ymoles FIGLU)
Water to 3 'k  ml
Mixed, incubated a t  37° fo r  a fu r t h e r  2 hours and added
3N HC1 1.5 ml
A f te r  mixing and al lowing to stand a t  room temperature fo r  
15 minutes the mixture was f i l t e r e d  and the op t ica l  densi ty  was read 
at  350 nm in a Unicam SP 500 semi-automatic spectrophotometer.
Blanks and standards (0 - 0 .2  ymoles FIGLU f in a l  concentrat ion)  
were c arr ied  through the same procedure.  Using th is  method in our 
laboratory  the recovery o f  added FIGLU to ur ine ranged from 89-95  
per cent.
The crude chicken l i v e r  enzyme preparation also contains  
urocanase, an enzyme cata lys ing  the conversion of  urocanic acid  
to FIGLU. The method, th e re fo re ,  est imates the combined urocanic  
acid and FIGLU excre t ion .  This combination is of  great  
importance, since in some f o l i c  acid d e f i c i e n t  pa t ien ts  urocanic  
acid may comprise up to 80 per cent of  h i s t i d in e  de r iv a t iv es  
appearing in the urine  (Bennett & Chanarin,  1961).  Urocanic acid  
has been estimated separate ly  in our studies by destroying FIGLU 
by autoclaving the urine at  a lk a l in e  pH (pH 9“ 11) .
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Section A
THE EFFECT OF DRUG-MEDIATED INDUCTION ON FOLATE METABOLISM IN MAN
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Results
Serum f o l a t e  leve ls  were s i g n i f i c a n t l y  lower in pat ien ts  
t rea ted  wi th ant iconvulsants and phenothiazines and RBC f o l a t e  
leve ls  were s i g n i f i c a n t l y  lower in a l l  groups o f  pa t ien ts  t re a ted  
with  drugs (Table b . 1 ) .  Serum B ^  leve ls  were of  the same order  
of  magnitude in a l l  pa t ien ts  studied,  including the c o n t ro ls .
The d ie ta ry  intake o f  f o l i c  acid did not d i f f e r  s i g n i f i c a n t l y  
among the c o n t ro l ,  anticonvulsant and phenothiazine group of  
p a t ie n ts ,  but i t  was s i g n i f i c a n t l y  lower in the t r i c y c l i c  group 
as compared to the control  group o f  p a t ie n ts .
The blood appearance o f  pat ien ts  wi thout any drug treatment  
was normal with  the exception of  one case o f  very mild lymphocytosis 
(Table b . 2 ) .  Of the pa t ien ts  trea ted  with  anticonvulsants ,  f i v e  
had abnormal red blood c e l l  appearance (burr c e l l s ,  1 /16 ,  
anisocytosis  3 /16 ,  hypochromia, 2 /16)  and three abnormal whi te  
blood c e l l  appearance (eos inophi1ia ,  2 /16 ,  and n e u t r o p h i l i a ,  1 / 1 6 ) .  
Four of  the pa t ien ts  t rea ted  with  phenothiazines had an abnormal 
red blood c e l l  appearance (burr c e l l s ,  1 /16 ,  an isocytos is ,  1 /16 ,  
polychromasia, 1 /16 ,  p o i k i l o c y t o s is , 1/16)  w i th  the appearance of  
the whi te  blood c e l l s  being normal in a l l  the pat ien ts  in th is  group.  
There were two cases of  eos inoph i l ia  (2 /7 )  but no RBC abnormal i t ies  
were seen in the pat ien ts  trea ted  wi th  t r i c y c l i c  drugs. No 
macrocytosis, hypersegmented polymorphs or giant band forms were 
observed. The p l a t e l e t s  were normal in a l l  the p a t ien ts  of  the  
groups studied.  None of the pa t ien ts  studied was anaemic.
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The other haematological  parameters th a t  were measured,
WBC and RBC counts,  Hb, PCV, MCV, MCH and MCHC, were w i th in  the  
normal range in a l l  the pa t ien ts  studied (Table k . 3 ) .
The ur inary  excret ion o f  FIGLU and urocanic acid was 
s i g n i f i c a n t l y  elevated fo l lowing an ora l  h i s t i d in e  load in p a t ien ts  
t rea ted  wi th  anticonvulsants and phenothiazines but not in those 
trea ted  wi th  t r i c y c l i c  drugs, as compared to controls (Table A .A).  
A ll  th ree groups o f  drugs s ig n i f i c a n t l y  increased the ur inary  
excre t ion  of  g lu c ar ic  acid (Table h . A),  i n d i r e c t l y  ind ica t ing  
tha t  these drugs induce the a c t i v i t y  o f  hepat ic  microsomal 
enzymes.
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Table 4 .4  Ur inary  excre t ion  of  FIGLU and urocanic acid  
fo l low ing  an oral  h i s t i d in e  load (15 gm) and 
g lu c a r ic  ac id ,  in pa t ien ts  t rea ted  with  a n t i ­
convulsant,  phenothiazine and t r i c y c l i c  drugs 
± SEM.
Group No. o f  pat ients
FIGLU 
m g/9 hrs
Urocanic acid 
m g/9 hrs
Glucar ic  acid  
ymoles/24 hrs
Controls 15 7.1 ± 1.6 2 .3  ± 0.9 9 .3  ± ' 1 .7
Anticonvulsants 16 21.7  ± 3.1 11.8 ± 1 . 7 93.3  ± '17.6
Phenothiazines 15 16.5 ± 1.6 8.8  ± 1.6 28.0 ± ' 5 .4
T r i c y c l ic s 7 10.5 ± 2 .7 4 .5  ± 1.4 32.5  ± 7 .2
Control v Anticonvulsants <0.0005 <0.0005 <0.0005
Control v Phenothiazines <0.0005 <0.0005 <0.0025
Control v T r i c y c l ic s NS NS <0.0005
Anticonvulsants v Phenothiazines NS <0.05 <0.0025
Anticonvulsant v T r i c y c l ic s <0.025 <0.005 <0.025
Phenothiazines v T r i c y c l ic s <0.025 <0.05 NS
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Pi scuss ion
The prolonged a dm in is t ra t ion  o f  anticonvulsants and pheno­
th iaz ines  has been shown to lower s i g n i f i c a n t l y  serum f o l a t e  l e v e ls .  
These drugs, as well  as t r i c y c l i c s ,  have also been shown to decrease 
the leve ls  of  red blood c e l l  f o l a t e .  Of the three groups o f  drugs 
studied,  only anticonvulsants  and phenothiazines increased the  
ur inary  excret ion of  FIGLU and urocanic ac id .  Al l  the drugs studied  
increased the excre t ion  o f  g lu c ar ic  acid in the ur ine .
Megaloblast ic  haemopoiesis
None of  the pa t ien ts  studied in the present in v e s t ig a t io n  was 
anaemic (Table 4 .2 ,  4 . 3 ) .  I t  is however, wel l  establ ished tha t  
megaloblastic haemopoiesis may occur as a complicat ion of  a n t i ­
convulsant therapy with  diphenylhydantoin alone (Hawkins S Meynell ,  
1954; Webster, 1954) or in combination with  other  anticonvulsant  
drugs (Kidd & Mol in ,  1957; Dahlke & Mertens-Rosler,  1967),  w ith  
mysoline alone (Chanarin,  Elmes £ M o l l in ,  1958; M i l l e r ,  1968) or  
in combination with  o ther  drugs (Kidd ejt aj_, 1957; Stokes £
Fortune,  1958),  and b arb i tu ra tes  such as phenobarbital  (Hawkins 
ejt 9_]_, 1954; Chanarin et  ^ a_j_, 1960). The absence of  macrocytosis  
in our pa t ien ts  is thus in contrast w ith  the high incidence  
reported by Hawkins e t  aj_ (1958) (27% with  diphenylhydantoin,  34% 
with phenobarb i ta l , and 45% with  diphenylhydantoin and phenobarbital  
combined, o f  159 p a t ien ts )  and K l ip s t e in ,  1964, (74% wi th  d iphenyl ­
hydantoin of  53 p a t ien ts )  but is in agreement wi th  the f ind ings  of  
Reynolds, M i ln e r ,  Matthews and Chanarin (1966a) who did not detect  
macrocytosis in a study involving 45 e p i l e p t i c s .  The g rea te r
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number o f  p a t ie n ts ,  th e re fo re ,  in the studies o f  Hawkins and
K l ip s te in  may only p a r t l y  exp la in  the d i f fe re n ce  in the
incidence o f  macrocytosis. The morphological abnormal i t ies  
found in some of the pa t ien ts  studied in the present ser ies  
(Table 4 .2 )  may r e f l e c t  non-spec i f ic  s id e -e f f e c ts  of  the drugs 
studied.
Drug-induced biochemical de f ic iency  of  f o l i c  acid
The f indings o f  the present study ind ica te  a high incidence  
of  biochemical f o l a t e  de f ic iency  in pa t ien ts  rece iv ing long-term  
ant iconvulsant ,  phenothiazine and, possib ly ,  t r i c y c l i c  therapy as 
judged by the decreased serum and red blood c e l l  f o l a t e
concentrat ions (Table 4 . 1 ) .  The high prevalence of  decreased
serum ( K l ip s t e in ,  1964; Reynolds e_t jal_, 1966 ; Dahlke et_ a_l_, 1967; 
Horwi tz  et  ^ £l_, 1968 ; Jensen et_ £l_, 1969; Houben et_ a_l_, 1971) and 
RBC (Preece et  ^ aj_, 1971) f o l a t e  concentrat ions in e p i l e p t i c  
pat ien ts  t rea ted  with  drugs is wel l  documented. There is ,  however, 
no such evidence in the l i t e r a t u r e  p e r ta in ing  to s im i la r  de f ic ie ncy  
induced by long-term phenothiazine and possibly  t r i c y c l i c  therapy,  
although in the l a t t e r  only the decrease in RBC f o l a t e  concentrat ion  
reached. levels  of  s ig n i f ic a n c e .  This may be a r e f l e c t i o n  o f  the  
low d ie ta r y  intake in the t r i c y c l i c s  group. These f ind ings  may 
w e l1 be in d ic a t iv e  o f  a common underlying mechanism in the 
p r e c i p i t a t i o n  of  the def ic iency  by these drugs,  despite  t h e i r  
s t ru c tu ra l  d i s s i m i l a r i t y .
Formiminoglutamic acid (FIGLU), which ar ises  from the in v ivo  
degradation o f  histidine^ is converted to glutamic a c id ,  the reaction  
being catalysed by te t ra h y d ro fo la te  (THFA) ( F i g . 4 . 1 ) .  In f o l i c
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acid def ic iency  the conversion cannot be e f fe c te d  and FIGLU, 
along with  i t s  precursor urocanic ac id ,  is excreted in the 
urine unchanged. In f o l i c  acid d e f i c i e n t  subjects the  
excre t ion  can be augmented by the p r io r  adm in is t ra t ion  of  
h i s t i d in e  (Luhby, Cooperman & T e l l e r ,  1959)* An ora l  
h is t i d in e  load resulted in a s i g n i f i c a n t l y  increased excret ion  
o f  FIGLU and urocanic acid in pa t ien ts  t rea ted  w i th  a n t i ­
convulsant and phenothiazine drugs when compared with control
F i g . 4.1 I n t e r r e la t io n s h ip  o f  h i s t i d in e  metabolism and f o l i c  acid
H i s t  idi  ne
Hi s t i  dase
V
Urocanic acid
Urocanase
Pyridoxal  phosphate
V
Imidazoloneprop ionic  acid
Imidazoloneprop. Ionic  acid  
hydrolase
Formiminoglutamic acid (FIGLU)
THFA Formiminoglutamate
formimi notransferase
y j/
Glutamic acid + N5-Formimino THFA
V
n5 N10Methenvl THFA
-NH^ Cyclodeaminase
l\
Deacylase Synthetase
NADP^l\Dehydrogenase 
NADPHN10-Formyl THFA
Ho0 ATP
\
Formate + THFA
N5 , N10-Methylene THFA
, . +  g lycine  ser ine  hydroxy-
 ^ Vc,ne methyl t rans fe rase
/
THFA + Seri ne
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pa t ien ts  (Table 4 . 4 ) .  In the case of  the patien ts  t re a ted  wi th  
t r i c y c l i c  drugs,  however, the increase in FIGLU and uro canic  
acid excre t ion  did not reach leve ls  of  s ig n i f ic a n c e ,  probably 
e i t h e r  because o f  the smaller  number o f  pa t ien ts  or  the shorter  
duration of  treatment in th is  group (Appendix 3)*  Urinary  
FIGLU excret ion above the upper l i m i t  o f  normal (18 mg) has been 
reported in a proport ion (23%) o f  t re a ted  e p i le p t i c s  (Reynolds
e_t aj_, 1966a). In the present ser ies  7 out of  14, 6 out of  15
and 1 out o f  7 pa t ien ts  t rea ted  wi th anticonvulsants ,  pheno- 
t h ia z in e  and t r i c y c l i c  drugs re s p e c t iv e ly ,  were excre t ing  FIGLU 
above the upper l i m i t  o f  the normal range. I t  can, however, be 
seen (Table 4 .4 )  that the group average fo r  FIGLU excre t ion  in 
the drug- t rea ted  p a t ien ts  is higher than the control  group and 
t h is  may well  be in d ic a t iv e  o f  subc l in ica l  f o l i c  acid in s u f f ic ie n c y .
Mechanism of  drug-induced f o l i c  acid def ic iency
I t  is in te res t in g  tha t  the increase in the ur inary  excre t ion  
of  FIGLU in the drug t rea ted  pat ien ts  is accompanied by a marked
increase in the ur inary  excret ion of  D-g lucar ic  acid (Table 4 . 4 ) .
The l a t t e r ,  a product of  the glucuronic  acid pathway in several  
animal species as well  as man (Marsh, 1963; Dutton,  1966 ) has been 
used as an index o f  hepatic  microsomal enzyme induction,  since  
i ts  excre t ion  in the urine is e levated fo l lowing the a d m in is t ra t io n  
o f  drugs th a t  induce hepatic  microsomal enzyme a c t i v i t y  (A ar ts ,  1965; 
Conney, 1967; W i l l iams,  Maxwell,  Hunter, 1972). The excre t ion  
o f  the metaboli te  has also been shown to be re la ted  to  drug dose 
in man (Hunter £ t  aj_, 1971b) and the to t a l  content of  hepat ic  
microsomal cytochrome P-450 in the guinea pig (Hunter et  ^ £]_, 1971a).
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Furthermore,  increased g lu c ar ic  acid excre t ion  has been reported  
to be s i g n i f i c a n t l y  c orre la ted  with  decreased serum and red blood 
c e l l  f o l a t e  concentrat ions (Maxwel1 e t  a l , 1972) in t rea ted  
e p i l e p t i c s ,  thus i n d i r e c t l y  ind ica t ing  th a t  such a decrease may 
be the re s u l t  o f  enhanced f o l a t e  u t i l i s a t i o n  fo l lowing the 
induction o f  hepatic  microsomal drug-metabolising enzymes by 
anticonvulsants .  In our p a t ie n ts ,  increased ur inary  FIGLU 
and g lu c a r ic  acid excre t ion  is accompanied by a decrease in both 
serum and red blood c e l l  f o l a t e  not only in the drug- t rea ted  
e p i le p t i c s  but a lso in pa t ien ts  t rea ted  wi th phenothiazines and 
possibly t r i c y c l i c s ,  ind ica t ing  th a t  hepat ic  microsomal enzyme 
induction may, indeed, be the underlying mechanism in the 
p r e c i p i t a t i o n  of  drug-induced biochemical f o l a t e  d e f ic ie n c y .  I t  
may also be, th e re fo re ,  tha t  the decrease in blood f o l a t e  leve ls  
in women taking oral  contraceptives (Necheles e t  a l ,  1970;
S t r e i f f ,  1970),  in p a t ien ts  wi th rheumatoid a r t h r i t i s  ( A l t e r ,  
Z v a i f l e r  & Rath, 1971) and in chronic a lcoho l ics  (Knowles e t  a l ,
1963) is the r e s u l t  of  the induction of  the hepatic  microsomal 
enzymes, although in the case of  a lcoho l ics  hepat ic  dysfunction  
may play a s i g n i f i c a n t  contr ibutory  ro le .
Ex is t ing  evidence suggests th a t  f o l i c  acid may play a ro le  
as a cofactor  in c e r ta in  hydroxyla t ion react ions ,  performed by 
hepat ic  microsomal enzymes. A hepatic  microsomal enzyme system 
has been described in the ra t  that catalyses the ox idat ion  of  
long chain a lk y l  ethers o f  g lycerol  to f a t t y  acids and f re e  
glycero l  ( T i e t z ,  Lindberg & Kennedy, 1964).  Repeated washing 
of the microsomal preparat ion resulted in the loss of  such a c t i v i t y ,  
which was restored by the add i t ion  of  a p te r id in e  cofactor  (2-amino-
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4-hydroxy-6 m ethy l te t rahydropter id ine)  or te t r a h y d r o fo la t e .  
Furthermore,  i t  has been shown tha t  in the hydroxyla t ion of  
phenylalanine (Kaufman, 1967; Goodfriend £ Kaufman, 1961), ty ros ine  
(El lenbogen, Taylor  £ Brundage, 1965) and progesterone (Hagerman,
1964) c e r ta in  p te r id ines  or te t ra h y d ro fo la te  is required as a 
cofactor .  A l t e r n a t i v e l y ,  f o l a t e  is required in the de novo 
synthesis o f  the cytochrome P-450 and bc involved in the non-
p
p te r id in e  microsomal hydroxyla t ion of  drugs, and induction of  
these enzymes w i l l  make large demands on th is  v itamin .  I f ,  indeed,  
f o l i c  acid de f ic iency  is the re su l t  of  i t s  augmented u t i l i s a t i o n  
due to hepatic  enzyme induction by drugs, then f o l a t e - d e f i c i e n t  
pat ien ts  might be expected to have an impaired capacity  to  
metabolise drugs and t h e i r  supplementation should restore  or even 
augment th is  capac i ty .  I t  has been shown tha t  the metabolism of  
phenytoin is accelerated during f o l i c - a c i d  treatment in patients  
with phenytoin in to x ica t io n  (Kut t ,  Winters £ McDowell, 1966) and 
tha t  a decrease in serum phenytoin levels  occurs during f o l i c  acid  
supplementation in s t a b i l i s e d  patien ts  rece iv ing long-term  
anticonvulsant therapy (Jensen £ Olesen, 1970; B ay l is ,  Crowley,
Preece et_ a j[, 1971),  and th is  may lead to d e te r io r a t io n  o f  f i t  
control  (Reynolds et_ a]_, 1966a) .
I t  is thus apparent tha t  the drug-mediated induction of  the 
hepat ic  microsomal drug-metabolising enzymesmay lead to increased 
metabolic requirements f o r  f o l i c  acid .  The f o l i c  acid requirements 
in man, in terms of  pure p te roy lg lu tamic  a c id ,  are thought to be 
about 50-100 yg per day (DHSS, HMSO, 1969) and th is  probably r e f l e c t s  
the minimum necessary fo r  w e l fa re .  The ca lcu la ted  d a i ly  d ie ta r y  
intake of  a l l  the pa t ien ts  in th is  study was around the 50 yg per
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day mark, w i th  the exception o f  the t r i c y c l i c  group of pa t ien ts  
whose intake is s i g n i f i c a n t l y  lower than th a t  o f  the control  
group (Table 4 .1 )  and well  below the recommended minimum r e q u i re -  
ments. The d ie ta ry  intake o f  f o l i c  acid in other  p s yc h ia t r ic  
hospi ta ls  appears to be around th is  l a t t e r  value (Dickerson,
Heald & Torrens,  personal communication). The f o l a t e  intake o f  
these p a t ie n ts ,  th e re fo re ,  is probably j u s t  s u f f i c i e n t  fo r  normal 
metabolic requirements,  and c e r t a i n l y  inadequate fo r  compensation 
of  the increased f o l a t e  u t i l i s a t i o n  due to the chronic adm in is tra t ion  
of  drugs. Because o f  the l a t t e r ,  i t  is possible tha t  these pa t ien ts  
may develop a chronic f o l a t e  d e f ic iency  which is re f le c te d  in the 
biochemical deplet ion  seen. I t  is in te res t in g  that  the biochemistry  
of  the pa t ien ts  t rea ted  with  t r i c y c l i c  drugs is not s i g n i f i c a n t l y  
d i f f e r e n t  from that o f  c o n tro ls ,  w i th  the exception of  red blood 
c e l l  f o l a t e ,  despi te  t h e i r  s ig n i f i c a n t l y  lower d ie ta ry  intake of  
f o l i c  ac id .  However, the shorte r  durat ion of  h o s p i ta l i s a t io n  and 
treatment (Appendix 3) of  these pa t ien ts  and fu r t h e r  the importance 
of the c h ro n ic i ty  o f  medication in the p r e c ip i t a t io n  o f  drug induced 
f o l a t e  def ic iency  may p a r t l y  account f o r  the d i f fe re n ce  seen.
In conclusion,  i t  would appear th a t  the prolonged admin­
i s t r a t io n  of  drugs which induce the a c t i v i t y  of  the hepatic  micro­
somal drug-metabolising enzymes may lead to an increased requirement  
and subsequent def ic iency  o f  f o l i c  a c id ,  i f  the increased requirements  
are not made good by supplementation o f  the v i tamin .  However, the  
p o s s i b i l i t y  tha t  drug-mediated enzyme induction of  the microsomal 
drug-metabolising enzymes, and f o l a t e  def ic iency  may be two d is c re te  
e f fe c ts  a r is in g  from the prolonged adm in is t ra t ion  o f  these drugs 
cannot be excluded.
Section B
THE EFFECT OF DRUG-MEDIATED INDUCTION OF THE HEPATIC FOLATE
METABOLISM IN THE RAT
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Materi  als  
Am majs
Rats: Sprague-Dawley were purchased from Bantin and Kingman L t d . ,
H u l l ,  Yorkshire .  A l l  rats were kept in polypropylene cages,  
covered with s ta in less  steel  tops (North Kent P la s t ic  Cages L t d . ) ;  
rats were kept on s t e r o l i t e  bedding (U.P.  Usher L td . )  and were 
in a room with  no other species present.  Each cage contained  
the same number o f  animals (6 ra ts )  to avoid v a r ia t io n s  due to  
crowding. For ur ine c o l le c t i o n ,  the rats were placed 
in d iv id u a l ly  in glass metabolic cages designed to separate ur ine  
from faeces by g r a v i t a t i o n .  The cages were washed on the morning 
of  c o l l e c t i o n .  Rats were k i l l e d  a t  9 hours ± 3 0  min and a l l  
operations were complete w i th in  two hours.
Djets
The d ie t  was that described by Thomson e_t aj_ (1972) (Appendix 1 ) .  
I t  was mixed in a Horbart mixer o f  40 kg capac i ty .  The powdered 
ingredients and the corn o i l  were mixed by add i t ion  in four stages 
al lowing seven minutes between each stage to ensure thorough mixing.
The hydrogenated vegetable o i l  was in the meantime melted and added 
in two stages.  The mixture was then allowed to mix f o r  twenty 
minutes,  before i t  was removed and stored in dark polythene bags at  
room temperature.  This const i tu ted  the f o l a t e - d e f i c i e n t  d i e t .
The semi-supplemented f o l a t e  d ie t  was prepared from the stock  
f o l a t e - d e f i c i e n t  d ie t  w ith  the add i t ion  o f  f o l i c  acid (0 .35 mg/kg 
food) .  The d ie t  provided the amount of  f o l i c  acid shown to be 
required to cure a l l  de f ic iency  symptoms i n t the r a t ,  35 yg per  
week (Asenjo, 1948).
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The ful ly-supplemented f o l a t e  d ie t  was prepared from 
the stock f o l a t e - d e f i c i e n t  d ie t  wi th the add i t ion  of  f o l i c  
acid (0.70  mg/kg food) .  Drugs s in g ly  or in combinations were 
added to the f o l a t e - d e f i c i e n t ,  semi-supplemented and f u l l -  
supplemented d ie ts  a t  amounts as fol lows:
Drugs Amount added (gm/kg food)
Succiny lsulphath iazole  15.00
Phenobarbitone sodium 0.50
D i la n t in  (Diphenylhydantoin sodium) 0.50
Phenobarbitone + D i l a n t in  (each) 0.35
Imipramine 0.24
Diets and water were fed ad l i b  to both control  ra ts  and ra t  
t rea ted  with  drugs fo r  12 weeks.
Results
A s ig n i f i c a n t  reduction occurred in the concentra t ion of  
serum and red blood ce l l  f o l a t e  in animals fed a f o l a t e -  
d e f ic ie n t  d ie t  and t rea ted  with succ iny lsu lpha th iazo le ,  pheno- 
barbitone,  d i l a n t i n ,  combined phenobarbitone and d i l a n t i n ,  and 
imipramine (Table 4 . 5 ) .  The excre t ion  o f  FIGLU was in v ar ia b ly  
increased in a l l  groups o f  animals t rea ted  with  drugs, the most 
marked increase occurring in the succ iny lsu lphath iazo le  group,  
w hi le  the excret ion o f  urocanic acid was s ig n i f i c a n t l y  increased 
only in the succ iny lsu lphath iazo le ,  d i l a n t i n  and imipramine groups 
(Table 4 . 5 ) .
-  140 -
There was no change in the leve ls  o f  hepatic microsomal 
cytochrome P-450 in f o l a t e - d e f i c i e n t  animals trea ted  with  pheno­
barbi tone and d i l a n t i n  alone (Table 4 . 6 ) .  However, combined 
phenobarbitone and d i l a n t i n  treatment e l i c i t e d  a marked increase  
in cytochrome P-450, whi le  treatment with  succ iny lsu lphath iazo le  
and imipramine resulted in a decrease in cytochrome le v e ls .  
Cytochrome b  ^ was s i g n i f i c a n t l y  e levated in animals t re a ted  wi th  
d i l a n t i n ,  but not in those t rea ted  with  succ iny lsu lphath iazo le  
and imi'pramine (Table 4 . 6 ) .  Hepatic microsomal pro te in  leve ls  
were s i g n i f i c a n t l y  increased in animals t rea ted  with pheno- 
barbitone and combined phenobarbitone and d i l a n t i n ,  w i th  no change 
in the other groups. The excre t ion  o f  ascorbic acid was reduced 
in animals t rea ted  wi th succ iny lsu lpha th iazo le ,  remained unchanged 
in the ones t rea ted  with d i l a n t i n ,  and was increased in those 
t rea ted  with  phenobarbitone, combined phenobarbitone and d i l a n t i n ,  
and imipramine (Table 4 . 6 ) .
Serum and red blood c e l l  f o l a t e  concentrations were 
s i g n i f i c a n t l y  reduced in rats  fed on a semi-supplemented f o l a t e  
d ie t  and t rea ted  with  succ iny lsu lphath iazo le ,  phenobarbitone,  
d i l a n t i n ,  combined phenobarbitone and d i l a n t i n  (Table 4 . 7 ) .
Animals t rea ted  with  imipramine had a s i g n i f i c a n t l y  reduced serum 
f o l a t e  concentrat ion but the reduction in red blood c e l l  f o l a t e  
did not reach leve ls  of  s ig n i f ic a n c e .  Although the excre t ion  
of  FIGLU was higher in a l l  groups of animals t rea ted  with  drugs,  
i t  only reached levels  of  s ig n i f ica n ce  in those trea ted  with  
succ iny lsu lphath iazo le ,  d i l a n t i n  and imipramine.  The e xcre t ion  
of  urocanic acid did not change in any of  the groups studied  
(Table 4 . 7 ) .
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Hepatic microsomal cytochrome P-450 was elevated in animals 
fed a semi-supplemented f o l a t e  d ie t  and t rea ted  with phenobarbitone,  
d i l a n t i n ,  combined phenobarbitone and d i l a n t i n  wi th no change in 
cytochrome leve ls  in the succ iny lsu lphath iazo le  and imipramine 
group (Table 4 . 8 ) .  S ig n i f ic a n t  e lev a t io n  of  cytochrome b^ 
concentrat ion only occurred in the su cc iny lsu lphath iazo le ,  and 
d i l a n t i n  group. The concentrat ion of  hepatic  microsomal pro te in  
was s ig n i f i c a n t l y  increased only in animals t rea ted  wi th  pheno- 
barbi tone,  d i l a n t i n  and combined phenobarbitone and d i l a n t i n .  
Ascorbic acid excret ion was s i g n i f i c a n t l y  reduced in animals 
t rea ted  with  succ iny lsu lphath iazo le ,  and increased in those t rea ted  
with  phenobarbitone,  combined phenobarbitone and d i l a n t i n  and 
imipramine. The increase in the excret ion  o f  ascorbic acid in 
animals t rea ted  with d i l a n t i n  did not reach leve ls  o f  s ig n i f ic a n ce  
(Table 4 . 8 ) .
The serum and red blood c e l l  f o l a t e  concentrat ions,  and 
the excre t ion  o f  FIGLU and urocanic acid was not changed in rats  
fed a ful ly -supplemented f o l a t e  d i e t  and t rea ted  with  pheno- 
barbi tone ,  d i l a n t i n ,  combined phenobarbitone and d i l a n t i n ,  and 
imipramine (Table 4 . 9 ) .  However, animals t re a ted  w i th  succ iny l ­
su lphath iazole  s t i l l  exh ib i ted  a s ig n i f i c a n t  decrease in serum 
and red blood c e l l  f o l a t e  concentrat ions ,  and an increase in 
FIGLU excret ion (Table 4 . 9 ) .
A l l  the animals t rea ted  wi th drugs had elevated concent­
ra t ions  of  hepatic  microsomal cytochrome P—450, with no change 
in the concentrat ion o f  cytochrome b^ (Table 4 . 1 0 ) .  S i g n i f ic a n t  
e le va t ion  in the concentrat ion of  microsomal prote in  only occurred
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in animals t rea ted  with  phenobarbitone,  d i l a n t i n ,  and combined 
phenobarbitone and d i l a n t i n .  Al l  d rug- t rea ted  animals had a 
s i n g i f i c a n t l y  increased excret ion of  ascorbic acid ,  w ith  the 
except ion .o f  those t rea ted  with  succ iny lsu lphath iazo le ,  in which 
the ascorbic acid excre t ion  was normal (Table 4 . 1 0 ) .
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D i scuss i on
Ant iconvulsant drugs,  alone or in combination,  the a n t i b i o t i c  
succ iny lsu lpha th iazo le ,  and the t r i c y c l i c  imipramine have been shown 
to (a) exacerbate f o l a t e  def ic iency  in rats fed a f o l a t e - d e f i c i e n t  
d i e t  (b) p r e c i p i t a t e  f o l a t e  de f ic iency  in rats fed a d i e t  providing  
the amount of  f o l i c  acid necessary to cure f o l a t e  de f ic iency  
symptoms but (c) f a i l  to induce f o l a t e  de f ic ienc y  in ra ts  fed a d i e t  
providing double the amount of  f o l i c  acid necessary to amel iora te  
symptoms of f o l a t e  d e f ic ien cy .  Furthermore,  increasing s e v e r i ty  of  
f o l i c  acid de f ic iency  led to an impairment of  the inducing propert ies  
of  these drugs on the hepatic microsomal drug-metabolising enzymes 
as judged by the hepat ic  microsomal leve ls  of  cytochrome P-450 and 
the ur inary  excret ion o f  ascorbic acid .
A reduction o f  the concentrat ion of  f o l i c  acid in the serum in
the ra t  fo l lowing the admin is tra t ion  o f  phenobarbitone has been
previously  reported (Smith & Racusen, 1973)* The present f indings  
extend th is  incidence not only to other  ant iconvulsant drugs,  alone  
or in combination,  but also to the t r i c y c l i c  imipramine.
Sulphonamides, such as succ iny l -  or p h th a ly 1su1pha th iazo le ,
have been used in the past to induce f o l i c  acid d e f ic ie ncy  in the r a t .
The ir  mode of act ion is thought to be by suppression o f  gut micro­
f lo r a  and i t  has been shown that  t h e i r  inc lusion in the d i e t  a t  0 .5  
to 2.0 per cent decreases the c o l i fo rm  count o f  the faeces with  no 
s ig n i f i c a n t  change in to t a l  anaerobes, to ta l  aerobes,  or anaerobic  
spores ( M i l l e r ,  1945)* Furthermore,  there is some evidence th a t  
the f o l i c  acid de f ic iency  resu l t in g  from the feeding o f  sulphonamides 
is due to the absence o f  b io t in  which is required fo r  the biosynthesis
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of  f o l i c  acid in the ra t  (Welsh & .Wright,  1943).  Thus, a 
sulphonamide-treated group o f  rats was included in th is  ser ies  of  
experiments to provide a reference fo r  any a l t e r a t i o n s  due to  
f o l a t e  de f ic ienc y .
Rats t rea ted  with succ iny lsu lphath iazo le  exh ib i ted  the most 
marked decrease in serum and red blood c e l l  f o l a t e  concentrat ions  
(Table 4 . 1 1 ) .  The percentage decrease in these parameters induced 
by the adm in is tra t ion  of  ant iconvulsants ,  alone or in combination,  
and the t r i c y c l i c  imipramine, is of  the same order  of  magnitude,  
thus ind icating  that no one drug or i t s  combination wi th other drugs 
is more or less apt in producing marked f o l a t e  d e f ic ie n c y ,  under 
the experimental  condit ions employed.
Folate de f ic iency  was accompanied by a reduction of  3Q and 22 
per cent in the concentrat ion o f  hepatic  microsomal cytochrome P-450 
in rats t rea ted  with succ iny lsu lphath iazo le  and imipramine re sp e c t iv e ly  
(Table 4 .1 1 ) .  Furthermore,  there  was no increase in the concentrat ion  
of cytochrome in animals treated with e i t h e r  phenobarbitone or  
d i l a n t i n .  However, the combination o f  phenobarbitone and d i l a n t i n  
e l i c i t e d  an increase of  215 per cent in cytochrome le v e ls .  The 
mechanism by which these e f fe c ts  are mediated is not c le a r .  The 
adm in is tra t ion  of  drugs capable of  inducing the a c t i v i t y  of  the 
hepat ic  microsomal drug-metabolising enzymes, such as phenobarbitone,  
is known to induce an increase in hepat ic  microsomal cytochrome P-450.  
Increased microsomal enzyme a c t i v i t y  probably involves the synthesis  
of new enzyme pro te in ,  since phenobarbital  a dm in is tra t ion  increases  
the incorporat ion,  both in v i t r o  and in v ivo ,  of  lab e l led  amino acids  
in to  l i v e r  microsomal pro te in  (Kato, Loeb & Gelboin,  1965) and the  
increase ( in  enzyme a c t i v i t y )  is inh ib i ted  by puromycin and actinomycin D
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(Conney S Gilman, 1963)• The synthesis of  new enzyme pro te in  may 
be due to an enhanced DNA-RNA polymerase a c t i v i t y  (Orrenius,  Ericsson 
S Ernster ,  1965)9 and RNA polymerase a c t i v i t y  (Gelboin,  Wortham & 
Wilson, 1967) as well  as the synthesis o f  a s p e c i f i c  class of  a c i d i c ,  
hepat ic  nuclear prote in  (Ruddon& Rainey, 1970) have been shown to be 
enhanced fo l low ing  phenobarbital adm in is t ra t ion  in the r a t .  Because 
of  the important ro le  of  f o l i c  acid in the biosynthesis o f  purine and 
pyrimidine nucleotides and c e r t a in  amino acids ,  i t  is possible tha t  
severe f o l a t e  de f ic iency  may c r i t i c a l l y  a f f e c t  the synthesis of  both 
nucle ic  acids and essentia l  enzyme pro te ins .  This might wel l  exp la in  
the decrease in,  or f a i l u r e  of  induction of  the hepatic  microsomal 
cytochrome P-450 in the f o l a t e - d e f i c i e n t  animals,  fo r  a gradual  
increase in induction occurs (Table 4 .11)  with increasing leve ls  o f  
f o l a t e  supplementation.  The increase in hepatic  cytochrome P-450 
in response to the combination o f  phenobarbitone and d i l a n t i n  in f o l a t e  
d e f i c i e n t  animals may ind ica te  tha t  the combination o f  f o l a t e  
def ic iency  and potency of  induction may be the deciding fa c to r  to  
response, that is a greater  amount o f  drugs may be required to e f f e c t  
a given leve l  of  induction.
The adm in is t ra t ion  o f  succ iny lsu lphath iazo le  in f o l a t e  
d e f i c i e n t  animals led to a decrease in the ur inary  excre t ion  o f  
ascorbic ac id ,  an e f f e c t  which disappeared wi th f o l a t e  supplementation.  
However, phenobarbitone,  combined phenobarbitone and d i l a n t i n ,  and 
imipramine but not d i l a n t i n ,  a dm in is tra t ion  in f o l a t e  d e f i c i e n t  rats  
increased the excret ion o f  the v itamin ,  an increase which was 
genera l ly  augmented wi th supplementation of  f o l i c  acid (Table 4 . 1 1 ) .  
Decreased ur inary  excret ion o f  ascorbic acid in d e f ic iency  of  
thiamine (Roy, Roy & Guha, 1946), r i b o f l a v i n  (Sure, Theis &
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Herrelson, 1939),  and f o l i c  acid (Schwartz & W i l l iams,  1952) has been 
reported in the r a t .  Moreover, f o l a t e  d e f ic iency  has been shown to  
cause a reduction of  60-90% in the synthesis of  ascorbic acid by ra t  
l i v e r  microsomes (C h at te r jee  & Kar, 1960).  The add i t ion  of  f o l i c  
ac id ,  or i t s  a c t iv e  coenzyme form, in v i t r o , did not a c t i v a t e  the 
synthesis of  ascorbic acid by the d e f i c i e n t  animals,  n e i th e r  did the 
addi t ion  of  a n t i f o l a t e s  depress the synthesis in normal t issues .  I t  
has, th e re fo re ,  been suggested that the decrease in synthesis is not 
because of the decrease in cofactor  a v a i l a b i l i t y ,  but ra ther  tha t  i t  
is p r im a r i ly  due to the derangement of  the microsomal enzymes brought  
about by the de f ic ie n cy .  I t  may well  be that the same mechanism is 
operat ive  in th is  series  of  experiments.  I t  is not,  however, c le a r  
whether the d i f f e r e n t i a l  response in the ur inary  ascorbic acid  
excret ion brought about by the drug treatments used, represents  
d i f f e r e n t  states of  functional  f o l a t e  de f ic ien cy .
A l l  the drugs studied have been shown to induce the a c t i v i t y  
of  the hepatic  microsomal drug-metabolising enzymes as indicated by 
the increase in cytochrome P-450 level  in the ful ly -supplemented  
animals,  and f u r t h e r ,  despite  t h e i r  s t ru c tu ra l  d i s s i m i l a r i t i e s ,  t h e i r  
admin is tra t ion  to rats has been shown to create  a biochemical f o l a t e  
de f ic ienc y .  I t  is d i f f i c u l t  to a sc er ta in  whether the induction o f  
hepat ic microsomal enzyme a c t i v i t y  and f o l a t e  d e f ic iency  is a d i r e c t  
cause and e f f e c t  phenomenon. However, i f  the mechanism of the a n t i ­
convulsant-mediated f o l a t e  def ic iency  was assumed to be due e i t h e r  to  
impairment of  f o l a t e  coenzyme biosynthesis (Hawkins et_ a_l_, 1954) or  
decreased in te s t in a l  f o l a t e  absorption (Meynel1, 1966) or  to a n t i f o l a t e  
act ion of  these drugs (Girdwood & Cenman, 1956),  i t  would be d i f f i c u l t  
to exp la in ,  on th is  basis,  the f o l a t e  d e f ic ie nc y  produced by pheno-
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thiazines (Section A) and imipramine, fo r  there  is no such evidence  
per ta in ing  to s im i la r  e f fe c ts  of  the two l a t t e r  drugs. I t  would,
th e re fo re ,  be more reasonable to assume that  the ensuing f o l a t e  
def ic iency  fo l lowing the adm in is tra t ion  o f  these drugs, may be due 
to t h e i r  common property ,  namely th a t  o f  enzyme induction,  although  
the p o s s i b i l i t y  tha t  phenothiazines and imipramine e f f e c t  f o l a t e  
def ic iency  via  an unrelated mechanism cannot be excluded.
The general impairment in the increase in cytochrome P-450 
levels  in f o l a t e - d e f i c i e n t  animals,  fo l low ing  the a d m in is t ra t ion  of  
the drugs studied fo r  twelve weeks, is of  special i n t e r e s t .  I t  is 
genera l ly  bel ieved that an increase in the leve ls  of  cytochrome P-450 
occurs soon (12-24 hrs) a f t e r  the adm in is tra t ion  o f  drugs capable of  
inducing the a c t i v i t y  of  the hepatic  microsomal drug-metabolising  
enzymes. This phenomenon is thought to be due to subst rate  induction  
and is accompanied by the synthesis of  new enzyme p ro te in .  I t  would 
have, th e re fo re ,  been of in te re s t  to have studied cytochrome P-450 soon 
a f t e r  the commencement of  feeding o f  the f o l a t e  d e f i c i e n t  d i e t ,  a t  
which time t rue  f o l a t e  def ic iency  would have not been estab l ished .
I f  the cytochrome leve ls  were increased, a t  an e a r ly  stage,  as they 
are in rats  fed a normal d i e t ,  then the impairment in cytochrome P-450 
seen at  12 weeks may represent a progressive decrease in induction  
capacity  with increasing biochemical d e f ic iency  of  f o l i c  ac id .  In view 
of  the c h ro n ic i ty  of  adm in is tra t ion  of  the drugs in these experiments  
and rapid turnover ra te  o f  reduced hepat ic  f o l a t e  ( t£  3 • 3—43 days) in 
the rat  (Thenen, Shin, Stokstand, 1973), i t  may well  be tha t  an e q u i l ­
ibrium may be reached in which any fu r t h e r  increase in induction may 
not be accompanied by a corresponding increase in enzyme a c t i v i t y  due 
to the lack of  the co factor ,  and i ts  progressive u n a v a i l a b i l i t y  may
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a c t u a l l y  re s u l t  in a decrease of  enzyme le v e ls ,  as i t  is seen in 
the animals t rea ted  wi th  succ iny lsu lphath iazo le  and imipramine.
In conclusion i t  would appear tha t  drug-mediated f o l a t e  
def ic iency  may lead to impairment of  the a c t i v i t y  of hepat ic  
microsomal enzyme induction,  although the two e f fe c ts  may not 
necessar i ly  be d i r e c t l y  re la te d .
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Section C
ARE ANTICONVULSANTS TERATOGENIC?
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I ntroduction
The e a r ly  work of  Warkany £ Nelson (1940) estab l ished the 
importance o f  maternal d ie ta r y  def ic iency  in congenital  anomalies
in the r a t .  Since then a number o f  studies have shown tha t  the
def ic iency  of  a number of  n u t r ie n ts ,  vi tamin A, vi tamin E, panto­
thenic  ac id ,  r i b o f l a v i n ,  f o l i c  ac id ,  may be te ra togenic  (Nelson, 1957).
Fo l ic  acid d e f ic iency  is notable fo r  the wide range and high 
incidence of  congenital  defects produced in the r a t .  This may be 
due to a number o f  fa c to rs ,  such as ( i )  the involvement of  the 
vitamin in key reactions in the developing embryo over the e n t i r e  
period of  d i f f e r e n t i a t i o n  and organogenesis,  ( i i )  the embryonic 
requirement fo r  the vitamin being so high that the development of  
the embryo is a f fe c ted  long before the mani festa t ion o f  maternal  
def ic iency  symptoms and ( i i i )  the ' te ra to g e n ic  zone1, i . e .  the 
d i f fe re n ce  between the s e v e r i ty  of  the d e f ic iency  required fo r  t e r a ­
togenic e f fe c ts  and tha t  fo r  le thal  e f fe c ts  in the embryo, is broad 
(Nelson, 1960).
A v a r ie t y  of  experimental  procedures have been used in the 
study o f  the te ra togenic  e f fe c ts  o f  f o l a t e  d e f ic ie n c y .  The d e f ic ie n c y ,  
which may be t r a n s i t o r y  or present throughout the gestat ion  per iod ,  
has successful ly  been induced by feeding a f o l a t e  d e f i c i e n t  d i e t  
fo r  several months (Richardson £ Hogan, 1946),  by the a d m in is t ra t ion  
of a n t i f o l a t e s  (Nelson, Asl ing £ Evans, 1952) or by the adm in is t ra t io n  
of sulphonamides such as succ iny lsu lphath iazo le  (Nelson e t  a l , 1952) .  
I r resp ect ive  of  the procedure used, f o l a t e  de f ic iency  resu l ts  in 
foe ta l  death or maldevelopment, despi te  the r e l a t i v e  lack of  
d ef ic iency  symptoms in the mother.
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The occurrence of  morphological abnormal i t ies  has been 
reported to be dependent on the time o f  i n s t i t u t i n g  the d e f ic iency  
and on the p a r t i c u l a r  organ system studied.  Thus, the in t roduct ion  
of the de f ic iency  of  the vitamin on ( i )  the day of  breeding 
in v a r ia b ly  leads to foe ta l  resorption (Nelson £ Evans, 1949),  ( i i )  the 
7th~9th day a f t e r  breeding leads to 100 per cent foe ta l  resorpt ion  
( i i i )  the 10 t h - 13th day a f t e r  breeding,  a period of  a c t iv e  embryonic 
organogenesis,  leads to a v a r i e t y  of  abnormal i t ies  including oedema, 
anaemia, c l e f t  p a la te ,  marked re ta rd a t io n  o f  f a c ia l  development,  
short and c ur ly  t a i l ,  widespread ske le ta l  de fo rm i t ie s ,  abnormal i t ies  
of the cardiovascular  and urogeni ta l  system (Nelson, Asl ing £
Evans, 1952),  exencephaly,  anencephaly and hydrocephalus (Nelson, 1960) 
and ( iv )  from the 15th day a f t e r  breeding a l l  the young have been 
reported to be normal (Nelson _et aj_, 1952).
Maternal f o l a t e  de f ic iency  in man has been impl icated in the  
genesis of  reproduct ive  f a i l u r e .  Thus, retarded foe ta l  growth 
( E l l i o t t ,  1970),  toxaemia of  pregnancy (Stone,  Luhby, Feldman e t  al , 
1967),  abort ion  (Hibbard,  1964),  l a t e  pregnancy bleeding ( S t r e i f f  
£ L i t t l e ,  1967) foe ta l  malformations (Fraser £ Watt ,  1964; Hibbard 
£ S m ithe l ls ,  1965) as well  as maternal anaemia have been considered  
by some, a t  le a s t ,  as stigmata of  maternal f o l a t e  d e f ic ie n c y .
I t  is now widely  recognised that  the chronic adm in is t ra t io n  
of anticonvulsants  in man and in the rat  leads to f o l a t e  d e f ic ie n c y .
In view o f  the profound e f f e c t  o f  f o l a t e  d e f ic iency  on foe ta l  
development in the ra t  and possibly in man (Nelson, i 960 ) ,  th is  
pre l im inary  study was undertaken to in v es t ig a te  the e f f e c t  o f  drug-  
mediated f o l a t e  defic iencyon the course and outcome o f  pregnancy in 
the r a t .
Methods
Female Sprague-Dawley rats  were fed a d e f i c i e n t ,  semi­
supplemented or ful ly -supplemented f o l a t e  d i e t  fo r  12 weeks. The 
e f f e c t  of  the combination of  phenobarbitone and d i l a n t i n  was studied  
and the drugs were added to the d i e t  a t  amounts described in Section  
B of  th is  chapter.  Each group consisted of  animals w i th  and without  
drug treatment .  The animals were caged to gether ,  s ix  per group,  
fo r  eleven weeks a t  the end of  which period they were caged 
i n d iv id u a l ly  fo r  a fu r t h e r  week. They were mated with  male Sprague- 
Dawley rats overn ight ,  noting the date ,  and ten days l a t e r  successful  
mating was decided by pa lpat ion .  The day of  mating was taken as 
day one. Blood samples were obtained by cardiac puncture on the  
21st day fo l lowing mating,  the day before p a r t u r i t i o n ,  the mother 
was s a c r i f i c e d  and the foetuses recovered by an abdominal in c is io n .
The foetuses were separated from the placentae and t h e i r  response 
to repeated gent le  palpat ions was in d ic a t iv e  o f  t h e i r  v i a b i l i t y .
They were counted, separated a l t e r n a t e l y  from each side of  the  
ute r in e  horns, and stained fo r  ske le ta l  and organ examination.  The 
assessment of  the s k e le ta l  o s s i f i c a t io n  was determined according to  
the system described in Appendix 4. The degree of  o s s i f i c a t i o n  of  
foe ta l  ax ia l  and appendicular skeleton was c l a s s i f i e d  as ( i )  o s s i f i e d ,  
i f  the shape of the bone was well  def ined and the s ta in  was dense 
and ( i i )  p a r t i a l l y  o s s i f i e d ,  i f  the shape of the bone was not wel l  
defined and the s ta in  was d i f f u s e .  Three degrees of  o s s i f i c a t i o n  
were used fo r  skul l  bones, namely ( i )  o s s i f i e d :  the shape o f
the bone was c l e a r l y  de fined,  the s ta in  was dense, and the sutures  
with  neighbouring bones were less than 0 .5  mm in width ( i i )  p a r t i a l l y  
o s s i f i e d :  the sutures wi th neighbouring bones were g reater  than 0 .5  mm 
in width ,  the s ta in ing  was less dense and the shape o f  the bone was
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n o t - c l e a r l y  defined and ( i i i )  s l i g h t l y  o s s i f i e d :  s ta in  was very d i f fu s e  
and bone shape was poorly de fined.  The appearance of  the bone might 
appear as a small speck on the l in e  o f  o s s i f i c a t i o n .  The fo l lowing  
marking system was adopted for  the o s s i f i c a t i o n  o f  skul l  bones:
6+ complete o s s i f i c a t i o n
5+ almost complete o s s i f i c a t i o n ,  sutures more than 
0.5  mm in width
4+ s l i g h t l y  d i f fused s ta in
3+ large pieces absent in f ro n t a ls  and p a r i e t a l s ,  
o c c ip i t a ls  d i f f u s e l y  stained
2+ o c c ip i t a l  absent, rest  of  s ta in  di f fused
1+ 1i t t l e  o s s i f i c a t i o n
0 no o s s i f i c a t io n
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The e x a m i n a t i o n  o f  t h e  o rgans  was a c h ie v e d  by a c o ro n a l  
s e c t i o n  in  t h e  case o f  t h e  b r a i n  and by an i n c i s i o n  a lo n g  th e  
m i d - l i n e  thus  e x p o s in g  t h e  o rgans  ( P l a t e  4 . 1 ) .
P l a t e  4.1 The o rgans  o f  r a t  f o e t u s  as r e v e a le d  by a m i d - l i n e  i n c i s i o n
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Maceration of  carcass and s ta in ing  o f  ra t  foe ta l  skeleton
The fo l lowing procedure was fol lowed and c lo se ly  adhered to:
The pups were k i l l e d  and f ixed  in in d u s tr ia l  methylated s p i r i t  
(IMS) fo r  3 days. They were then gutted and any v iscera l  abnormal i t ies  
recorded.
The pups were t ra ns fe rre d  to KOH (2% w/v) in which they remained 
fo r  about 4 days. They were c lo se ly  watched throughout th is  period  
fo r  premature maceration.  When maceration was complete,  the s k e le ta l  
structures  were c le a r l y  v i s i b l e  through the transparent  body w a l l .
The pups were then t ra ns fe rre d  to the s ta in ing  so lu t ion  in
which they remained fo r  2 days. The depth of  s ta in ing  was c lo se ly
checked.
They were t ra ns fe rre d  to the c le a r in g  agent and remained in 
i t  f o r  4 days before they were t rans fe rred  to the s tor ing agent.
The pups remained in the stor ing agent fo r  a t  least  one day p r io r  to  
examination,  according to the scoring system used in our department 
(Appendix 4 ) .
The s ta in ing  so lut ion  consisted of  4% aqueous a l i z a r i n  so lu t ion  
(9*5 ml) in M a l l ' s  so lu t ion  (10 l i t r e s ) .  M a l l ' s  so lu t ion  was composed 
of d i s t i l l e d  water (24 l i t r e s ) ,  glycerol  (6 l i t r e s )  and KOH (3 .0  gm).
The c lear ing  agent consisted o f  glycerol  (200 m l ) ,  IMS (200 ml) 
and benzyl alcohol (100 m l) .
The s tor ing agent was composed o f  glycerol  and IMS in a r a t i o
o f  1:1.
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The d e ta i l s  of  the method were obtained from the Huntingdon 
Research Centre.; Huntingdon, England. The constancy of  f ixed  day 
changes overcomes the p o s s i b i l i t y  of  e r ro rs .  The maceration stage  
was c r i t i c a l  and great  care was taken to a l low fo r  temperature  
va r ia t io n s  or premature maceration.
Sta in ing o f  ra t  foetus for  v is cera l  examination
The pups were k i l l e d  and f ixed  in Bouin's f l u i d .  The l a t t e r  
consisted of  saturated p i c r i c  acid (75 m l ) ,  g la c ia l  a c e t i c  acid (1 .0  
ml) and formaldehyde (25 m l) .  They remained in Bouin's f l u i d  fo r
a t  least  3 days p r io r  to examination.  For examination of  the bra in
a coronal section was made along the l in e  jo in in g  the upper end of  
the ear and the lower jaw. The upper part  o f  the head was then 
t h i n l y  s l iced  (1mm th ic k  sections) thus reveal ing d i f f e r e n t  bra in  
parts .  The sections were examined and compared wi th  those o f  fo e ta l  
contro l 's .
For examination of  the v isc era ,  a m id - l in e  inc is ion  was made 
and a l l  v iscera exposed, examined and compared to those of  fo e ta l  
contro ls  (Appendix 4 ) .
Results
Concentrations of  f o l i c  acid in the serum and red blood c e l l s
was s i g n i f i c a n t l y  reduced in a l l  animals t rea ted  with  combined pheno-
barbitone and d i l a n t i n  adm in is t ra t ion  when compared with  contro ls  
(Table 4 .1 2 ) .
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There was no ov era l l  s ig n i f i c a n t  d i f fe re n c e  in the mean l i t t e r  
and foe ta l  weight between control  and drug- t rea ted  animals (Table  4 . 1 3 ) .  
However, the mean l i t t e r  weight o f  f o l a t e  d e f i c ie n t  animals and 
without drug treatment was s i g n i f i c a n t l y  lower than th a t  o f  drug 
t rea ted  ra ts .  There was an o v era l l  progressive increase in the mean 
foe ta l  weight with  f o l a t e  supplementation (P la te  4 . 2 ) .
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P l a t e  4 . 2  The f o e t u s e s  o f  mo thers  fed  d i e t s  c o n t a i n i n g  d i f f e r e n t
amounts o f  f o l i c  a c i d  w i t h  and w i t h o u t  drug  t r e a t m e n t .
A S B The f o e t u s e s  o f  m o thers  fe d  a f u l l y - s u p p l e m e n t e d  
d i e t  w i t h  f o l a t e  (A) and t r e a t e d  w i t h  combined 
p h e n o b a r b i t o n e  and d i l a n t i n  (B) f o r  12 weeks and 
d u r i n g  t h e  g e s t a t i o n  p e r i o d .
C S D The f o e t u s e s  o f  mo thers f ed  a s e m i -s u p p le m e n te d  
d i e t  w i t h  f o l a t e  (C) and t r e a t e d  w i t h  d ru gs  as 
above ( D ) .
E & F The f o e t u s e s  o f  mo thers  fed  a f o l a t e  d e f i c i e n t  d i e t  
(E) and t r e a t e d  w i t h  d rugs  as in  A & B ( F ) .
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The mean number o f  foetuses per l i t t e r  of  f o l a t e - d e f i c i e n t  
mothers was higher in the drug- t rea ted  animals (Table 4 . 1 4 ) ,  and the 
percentage m o r t a l i t y  was a lso greater  than contro ls .  The untreated  
animals in th is  group, however, had the highest overa l l  number of  
resorpt ions,  accounting fo r  some 16.7 per cent o f  foe ta l  loss.
Animals fed the semi-supplemented f o l a t e  d i e t  and t rea ted  with  drugs 
had a lower mean number o f  v ia b le  young per l i t t e r  and a higher  
foe ta l  m o r t a l i t y  than co n tro ls ,  although the number o f  resorptions  
and the percentage foe ta l  loss was of  the same order o f  magnitude.
The percentage fo e ta l  m o r t a l i t y  and fo e ta l  loss in animals fed a 
f u l l y  supplemented f o l a t e  d i e t  and t rea ted  wi th  drugs was s im i la r  
to that o f  controls  (Table 4 . 1 4 ) .
Fo la te  supplementation led to a progressive improvement of  
o s s i f i c a t i o n  (Table 4 .1 5 ,  p la tes 4 .3 ,  4 .4 )  w ith  no marked d i f fe rences  
between drug- t rea ted  and untreated foetuses.
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A C E
B D F
P l a t e  A . 3 Compar ison o f  o s s i f i c a t i o n  and s k e l e t a l  s t r u c t u r e s  o f  21 day 
o l d  f o e t u s e s ,  c l e a r e d  and s t a i n e d  w i t h  a l i z a r i n  r e d ,  f ro m  
mothers f ed  on d i e t s  o f  d i f f e r e n t  f o l a t e  c o n t e n t  and t r e a t e d  
w i t h  d rugs  f o r  12 weeks and d u r i n g  th e  g e s t a t i o n  p e r i o d .
A S B L a t e r a l  v ie w  o f  f o e t u s e s  f r om  mothers  fed a f u l l y
supp lemen ted  f o l a t e  d i e t  (A) and t r e a t e d  w i t h  combined 
p h e n o b a r b i t o n e  and d i l a n t i n  ( B ) .
C S D L a t e r a l  v iew  o f  f o e t u s e s  f r om  mothers fe d  a s e m i ­
supp lem en ted  f o l a t e  d i e t  (C) and t r e a t e d  w i t h  d rug s
as above ( D ) .
E & F L a t e r a l  v ie w  o f  f o e t u s e s  f r om  mothers  fed  a f o l a t e
d e f i c i e n t  d i e t  (E) and t r e a t e d  w i t h  d rugs  (F) as in
A & B above.
Note s t r i k i n g  dec rease  in  s i z e  o f  a l l  bones ,  absence o f  o s s i f i c a t i o n  
e s p e c i a l l y  in  t h e  d i g i t a l  bones,  ex t reme s h o r t n e s s  o f  r i b s  and mishapen 
appea rance  o f  bones w i t h  i n c r e a s i n g  s t a t e  o f  f o l a t e  d e f i c i e n c y .
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However ,  t h e r e  was a g r e a t e r  i n c i d e n c e  o f  m a l r o t a t i o n  o f  
the  s p i n a l  column ( P l a t e s  4 , 3 ,  4 , 4 )  and b roken  o r  m is p la c e d  r i b s  
( P l a t e  4 , 5 ,  T a b le  4 .1 5 )  in  f o l a t e  d e f i c i e n t  d r u g - t r e a t e d  f o e t u s e s .
A C E
B D F
P l a t e  4 .4  Compar ison o f  s k e l e t a l  s t r u c t u r e s  o f  21 day o l d  f o e t u s e s ,  c l e a r e d
and s t a i n e d  w i t h  a l i z a r i n  re d ,  f r om  mothers  m a i n t a i n e d  on d i e t s  o f
d i f f e r e n t  f o l a t e  c o n t e n t  and t r e a t e d  w i t h  drugs f o r  12 weeks and 
d u r i n g  t h e  g e s t a t i o n  p e r i o d .
A & B V e n t r a l  v ie w  o f  f o e t u s e s  f rom  mothers  fed  a f u l l y  s upp lem en te d
f o l a t e  d i e t  (A) and t r e a t e d  w i t h  combined p h e n o b a r b i t o n e  and 
d i l a n t  i n ( B ) .
C & D V e n t r a l  v ie w  o f  f o e t u s e s  f r om  mothers  fed a s e m i - s u p p le m e n te d  
f o l a t e  d i e t  (C) and t r e a t e d  w i t h  d rugs  as above ( D ) .
E & F V e n t r a l  v ie w  o f  f o e t u s e s  f r om  m o th e rs  fed  a f o l a t e - d e f i c i e n t
d i e t  (E) and t r e a t e d  w i t h  (F) as in  A & B above.
Note t y p i c a l  m a l r o t a t i o n  o f  th e  s p i n a l  column in  the  f o e t u s  f r o m  m o the rs  
fed  a f o l a t e - d e f i c i e n t  d i e t  and t r e a t e d  w i t h  d r u g s .
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Broken r ibs were also present in a smaller  proport ion  of  the  
foetuses of  mothers fed a f u l l y  supplemented f o l a t e  d i e t  w ith  and 
without  drug treatment (Table 4 . 1 5 ) .  There was a high incidence of  
head and abdominal haemorrhages in the foetuses of  mothers in a l l  
groups studied wi th  the highest occurring in  the d rug - t rea ted  f o l a t e  
d e f i c i e n t  animals. The highest incidence of  hydrocephalus (Table 4 .1 5 ,  
P la te  4 .6 )  occurred in the foetuses of  drug t rea ted  f o l a t e - d e f i c i e n t  
mothers, when compared w i th  c o ntro ls ,  and th is  decreased in the foetuses  
of  semi-supplemented animals and did not occur in the foetuses o f  the  
ful ly -supplemented group.
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P l a t e  4 .5  L a t e r a l  v ie w  o f  21 day o l d  f o e t u s ,  c l e a r e d  and s t a i n e d  
w i t h  a l i z a r i n  re d ,  f rom  a m other  f e d  a f o l a t e - d e f i c i e n t  
d i e t  and t r e a t e d  w i t h  a c o m b i n a t i o n  o f  p h e n o b a r b i t o n e  and 
d i l a n t i n  f o r  12 weeks and d u r i n g  t h e  g e s t a t i o n  p e r i o d .  
Note broken  r ib s a n d  d i s p l a c e d  r i b s .
A B
C D
P l a t e  4 . 6  B r a i n  s e c t i o n s  o f  a 21 day o l d  f o e t u s ,  f i x e d  in  p i c r i c  a c i d ,  
f ro m  mothers  f e d  a f o l a t e - d e f i c i e n t  d i e t  and t r e a t e d  w i t h  
d rugs  f o r  12 weeks and d u r i n g  t h e  g e s t a t i o n  p e r i o d .
A S B B r a i n  s e c t i o n s  o f  a f o e t u s  f r o m  a m other  f e d  a f o l a t e - d e f i c i e n t
d i e t  and t r e a t e d  w i t h  combined p h e n o b a r b i t o n e  and d i l a n t i n .  Note 
e n l a r g e d  s l i t s  and v e n t r i c l e s .
C & D B r a i n  s e c t i o n s  o f  a f o e t u s  f r om  a m other  f e d  a s e m i - s u p p le m e n te d
f o l a t e  d i e t .
S i m i l a r l y ,  t he  i n c i d e n c e  o f  h y d r o n e p h r o s i s  and h y d r o u r e t e r  ( P l a t e  4 .7 )  
and o f  e n l a r g e d  b la d d e r  ( P l a t e  4 .8 )  was h i g h e s t  in  the  f o e t u s e s  o f  f o l a t e -  
d e f i c i e n t  d r u g - t r e a t e d  m o t h e r s ,  when compared w i t h  c o n t r o l s ,  and i t  
dec reased  w i t h  f o l a t e  s u p p l e m e n t a t i o n .
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P l a t e  4 . 7  A c r o s s - s e c t i o n  o f  t h e  k id n e y s  o f  a 21 day o l d  f o e t u s ,  
s t a i n e d  in  p i c r i c  a c i d ,  f r om  a m o the r  fed  a f o l a t e -  
d e f i c i e n t  d i e t  and t r e a t e d  w i t h  combined p h e n o b a r b i t o n e  
and d i l a n t i n  f o r  12 weeks and d u r i n g  t h e  g e s t a t i o n  
pe r  i o d .
Note  e n la r g e d  p e l v i s  and spongy appea rance  o f  t h e  k i d n e y s .
P l a t e  4 . 8  D i s s e c t i o n  o f  a 21 day o l d  f o e t u s ,  s t a i n e d  in  p i c r i c  a c i d ,  
f r o m  a mothe r  f ed  a f o l a t e - d e f i c i e n t  d i e t  and t r e a t e d  w i t h  
combined p h e n o b a r b i t o n e  and d i l a n t i n  f o r  12 weeks and d u r i  
th e  g e s t a t i o n  p e r i o d .
Note e n la r g e d  and d i s t e n d e d  b l a d d e r .
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Drug treatment did not a l t e r  the incidence of  gonadal 
misplacement in the foetuses of  f o l a t e  d e f i c i e n t  mothers and the 
incidence decreased with  f o l a t e  supplementation.
Pi scussi on
Folate  de f ic iency  throughout the gestat ion  period has been 
shown to lead to a number of  congenital malformations in the ra t  
and furthermore the incidence o f  c e r t a in  o f  these malformations is 
higher among the foetuses of  mothers in which f o l a t e  de f ic ien cy  is 
f u r t h e r  exacerbated by the prolonged adm in is t ra t ion  of  anticonvulsants .
Maternal f o l a t e  de f ic iency  throughout the gestat ion  period has 
been shown to resu l t  in ( i )  re ta rd a t io n  or absence of  o s s i f i c a t i o n  of  
a l l  bones, p a r t i c u l a r l y  metacarpals,  m eta tarsa ls ,  phalanges and s te rn -  
ebrae ( i i )  shortening of  a l l  bones ( i i i )  ma lrota t ion  of  the spinal  
column and ( iv )  cracked and misplaced r ib s .  These f ind ings  confirm  
e a r l i e r  observations of  the e f f e c t  o f  f o l a t e  d e f ic iency  on s ke le ta l  
development (Asl ing,  Nelson, Wright S Evans, 1955). The e a r ly  
morphologic e f fe c ts  o f  f o l i c  acid d e f ic iency  have been shown to manifest  
i n i t i a l l y  as a reduction o f  m i t o t i c  a c t i v i t y  (Johnson, Nelson S 
Monnie,1963) and d i r e c t  in te r fe ren ce  with  embryonic DNA synthesis  
(Nelson, As l ing ,  1962).  Furthermore chromosomal separat ion has been 
shown to be ATP dependent in g ly c e ro l -e x t ra c te d  c e l l s  (Hoffman- 
Ber l ing ,  1959) and recent ly  a marked reduction in the leve ls  o f  ATP 
and the pool of  adenosine (ATP, ADP and AMP) has been demonstrated 
in the embryos : of  f o l a t e  d e f i c i e n t  mothers (Chepenik, Johnson &
Kaplan, 1970).  These observations may p a r t l y  exp la in  the 
abnormal i t ies  seen. With the exception of  the m a lro ta t ion  of  the  
spinal  column and the cracked r ibs (Table 4 .1 5 ) ,  there  was no
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s ig n i f i c a n t  d i f fe re n c e  in the o v era l l  s ta te  of  the skeleton in the 
foetuses of  untreated and drug- t rea ted  f o l a t e - d e f i c i e n t  mothers,  
despite  the lower serum and red c e l l  f o l a t e  leve ls  in the l a t t e r  group 
(Table 4 . 1 3 ) .  I t  is not,  however, possible  to ascer ta in  whether  
( i )  the lowering of  the serum and red blood c e l l  f o l a t e  concentrat ions  
correspond to a s ta te  o f  functional  f o l a t e  de f ic iency  in these animals 
s im i la r  or g reater  than in the c o n t ro ls ,  or whether ( i i )  the degree of  
d ef ic iency  is severe enough to a f f e c t  the ske le ta l  development of  the 
foetus to a d i f f e r e n t  e x ten t .
A high incidence o f  brain  and abdominal haemorrhages which was 
higher in d rug- t rea ted  animals was present in a l l  groups studied.
Whether th is  is due to incomplete formation,  not apparent on macroscopic 
examination,  or increased f r a g i l i t y  of  blood vessels is not c le a r .  
Congenital cardiac and vascular a bnorm al i t ies ,  including i n t e r v e n t r i c u l a r  
septal de fects ,  double or r ig h t  a o r t i c  arch,  p e rs is ten t  truncus a r te r io s u s  
and absence of  ductus a r te r io su s  have been demonstrated in rats  fed f o l a t e  
d e f i c i e n t  d ie ts  during the f i r s t  ten days of  gestat ion  (Baird ,  Nelson,  
Monnie S Evans, 1954).  The pathogenesis of  these abnormal i t ies  is not 
c le a r ,  but f o l i c  acid e v id e n t ly  plays an important ro le  in normal 
development.
Abnormali t ies of  the urogeni ta l  system found in th is  ser ies  of  
experiments included hydronephrosis and hydroureter ,  ectopic  gonads 
and enlarged bladder .  The greatest  incidence of these abnormal i t ies  
was seen in the foetuses from f o l a t e - d e f i c i e n t ,  an t iconvu lsant -  
t rea ted  mothers (Table 4 . 1 5 ) .  S im i la r  abnormal i t ies  in response to  
f o l i c  acid de f ic iency  have been reported and include renal and u r e t e r i c  
hypoplasia,  hydronephrosis and hydroureter,  apparent absence of  a kidney,  
u r e t e r ic  a t r e s i a ,  closure of  o r i f i c e s  of  urete rs  and ure thra l  a t r e s i a  
(Monnie, Nelson & Evans, 1954; 1957).  I t  has been shown th a t  kidney
abnormal i t ies  are associated with retarded growth or abnormali ty of  
the ver tebra l  column and tha t  the c r i t i c a l  time in renal migrat ion is 
the 13th day fo l lowing conception in the ra t  (Nelson, i 960 ) .  11 has
been suggested th a t  i f  by the 13th day ver tebra l  column growth or  
d i f f e r e n t i a t i o n  is markedly retarded, then the growing kidney would 
be restra ined or d iver ted  by abutt ing on an umbil ica l  a r t e r y ,  thus 
giv ing r is e  to renal malformation or ec top ia .  The present f indings  
are consistent w ith  th is  observation since the f o l a t e - d e f i c i e n t  drug-  
t rea ted  group, which had the highest incidence of  ske le ta l  abnormal i t ies  
also had a high incidence of  urogeni ta l  abnormal i t ies .
Hydrocephalus was present in 32.2 and 23.5  per cent o f  the 
foetuses from mothers fed a f o l a t e - d e f i c i e n t  d i e t  w i th  and w i thout drug 
t reatment ,  re sp e c t ive ly .  The incidence was decreased in the semi­
supplemented group and disappeared in the ful ly -supplemented group.
Folate  de f ic ienc y  induced by f o l a t e  antagonists has been reported to  
provoke spina b i f i d a ,  cranium bi f idum, anophthalmia,  microphthalmia,  
c l e f t  p a la te ,  short mandible and oedema in add i t ion  to hydrocephalus 
(O 'D e l l ,  Whit ley  & Hogan, 1951). The morphology and histopathology  
of  f o l i c  acid defic iency- induced hydrocephalus has shown that  the  
l a t e r a l  v e n t r i c l e s ,  i n t e r v e n t r i c u l a r  foramina and t h i r d  v e n t r i c l e  
were g re a t ly  distended. H is to log ica l  studies were not car r ied  out  
in the present ser ies of  experiments,  but the incidence of  hydro­
cephalus in f o l a t e  de f ic iency  is in agreement with  previously  
documented data.
Since the hypothesis o f  possible  ant iconvulsant-mediated  
te r a to g e n ic i ty  due to f o l a t e  de f ic iency  was put forward (see Parke,  1972) 
the question of  a n t ic o n v u ls a n t - te ra to g e n ic i ty  has been revived by a 
number of  independent reports in the l i t e r a t u r e .  The possible  
associat ion between anticonvulsant drugs administered to pregnant
women and congenital malformations in the o f fsp r in g  was f i r s t  
documented by Meadow (Meadow, 1968),  who described c l e f t - l i p  in s ix  
in fants  de l ivered  to e p i l e p t i c  mothers on ant iconvulsants .  Since 1968,  
the author has f u r t h e r  described 32 such cases (Meadow, 1970).  A 
higher than normal frequency of c l e f t - l i p ,  or p a la te ,  or both,  and 
other  congenital abnormali t ies  among in fants  born to e p i l e p t i c  mothers 
on anticonvulsant drugs has been confirmed in a number o f  o ther  s tudies .  
Thus frequencies of  congenital abnormal i t ies  o f  15.4 per cent (10 out  
of  65 l i v e  b i r th s )  (Elshove & Eck, 1971),  5 .8  per cent (13 out of  243 
l i v e  b i r th s )  (German, Ehlers jet aj[, 1970),  5 .2  per cent (17 out of  329 
in fan ts )  (Speidel & Meadow, 1972), and 6 .7  per cent of  134 in fants  in 
a population-based study (Lowe, 1973) have been reported.  In another  
study the outcome of  372 pregnancies among e p i l e p t i c  women consisted  
of  66 spontaneous abort ions (18 per cent)  and 9 cases o f  s t i l l b i r t h s  
(2 .5  per c e n t ) .  Of the 297 b i r t h s ,  congenital  malformations were present  
in 22 in fan ts ,  an incidence o f  7 .4  per cent (Starreveld-Zimmerman, Van 
Der K?1k e t  a l , 1973).  The congenital abnormal i t ies  included 9 cases 
of  h a r e - l i p  with or without  c l e f t  pa la tes ,  7 cases of  congenital  heart  
les ions,  and cases of  ectopic  bladder,  meningomyelocele, a n a l a t r e s i a ,  
Down's syndrome, anencephaly and polydac ty ly .
The Oxford Record Linkage study i d e n t i f i e d  223 in fants  d e l ive red  
to 168 e p i l e p t i c  mothers as the outcome of 218 pregnancies (F re d r ick ,  
1973).  In th is  study each pregnancy in an e p i l e p t i c  mother re s u l t in g  
in a l i v e  b i r t h  was matched fo r  social  c lass ,  c i v i l  s ta tu s ,  maternal  
age, p a r i t y  and year of  d e l iv e ry  wi th  three  control  d e l i v e r ie s  r e s u l t in g  
in l i v e  b i r t h s .  There was a highly  s ig n i f i c a n t  excess of  congenital  
malformations among infants  born to e p i l e p t i c  mothers* 13.8 per cent  
as compared w i th  5 .6  per cent in co n tro ls .  The type o f  congenital  
abnormali t ies  reported,  included cases of  spina b i f i d a ,  hydrocephalus,
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undescended testes in mature in fa n ts ,  congenital  heart  de fects ,  
h a r e - l i p  and c l e f t - p a l a t e .  Perhaps of  g reater  s ig n i f ic a n c e  in 
th is  study,  is the frequency of  defects among infants  o f  e p i l e p t i c  
women when re la ted  to the length of  t ime since the onset o f  
ep i lepsy.  Thus, the incidence o f  defects was highest in women 
in whom the onset o f  ep i lepsy occurred in the f i r s t  t r im e s te r  of  
pregnancy (100 per cent ,  there  were only two cases) and in those who 
were su f fe r in g  from epi lepsy from two to ten years and over ,  p r io r  
to pregnancy (16 to 19 per c e n t ) .  I t  is not c le a r ,  however, 
whether these f indings can be in te rpre ted  as the d i f f e r e n t i a l  e f f e c t s  
o f  acute and chronic f o l a t e  de f ic iency  re sp e c t iv e ly ,  or drug e f f e c t s  
per se , or to a compound e f f e c t  o f  a number o f  unrelated fac to rs  
such as genet ic  d is p o s i t io n ,  and i l ln e s s .
Anticonvulsant drugs have been reported to have a profound 
e f f e c t  on the ov era l l  metabolism of  the body. Thus, they a f f e c t  
the metabolism of  s te ro id  hormones (Wilson, 1969),  increase hepatic  
uptake of  serum b i l i r u b i n  (Matsuda & Takase, 1969) ra ise  plasma gamma- 
glutamyl transpeptidase leve ls  ( Ideo,  Franchis et  ^ al_, 1971),  reduce 
serum calcium and increase serum a l k a l i n e  phosphatase leve ls  as a 
re s u l t  o f  a l t e r e d  vitamin D metabolism (Hunter, Maxwell e_t £]_, 1971) 
and induce f o l i c  acid d e f ic ie n cy .  Furthermore,  the a d m in is t ra t ion  
o f  phenytoin to pregnant mice resul ted in c l e f t  p a la te  in a 
s ig n i f i c a n t  proport ion in the o f fsp r in g  (Elshove,  1969).  This drug 
when administered to rats a lso resul ted in s i g n i f i c a n t l y  more 
chromosomal breaks than was observed in control  ra ts ,  and a n t i ­
convulsant therapy has been reported to increase the number of  
t e t r a p lo id  and heteroplo id  mitoses (de Toni ,  Massino e_t a_j_, 1966) 
and chromosomal breaks (Ayrand, Kermarec S Mart i  non, 1968) in 
c i r c u l a t i n g  lymphocytes o f  ch i ld ren  born to e p i l e p t i c  mothers.
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In the face o f  the var ied  e f fe c ts  of  these drugs, i t  is 
possible  t h t  d i f f e r e n t  defects  may be induced by d i f f e r e n t  mechanisms. 
Thus, the increased incidence o f  malformations in the g e n i t a l i a  
(F re d r ic k ,  1973) may represent the re s u l t  of  a l t e r e d  s te ro id  hormone 
metabolism, and the increased incidence of  s ke le ta l  anomalies in 
the o f fsp r in g  o f  d rug- t rea ted  rats in the present experiments may be 
the r e s u l t ,  a t  leas t  in p a r t ,  o f  a l t e r e d  vitamin D metabolism.  
Furthermore,  the importance, i f  any, o f  a genetic  component in the 
increased incidence o f  malformations in ch i ld ren  o f  e p i l e p t i c  women 
cannot be excluded. I t  is ,  however, of  considerable in te r e s t  th a t  
there  ex is ts  a broad overlap in the incidence and type of  genet ic  
defect produced by f o l a t e  d e f ic iency  in the ra t  and those reported  
to occur in humans.
I t  is ,  of  course,  unreasonable and sometimes dangerous to  
ex t rap o la te  d i r e c t l y  animal data to the human s i t u a t i o n ,  but in view 
of  the fundamental ro le  o f  f o l i c  acid in b iosynthesis ,  c e l l  d iv is io n  
and d i f f e r e n t i a t i o n ,  in genera l ,  the overlap between the ra t  and 
man in the incidence and type of  genet ic  defect may be o f ,  a t  le a s t ,  
some importance. I t  i s ,  moreover, s i g n i f i c a n t  tha t  the incidence  
and type o f  genet ic  defect decreases,  in the present experiments,  
with increasing leve ls  o f  f o l a t e  supplementation,  thus in d ica t in g  tha t  
the vitamin is ,  in part  a t  le a s t ,  important fo r  normal reproduction in 
the r a t ,  as i t  is known to be in man.
I t  is concluded th a t  f o l i c  acid de f ic iency  induced by the  
chronic adm in is tra t ion  of  ant iconvulsants is one of  the fac to rs  p re ­
disposing to congenital  abnormali t ies  in the ra t  and tha t  th is  may 
also be of  some importance in the congenital abnormal i t ies  seen in 
ch i ld re n  born to e p i l e p t i c  mothers on anticonvulsant therapy.
Chapter Five
GENERAL DISCUSSION 
AND 
CONCLUSIONS
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For m i l l io n s  of  years man and other mammals have been a t  r isk  
from an environment contaminated wi th a v a r i e t y  of  p o t e n t i a l l y  harmful 
chemicals,  and the microsomal enzyme system in the l i v e r  and gastro ­
in te s t in a l  t r a c t  has evolved as an e f f i c i e n t  means of de tox ica t ing  
such substances when they enter  the body. Some compounds are  able  
to s t im ula te  the formation of  microsomal enzyme prote in  -  a process 
known as enzyme induction -  and by doing so they s t im ula te  t h e i r  
own metabolism and e l im in a t io n  from the body, the enzyme a c t i v i t y  
re turning to normal once excret ion has occurred (Conney, 1967).  Such 
t ra n s ie n t  enzyme induction is a b e n e f ic ia l  adapt ive process which must 
have contr ibuted s i g n i f i c a n t l y  to the v i a b i l i t y  of  mammalian l i f e ,  but 
in modern therapeut ics  th is  e f f e c t  is also the basis o f  numerous 
adverse drug in te ra c t io n s .  This is because enzyme• inducing agents 
g enera l ly  s t imulate  a wide spectrum of  microsomal enzymes, so tha t  
adm in is t ra t ion  of  drugs with  th is  property w i l l  increase the ra te  of  
metabolism and thus decrease the therapeut ic  e f f i c a c y  of  other  
compounds given concurrently .  The well  known in te ra c t io n  between 
w ar fa r in  and the b a rb i tu ra tes  (B reckenr idge 'e t  aj_, 1970) is one 
such example.
In c l i n i c a l  medicine i t  has been popular to determine the 
e f f e c t  of  one drug upon the e f f i c a c y  or metabolism of another drug 
but l i t t l e  considerat ion has been given to the e f f e c t  o f  drugs upon 
n u t r i t i o n ,  or fo r  tha t matter ,  of  n u t r i t i o n  upon drug metabolism.  
Probably the most widely  known examples of  d ru g -n u t r ien t  in te r a c t io n  
include the e f fe c ts  of  d iu r e t ic s  on body potassium and the e f f e c t s  
of  alcohol upon the metabolism of c e r t a in  n u t r ie n ts  and upon tha t  
of  f o l i c  acid in p a r t i c u l a r .  However, one is becoming aware of
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an increasing number o f  d ru g -n u tr ien t  in te ra c t io n s .  A s in g le  dose 
of neomycin, fo r  example, induces malabsorption o f  f a t  (Thompson,
Dowling and G u t t i e r r e z ,  1970) and f a t  soluble vitamins (Barrowman, 
D'Mello and Hezheimer, 1973) and cholestyramine induces malabsorption  
of iron (Thomas, McCullough and Greenberger,  1971). Apart  from the  
d i r e c t  e f f e c t  o f  drugs on g a s t r o in te s t in a l  func t ion ,  some drugs,  
because of  t h e i r  a b i l i t y  to induce the a c t i v i t y  of  the hepatic  drug-  
metabolising microsomal enzymes and of  t h e i r  prolonged a d m in is t ra t io n ,  
may lead to severe metabolic derangements. The d ivers ion o f  the  
metabolism of v i tamin D towards the formation o f  b i o l o g i c a l l y  in a c t iv e  
d e r iv a t i v e s ,  wi th the subsequent development of  osteomalacia (Hunter,  
Maxwell £ t  a_l_, 1971) is probably the best documented example o f  th is  
type of  abnormal i ty .  Thus, among the many side e f fe c ts  o f  drugs the 
p o s s i b i l i t y  of  crea ting  a n u t r i t i o n a l  d e f ic iency  must always be borne 
in mind.
The E f fe c t  of  Drugs on Ascorbic Acid Metabol?sm
The synthesis and u t i l i s a t i o n  of  ascorbic acid is known to be 
increased in the ra t  in response to the adm in is tra t ion  of  enzyme- 
inducing drugs (Conney £ t  aj_, 1961).  Thus, in th is  species increased  
metabolic requirements are compensated by increased endogenous 
synthesis.  However, the e f f e c t  of  drug adm in is tra t ion  on ascorbic  
acid requirements and u t i l i s a t i o n  in species unable to synthesise  
the vitamin is less c le a r - c u t .  The e f f e c t  of  the chronic a d m in is t ra t io n  
of two drugs,  namely Librium and prednisone has been considered in 
th is  thesis  in such a species, the guinea pig.
Both Librium and prednisone i n i t i a l l y  increased the u r in a ry  
excret ion o f  ascorbic acid during the f i r s t  10 days fo l lowing t h e i r
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ad m in is t ra t io n .  This was fol lowed by a decreased ur inary  excret ion  
of the v i tam in ,  which in the case of  Librium continued up to 117 days 
fo l lowing i t s  a d m in is t ra t io n ,  whereas in the case of  prednisone the 
excretory  level o f  vi tamin returned to normal on the 78th day fo l lowing  
prednisone ad m in is t ra t io n .  Furthermore,  Librium induced a deplet ion  
o f  ascorbic acid in some o f  the t issues s tudied,  whereas prednisone 
did not.  Whether the f a i l u r e  o f  prednisone to deplete  t issue  ascorbic  
acid is due to the induction o f  de novo synthesis o f  the vitamin in 
the t rea ted  animals is not c le a r .  The prednisone-induced synthesis  
of ascorbic acid was an unexpected and ra ther  surpr is ing  f in d in g  in 
view of  the g e nera l ly  accepted concept tha t  the guinea pig is unable 
to synthesise the v i tam in .  I t  does appear,  however, t h a t  th is  is 
a s p e c i f ic  drug e f f e c t ,  since Librium does not induce a s im i la r  e f f e c t ,  
even on a more prolonged period of  a d m in is t ra t io n .  The mechanism by 
which prednisone induces ascorbic acid synthesis is f a r  from c le a r .  
However, L-gulonolactone oxidoreductase is known to be under hormonal 
regu la t io n .  In the adrenalectomised r a t ,  hydrocort isone adm in is t ra t io n  
stimulates the a c t i v i t y  o f  th is  enzyme, an e f f e c t  which is reversed by 
actinomycin D (Majumder, Banerjee ejt £]_, 1973).  Furthermore,  i t  has 
recent ly  been shown that  the a dm in is t ra t ion  o f  c e r ta in  s te ro id s ,  
e .g .  dexamethasone, and i t s  add i t ion  in v i t r o  to ra t  l i v e r  microsomes 
e l i c i t s  a 10- fo ld  increase in the a c t i v i t y  o f  biphenyl -2 -hydroxylase  
by a mechanism as yet  unresolved (Chakraborty, 1975, personal  
communication). Cort icostero ids  play an important ro le  in adapt ive  
enzyme changes (Waterlow, 1968), and i t  has been shown th a t  in rats  
fed a p r o t e i n - d e f i c ie n t  d i e t  fo r  2 to k  weeks increased plasma 
cort icosterone  leve ls  are  associated w i th  increased hepat ic  b ipheny l -  
4-hydroxylase a c t i v i t y  (Basu, Dickerson and Parke,  1971).  I t  may,
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th e re fo re ,  be possible th a t  s te ro id s ,  in genera l ,  have an e f f e c t ,  as 
yet unrecognised, on enzyme leve ls  and synthesis.  In the event ,  i t  
would have been of considerable in te re s t  to have q u a l i f i e d  and 
q u a n t i f ie d  d i r e c t l y  the presence of L-gulonolactone oxidoreductase in 
the l i v e r  of  these guinea pigs under the experimental  condi t ions employed, 
and f u r t h e r  to have investigated the in v?tro  e f f e c t  o f  prednisone on 
ascorbic acid synthesis in guinea pig l i v e r  microsomes.
I t  is tempting to consider the importance, i f  any,  o f  these 
studies to man, in the sense tha t  l i k e  the guinea p ig ,  man cannot 
e f f e c t  the synthesis of  ascorbic a c id .  There is evidence tha t  c e r t a in  
groups w i th in  the populat ion,  e s p e c ia l ly  among the e ld e r l y  ( K a ta r ia ,
Rao and C u r t is ,  1965; Tay lor ,  1966; Burr, Elwood, Hole £ t  a]_, 197*0 
and ch i ld ren  (Henderson-Smart, 1972) are p a r t i c u l a r l y  susceptib le  to  
s u b -c l in ic a l  or even, in some cases, over t  c l i n i c a l  d e f ic ie ncy  of  
ascorbic ac id .  In the present s tud ies ,  the chronic a d m in is t ra t io n  o f  
Librium, a widely  prescribed drug, increases the requirements fo r  
ascorbic  acid in the guinea pig as evidenced by decreased u r ina ry  
excret ion and t issue  deplet ion of  the v i tam in .  S i m i l a r l y ,  prednisone  
e l i c i t s  an increase in ascorbic acid requirements,  as evidenced by 
decreased excret ion of  the n u t r i e n t ,  which is l a t e r  ameliorated due to 
the induction o f  the synthesis of  the v itamin by the drug. In man, 
too,  evidence is accumulating tha t  drug admin is tra t ion  a l t e r s  the 
a v a i l a b i l i t y  of  ascorbic acid and may increase the requirements fo r  
the v itamin .  I t  is ,  moreover, o f  great importance t h a t ,  in the 
guinea pig a t  l e a s t ,  a s ig n i f i c a n t  decrease in o vera l l  drug o x id a t io n  
occurs long before any appreciable  weight loss and frank scorbut ic  
symptoms become apparent (Zannoni, Flynn and Lynch, 1972).  The 
p o s s i b i l i t y ,  th e re fo re ,  should ser ious ly  be considered,  th a t  humans
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with  d i r e c t  or r e su l ta n t  suboptima] intakes of  ascorbic acid may 
develop s e n s i t i v i t y  and possible t o x i c i t y  to drugs,  due to increased 
requirements fo r  the v itamin by chronic drug a d m in is t ra t io n .
The E f fe c t  o f  Anticonvulsants on Fola te  Metabolism
I t  has been known fo r  many years tha t  pa t ien ts  c h ro n ic a l ly  
t rea ted  with  anticonvulsants  may become f o l i c  acid d e f i c i e n t ,  and 
a v a r i e t y  of  d i f f e r e n t  mechanisms have been proposed to exp la in  the 
phenomenon.
A s ig n i f i c a n t  proport ion o f  d ie ta r y  fo la te s  is ingested in 
the form of polyglutamates,  but before they can be absorbed these 
are hydrolysed by in te s t in a l  conjugases to form monoglutamates 
(Butterworth et_ £]_, 1969). I t  has been suggested that  anticonvulsants  
produce f o l a t e  malabsorption e i t h e r  by in h ib i t in g  f o l a t e  conjugase 
a c t i v i t y  (Hoffbrand and Necheles, 1968),  or by i n t e r f e r in g  wi th  the 
uptake o f  the monoglutamate into the enterocyte  (Dahlke and Mertens-  
Rosler,  1967). A l t e r n a t i v e l y ,  these compounds, because o f  t h e i r  
potent enzyme inducing p ro p e r t ies ,  may increase d ie ta r y  requirements  
fo r  f o l i c  ac id ,  since th is  v itamin plays an essent ia l  ro le  in the 
formation of  cytochrome enzymes. In support o f  th is  l a t t e r  hypo­
thesis is the fa c t  th a t  an inverse c o r r e la t io n  was obtained between 
the degree o f  enzyme induction,  as measured by ur inary  g lu c a r ic  acid  
e xcre t ion ,  and serum and red c e l l  f o l a t e  in a group o f  ch i ld ren  on 
long term anticonvulsant therapy (Maxwel1 et  a l , 1972).  I f  enzyme 
induction does lead to f o l a t e  d e f ic ie n c y ,  then any drug wi th enzyme 
inducing propert ies  should produce th is  e f f e c t .  The in ves t iga t ions  
in th is  thesis  have shown tha t  pa t ien ts  rece iv ing ant iconvu lsants ,  
phenothiazines and t r i c y c l i c  antidepressants were a l l  found to have
-  190 -
s i g n i f i c a n t l y  elevated leve ls  of  u r inary  D-g lucar ic  a c id .  However, 
only pa t ien ts  rece iv ing anticonvulsants  and phenothiazines were 
s i g n i f i c a n t l y  f o l i c  acid d e f i c i e n t ,  as manifested by the reduced
serum and red blood c e l l  f o l a t e  concentrat ions and abnormally high
leve ls  o f  ur inary  FIGLU excre t ion  (Table 5 . 1 ) .  The only  
dif fe re nce s  between the p a t ien ts  rece iv ing ant iconvulsants  and 
phenothiazines and those taking t r i c y c l i c s  was the length o f  time 
fo r  which they had been t re a te d ,  and i t  appears th a t  prolonged 
exposure to enzyme inducing agents is necessary before f o l i c  acid  
de f ic ienc y  ensues. However, a l l  these resu l ts  must be in te rp re ted  
with  caut ion fo r  the demonstrat ion o f  a c o r re la t io n  between enzyme 
induction and f o l i c  acid de f ic ienc y  is not proof th a t  one is the
cause and the other  the e f f e c t .
The c r u c i a l : r o l e  of  f o l i c  acid in the formation of  microsomal 
enzymes can be demonstrated in rats fed d ie ts  containing var ied  
amounts of  f o l i c  acid  and t rea ted  wi th  drugs possessing inducing 
p ro p e r t ies .  Depending on the extent o f  f o l a t e  d e f ic ie n c y ,  such 
animals show subnormal leve ls  of  hepatic  microsomal cytochrome P-450,  
and f a i l  to respond with  a r i s e  in th is  enzyme fo l lowing treatment  
with enzyme inducing agents fo r  12 weeks ( F i g . 5 . 1 ) .
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Table 5.1
Ur inary excret ion of  g lu c a r ic  ac id ,  and of FIGLU fo l low ing  an 
oral  load of  h i s t i d in e  (15 gm) in pa t ien ts  t rea ted  wi th a n t i ­
convulsant,  phenothiazine and t r i c y c l i c  drugs (± SEM).
Group No. FIGLU mg/9 hrs
D-g lucar ic  acid  
ymol/2A hrs
Mean 
Duration of  
T reatment  
(yrs)
Controls 15 7.1 ± 1.6 9 .3  ± 1.7
Ant i convulsants 16 21.7  ± 3 .1 * 93 .3  ±" 17.6* 12
Phenothiazi  nes 15 16.5 ± 1 .6 * 28.0  ± 5 .4 + 15
T r ic y c l ic s 7 10.5 ± 2 .7 32.5 ± ' 7 . 2 * 2
S t a t i s t i c a l  s ig n i f ic a n c e  as compared with  controls  
*p <0.0005  
+p <0.0025
40-
HEPATIC
30-
CYTOCHROME P450 
(n moles/g liver) 20-
10-
□  controls 
H  phenobarbitone
FOLIC ACID FOLIC ACID
DEFICIENT SUPPLEMENTED
F i g . 5.1 The leve ls  o f  hepatic  microsomal cytochrome P-^50 in 
rats fed on d ie ts  of  d i f f e r e n t  f o l i c  acid content and 
trea ted  with  phenobarbitone.
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The data presented in th is  thesis  permit the assessment of  the 
re la t io n s h ip  between f o l i c  acid s ta tus ,  as measured by ur inary  FIGLU 
excre t ion ,  and hepatic  microsomal enzyme a c t i v i t y ,  as measured by 
ur inary  D-g lucar ic  a c id ,  in pat ien ts  rece iv ing enzyme inducing drugs 
fo r  varying periods o f  t ime. F o l ic  acid def ic iency  was present in 
pat ien ts  rece iv ing enzyme inducing drugs fo r  2-5 years,  but was f a r  
more marked in those t rea ted  fo r  longer periods of  t ime ( F i g . 5 . 2 ) .
URINARY FIGLU 
(mg/9hours)
controls 2 -5 6-10 11+
DURATION OF TREATMENT (YEARS)
F i g . 5 .2  The ur inary  excret ion of  FIGLU in controls  and pa t ien ts
trea ted  with  anticonvulsants fo r  d i f f e r e n t  periods o f  time,
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With increasing d e t e r io r a t io n  in f o l a t e  s ta tus ,  the ur inary  
excre t ion  o f  D -g lucar ic  acid was markedly lower in pa t ien ts  who had 
been t rea ted  fo r  f i v e  years or more, than in those who had received 
drugs fo r  a shorter  period ( F i g . 5 . 3 ) .  The impairment of  the 
glucuronic acid pathway (as judged by a decrease in u r ina ry  D -g luca r ic  
acid excret ion) with  progressively  increasing f o l a t e  d e f ic ie n c y  in 
man, is of  added in t e r e s t ,  fo r  a s im i la r  impairment in the glucuronic  
acid pathway in response to f o l a t e  d e f ic iency  is seen in the r a t ,  as 
judged by decreased ur inary  ascorbic acid excre t ion .  I t  the re fo re  
seems th a t  the degree to which an indiv idual  can respond to an enzyme 
inducing agent is re la te d ,  a t  l e a s t ,  in part  to his f o l i c  acid s ta tus .  
When f o l i c  acid de f ic iency  occurs,  due to an intake inadequate to meet 
c h ro n ica l ly  increased requirements f o r  th is  v i tam in ,  enzyme a c t i v i t y  
diminishes,  an e f f e c t  which may a lso be t rue  for  ascorbic ac id .  Thus, 
in p a t ien ts  rece iv ing long term treatment wi th  ant iconvulsants ,  
ur inary  D-g lucar ic  acid excret ion c o r re la te s  s i g n i f i c a n t l y  w i th  the 
f o l i c  acid status of  these subjects ( F i g . 5 . ^ ) .
URINARY
D-GLUCARIC ACID 
(jj moles /2 4  hours)
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11+6-10controls 2 -5
DURATION OF TREATMENT (years)
. 5 .3  The ur inary  excret ion of  D -g lucar ic  acid in contro ls  and
pat ien ts  t rea ted  with  anticonvulsants  fo r  d i f f e r e n t  periods  
of  t ime.
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URINARY FIGLU 
(mg/9hours)
!
R =0.62
80 100 120 140 160
URINARY D-GLUCARIC ACID (|i moles/24hrs)
F i g . 5.^  Showing the c o r re la t io n  between ur inary  FIGLU and 
D -g lucar ic  acid excret ion in contro ls  (shaded area)  
and pat ien ts  t rea ted  with  ant iconvulsants .
-  197 -
This could be the reason why pat ien ts  apparent ly  s ta b i l i s e d  
fo r  many years on ant iconvulsants ,  suddenly develop symptoms of  
t o x i c i t y  fo r  no apparent reason ( F i g . 5 . 5 ) .  C e r ta in ly  the c l i n i c a l  
s ig n i f ic a n c e  o f  th is  in te re s t in g  in te rac t io n  requires fu r t h e r  
in v e s t ig a t io n .
In view of  the high incidence o f  f o l a t e  def ic iency  in p a t ien ts  
on prolonged therapy with  anticonvulsants  (27 to 91 per cent)
(Reynolds, 1973),  supplementation of  these pa t ien ts  wi th  f o l i c  acid  
seems necessary.  However, co n tro l led  ra ther  than empir ical  supple­
mentation gives r ise  to such considerat ions as ( i )  the e f fe c t iv e n e s s ,  
( i i )  the e x ten t ,  and ( i i i )  the nature and q u a l i t y ,  o f  supplementation,  
or in short ,  q u a n t i ta t io n  of  requirements which is a t  present lack ing .
I t  is known th a t  f o l i c  acid is a convulsant when given in t ra c e re b ro -  
v e n t r i c u l a r l y  to dogs (Hayashi, 1959) and rats (Hommes and Obbens,
1972),  and i t  has been suggested that  the a n t i f o l a t e  e f f e c t  o f  a n t i ­
convulsants may be re la ted  to t h e i r  therapeut ic  act ion (Reynolds, 1967).  
A proport ion o f  e p i le p t i c s  on prolonged therapy wi th high f o l i c  acid  
doses (15“ 30 mg) fo r  the correc t ion  o f  over t  megaloblastosis or  
uncomplicated f o l a t e  de f ic iency  show a d e te r io r a t io n  in se izure  
control  (Chanarin,  Laid 1 aw jet aj_, 1960; Reynolds, 1967).  This has 
been a t t r i b u t e d  to the slow accumulation o f  f o l a t e  in the nervous 
system o r ,  in the l i g h t  o f  the evidence presented in th is  th e s is ,  
to the enhanced a c t i v i t y  of  the hepat ic  microsomal drug-metabolising  
enzymes fo l lowing supplementation,  and the possible  consequent 
reduction o f  t issue  and c i r c u la t in g  plasma drug le v e ls ,  or both.  
Whichever the mechanism, from a n u t r i t i o n a l  point  of view there  
seems to be an urgent need fo r  the q u a n t i ta t io n  o f  the requirements of  
these pa t ien ts  fo r  f o l i c  acid ,  a t  a leve l  which w i l l  both maintain
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a p o s i t iv e  f o l a t e  status and t h e r a p e u t ic a l ly  e f f e c t i v e  drug le v e ls ,  
thus es tab l ish ing  optimal medical care for  these p a t ie n ts .  F u r th e r ­
more, one ought to be aware of  the increased potassium requirements 
in pa t ien ts  recovering from megaloblast ic anaemia due to a n t i ­
convulsant treatment .  These pa t ien ts  have been reported to die  
suddenly fo l lowing i n s t i t u t i o n  of  treatment with  f o l i c  acid  and 
vitamin or wi th  transfusion (Lawson, Murray and Parker,  1972).  
The ir  deaths have been ascribed to arrhythmia from hypokalaemia 
developing during rapid red blood c e l l  maturat ion and overloading  
of the c i r c u l a t i o n .
Conclus ions
I t  is concluded th a t  a v a r i e t y  o f  drugs may i n t e r f e r e  w i th  
the a v a i l a b i l i t y  and u t i l i s a t i o n  o f  c e r ta in  n u t r ie n ts  and may thus 
a f f e c t  the n u t r i t i o n a l  status o f  the p a t i e n t .  Orthomolecular  
n u t r i t i o n  in the prevention or treatment of  any detr imental  e f f e c t s  
o f  drugs upon n u t r i t i o n a l  status e n t a i l s  a con tro l led  increase in 
the concentrat ion of  the n u t r i t i v e  fa c to r  or a decrease in the 
concentrat ion of  the drug. Such considerat ions are o f  great  
importance in adul t  man and even more so in the in fant  and the  
e ld e r ly  in whom the d i e t  may l i m i t  the intake of  n u t r i e n t s .  Moreover,  
excretory  and metabolic a b i l i t i e s  in the l a t t e r  two groups may l i m i t  
the disposal of  drugs, w hi le  indiv idual  v a r i a b i l i t y  of  an enzyme may 
impose fu r t h e r  l im i t a t io n s  on the a b i l i t y  to metabolise drugs.
Further ,  many drugs are known to a f f e c t  a p p e t i te  and some have 
profound e f fe c ts  on pro te in  metabolism. A s p i r in ,  fo r  instance,  
is known to uncouple o x id a t iv e  phosphory lat ion,  increase u r inary  
excre t ion  of  n i t rogen,  i n h i b i t  the incorporation of  glutamic acid
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into p ro te in ,  i n t e r f e r e  wi th  the u t i 1isa t ion  and uptake of  ascorbic  
a c id ,  and contr ibu te  to the p r e c i p i t a t i o n  o f  iron d e f ic iency  
anaemia, e s p e c ia l ly  in young women, by causing g a s t r o in te s t in a l  
bleeding.  F i n a l l y ,  c e l l  function is regulated by a v a r i e t y  of  
multi -enzyme systems, in which a t  least  one of  the known vitamins  
is required as a co fa ctor .  Therefore adequacy or inadequacy o f  a 
vitamin may d i r e c t l y  or i n d i r e c t l y  in f luence c e l l  fu n c t io n .  For 
example, such important functions as haemopoiesis, neurological  
and mental a c t i v i t y  are dependent on more than one v i tam in .  
S p e c i f i c a l l y ,  v i tamin anc* f o l i n i c  acid are re la ted  to the 
maturation o f  the red c e l l s  ( H a r r e l l ,  1946) and the conversion of  
f o l i c  to f o l i n i c  acid is enhanced by ascorbic acid ( H a r r e l l ,  Woodyard. 
and Gates, 1955) and vitamin (Goldsmith, 1950). Furthermore,  
ascorbic acid d e f ic iency  has been shown to remove reduced fo la te s  
from the metabolic pool due to a rapid and i r r e v e r s i b l e  ox idat ion  
of  f o l i c  acid to 10-formyl f o l i c  acid (Stokes,  M e l ik ian  et  ^ aj_, 1975)*  
Thus i t  becomes c le a r  th a t  the possible  secondary n u t r i e n t - n u t r i e n t  
in te ra c t io n  fol lowed by the primary d ru g -n u tr ien t  one is o f  utmost 
importance, in the sense that a def ic iency  o f  a s in g le  n u t r i e n t ,  
however caused, may increase the requirements f o r ,  or i n t e r f e r e  
with  the u t i l i s a t i o n  o f  other n u t r ie n ts .
Appendix One
THE COMPOSITION OF DIETS FED TO ANIMALS
A. Ascorbic a c i d - f r e e  d ie t
Ingredients
Broad bran 
Broad oats
Dried f u l l  cream mi lk  
Dried skimmed milk  
S a l t  mixture (see below) 
Magnesium oxide -  heavy 
Dried yeast
2-M ethy l - 1 -4-Naphthoquinone
The s a l t  mixture was o f  the fo l low ing  composition (De
Ingred i ents 
Sodium ch lo r ide
Calcium phosphate te t ra h y d ra te  
Potassium c i t r a t e  monohydrate 
Magnesium sulphate decahydrate  
Ferrous c i t r a t e  
'Trace m ix tu re 1 TM2
'Trace M ix tu re 1 TM2 ( fo r  s a l t  m ix ture )
Ingred ients
Potassium iodide
Sodium f lu o r i d e
Manganese sulphate anhydrous
Cuprous iodide
Potash alum anhydrous
Zinc sulphate heptahydrate
%
38.5
22.0
25.0
1 0 . 0
1 . 0
0 .5
3.0
0.0025
100.0025
Lour ioro,  1931)
grn
2 . .0
130.0c  
125.0  
30 . 0  
5 .0  
. 0 .7
.312.7
gm
12. 0  
1 0 . 0  
2 . 0  
1 . 0  
: 1 . 0  
1 . 0
27.0
B. F o l ic  acid d e f i c i e n t  d ie t
Ingred ients %
Gela t in  8 .0
Glucose 45.8
Corn o i l  2 .0
V i ta m in - f re e  casein 20.0
Hydrogenated vegetable o i l  16.8
S a l t  mixture 6 .0
Vitamin mixture 2 .2
1 0 0 . 8
The s a l t  mixture contained:
Ingred ? ent %
Calcium carbonate 16.6
Calcium phosphate 47.3
Copper sulphate 0.017
F e r r ic  c i t r a t e  0.333
Magnesium sulphate 5.0
Manganese sulphate 0.417
Potassium ch lo r ide  11.6
Potassium iodide 0.017
Sodium ch lor ide  6 .6
Dibasic sodium phosphate 11.6
Zinc carbonate 0.217
99.701
The vitamin mixture  t r i t u r a t e d in dextrose contained:
Ingred ients g/kg
Vitamin A concentrate (200,000 U/g) 4 .5
Vitamin D concentrate (400,000 U/g) 0.25
a-tocopherol  5.00
Ascorbic acid 45.00
Inos i to l  5.00
Choline c h lo r ide  75.00
Menadione 2 .25
p-Aminobenzoic acid 5.0
N ic o t in ic  acid 4 .5
Ri b o f1avi n 1.0
Pyr idoxal-hydrochlor ide  1.0
Thiamine hydrochloride 1.0
Calcium pantothenate 3 .0
Biotin  0.02
Vitamin B ^  0.00135
The vitamin content of  the 'v i t a m in - f r e e '  casein was by the 
manufacturer 's analysis  as fo l lows:
Vi tamins yg/g
Niacin 0 .68
Bio t in  0.005
F o l ic  acid 0.048
Ri b o f1avin 1.68
Calcium pantothenate 0 .46
Pyridoxine 0 .36
Thiamine 0.10
Vitamin B,„ Not de te ctab l f
12
Other d ie ts
Rats included in other  experiments were fed on the S p i l l  
tandard laboratory  d i e t  no. l  (small animal d i e t ,  autoc laved) .
Appendix Two
THE DUAL VALUES OF CONTROLS AND PATIENTS 
SUFFERING FROM RHEUMATOID ARTHRITIS
43
Table showing the ur inary  excre t ion  of  kynurenine,  3” hydroxy-  
a n t h r a n i l i c  a c id ,  xanthurenic acid and N-^-methylnicotin-  
amide in pa t ien ts  t rea ted  with  an t i - rheum at ic  drugs.
Name Kynurenine 
(mg/24 hrs)
3 -Hydroxyanthrani1i c 
acid  
(mg/24 hrs)
Xanthurenic  
acid 
(mg/24 hrs)
N1 Methyl nicotinamide  
(mg/24 hrs)
FJ - 0.3 224.4 9.1
LB 1.8 0.8 115.3 8 .5
LS 1.6 0.1 67.3 1.8
DOV 1.4 0.8 153.8 4 .3
RM 6.7 0.1 85.6 3 .7
EM 1.8 0.2 77.3 7 .7
LA 3.2 0.6 57.5 2.0
JC 7.1 0.7 35.3 7 .5
GD 3.3 0.9 135.1 4 .8
JB 1.1 0.4 29.9 2 .5
EB 1.6 1.2 36.4 6 .6
AM 1.3 1.2 19.5 3 .7
IS 3.6 0 .2 115.2 5.1
SW 12.1 0.3 272.7 14.5
ES 4 .4 0.1 60.6 5 .4
Table showing the u r inary  excret ion of  kynurenine, 3"hydroxy-  
a n t h r a n i l i c  a c id ,  xanthurenic acid and N-^methyln icotin  
amide in control  p a t ie n ts .
Name Kynureni ne 
(mg/24 hrs)
3"Hydroxyanthran i 1i c 
acid  
(mg/24 hrs)
Xanthuren i c 
acid 
(mg/24 hrs)
N1 Methylnicotinamide  
(mg/24 hrs)
MQ 0.4 0.1 15.5 5.5
CL 1.9 0.1 21.0 7 .9
AW 1.1 0.1 16.9 4 .0
EM 1.7 0.1 21.7 3.6
KT 2 .2 0.2 17.1 7 .7
RM 1.8 0.1 41.0 5 .8
. VM 2.8 0.1 7 .4 6 .7
Table showing the haematocri t ,  serum t o t a l  tryptophan and
whole blood n ic o t in ic  acid leve ls  in pat ien ts  t rea ted  
with  an t i - rheum at ic  drugs.
Name Haematocri t  {%)
T ryptophan 
(ymol/ml)
N ic o t in ic  acid  
(yg/ml e rythrocy te )
FJ 47.0 4 .4 36.2
LB 43.0 7.6 41.9
LS 39.0 3 .2 33.3
DOV 43.0 3.2 29.5
RM 38.0 3 .5 23.8
EM 36.0 5.0 48.7
LA 37.0 3.2 35.2
JC 51.0 3.6 31.1
GD 48.0 6 .8 29.9
JB 41.0 4 .2 38.5
EB 39.0 4 .5 28.0
AM 42.0 4 .8 30.8
IS 42.0 3 .8 26.2
SW 40.0 3.1 33.3
ES 39.0 5.2 ................45.0  ............
-  i v
Table showing the haematocri t ,  serum to ta l  tryptophan and
whole blood n i c o t i n ic  acid leve ls  in control  p a t ie n ts .
Name Haematocri t  {%)
Tryptophan 
( l imol/1)
N ic o t in ic  acid  
(yg/ml erythrocytes)
MQ 49.0 7.8 24.5
CL 46.0 5.2 35.9
AW 43.0 7.1 36.0
EM 41.0 6.7 30.5
KT 35.0 6 .0 38.6
RM 37.0 6 .3 ' 31.1
VM 45.0 6 .7 31.1
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T a b le  showing th e  sex ,  age ,  d i a g n o s i s  and t r e a t m e n t  o f
p a t i e n t s  r e c e i v i n g  a n t i - r h e u m a t i c  d r u g s .
. Name . Sex Age ............. Diagnos i s ............. .........Treatment
FJ F 71 Rheumatoid A r t h r i t i s Predn i sone
LB F 60 i i  i i Indocid
LS F 50 n  i i Aspi r in  
Indocid
DOV M 63 i i  i i Paracetamol
RM F k l i i  t i Predn i sone
EM F 65 h  i i Aspi r in
LA F 67 i i  i i S i nt i zone 
Palapr in  Forte
JC F 59 ACTH
GD M 58 Codeine
Synacthen Depot
JB F 5b i i  n Predni sone
EB M 39 i i  i i I ndocid 
Predni sone
AM F 5b i i  i i Dis ta lg e s ic
IS F 63 Aspi r in  
Indocid
SW F 56 i i  n Aspi r in  
Butazo l id ine
ES F 5b i i  i i Indocid,  Panadol 
. . .  Gold . . . .
T a b le  show ing th e  s e x ,  age ,  d i a g n o s i s  and d ru g  t r e a t m e n t
o f  c o n t r o l  p a t i e n t s .
Name . Sex : Age.. ........... Di a g n o s is .  .. Drugs
MQ M 55 Hypertens ion Benzof1uazide
CL M 45 U re te r ic  calculus No drugs
AW F 43 T ryptazol
EH 68 Cerebral  Embolus Septrin  
Amp i c i 11i n
KT 66 Amp i c i 11i n
RM F 64 Hypertens ion Septr in
VM F 41 Peptic u lcer Phenergan
Appendix Three
DATA OF CONTROLS AND PATIENTS TREATED WITH ANTICONVULSANT, 
PHENOTHIAZINE AND TRICYCLIC DRUGS
Table showing the sex, age, durat ion and reasons o f  h o s p i ta l i s a t io n  
of pa t ien ts  without any drug treatment
Sex Age
(yrs)
Diagnosi s
Duration of  
hosp i t a l -  
i sat  ion 
(yrs)
Drug
treatment
Duration of  
treatment  
(yrs)
J.M. F k k Desti tu te 0,5 None -
E.R. F 66 Dest i tu te 0.5 None -
E.B. F 65 Desti tu te 5.0 None -
D.S. F 8A Desti tu te 32.0 None -
E.H. F 89 Dest i tu te 10.0 None -
D.W. F 81 Dest i tu te 8.0 None -
J.D. F 60 Dest i tu te 2 k .  0 None -
A.T. M 83 Desti tu te 60.0 None -
L.S. M 65 Dest i tu te 1A.0 None -
C.W. M 72 Dest i tu te 38.0 None -
T.H. M 59 Desti tu te AO.O None -
C.S. M 6k Desti tu te 5.0 None -
G.S. M 73 Desti tu te 38.0 None -
R.W. M I k Desti tu te A6.0 None -
J.W. M 69 Desti tu te 6 .0 None -
T a b le  showing t h e  s e x ,  age,  d i a g n o s i s ,  d u r a t i o n  o f  h o s p i t a l i s a t i o n  and
t r e a t m e n t  and t y p e  o f  t r e a t m e n t  o f  p a t i e n t s  on a n t i c o n v u l s a n t
drugs
Sex Age(yrs) Diagnos i s
Duration of  
hospi t a l -  
i sat ion  
(yrs)
Drug treatment Duration of  treatment  
(yrs)
J .T . F 52 Epi1epsy 2.0 Epanutin 100 mg tds 
Phenobarbitone 50 mg 
Valiurn 5 mg tds
tds
2.0
C.H. M 68 Epilepsy **3.0 Phenobarbitone 60 mg bd 8.0
F.L. M bb Epi1epsy 37.0 Epanutin 100 mg bd 
Mysoline 300 mg bd
**.0
R.D. M 41 Epilepsy 14.0 Epanutin 200 mg bd 
Mysoli ne 250 mg bd
14.0
A.B. M 63 Epilepsy 30.0 Phenobarbitone 30 mg tds 30.0
J.B. M 60 Epi1epsy 13.0 Phenobarbitone 30 mg 
Valium 10 mg prn 
Chiorpromazine 75 mg
bd
bd
10.0
D.P. M 25 Epilepsy **.0 Phenytoin 100 mg tds 
Valium 5 mg 
Phenobarbitone 30 mg tds
4 .0
C.M. M 37 Epilepsy **.0 Epanutin 100 mg tds 
Valium 10 mg nocte 
Phenobarbitone 30 mg tds
3.0
A.A. F b2 Epilepsy 5 .0 Epanutin 100 mg tds 
Phenobarbitone 30 mg tds
5 .0
E.T. M 58 Epilepsy 19.0 Phenobarbitone 60 mg 
Epanutin 100 mg tds 
Valium 15 mg nocte
tds 20.0
W.F. F 63 Epilepsy 18.0 Phenobarbitone 60 mg tds 18.0
E.M. M 50 Epi lepsy -*
Cerebral
Atrophy
7.0 Epanutin 100 mg 7.0
A. L. M 70 Epilepsy ****.0 Epanutin 100 mg tds 33.0
W.M. M 55 Ep i 1epsy 28.0 Phenobarbitone 30 mg tds 20.0
L. A. M 70 Epi1epsy 34.0 Phenobarbitone 30 mg 
Epanutin 100 mg tds 
Valium 5 mg tds
tds 25.0
J.D. M 68 Epilepsy 28.0 Phenobarbitone 60 mg 
Epanutin 100 mg tds 
V al i  um 10 mg tds
tds 20.0
T a b le  showing th e  age ,  sex ,  d i a g n o s i s ,  d u r a t i o n  o f  h o s p i t a l i s a t i o n
and t r e a t m e n t  and t y p e  o f  t r e a t m e n t  o f  p a t i e n t s  on pheno -
t h i a z i n e  d rugs
Sex Age(Yrs) Diagnos is
Duration of  
hospi t a l -  
i sat ion 
(yrs)
Drug treatment
Duration of  
treatment  
(yrs)
C.H. F 83 Schi zophrenia 10.0 M e l l e r i 1 50 mg tds 10.0
B.D. F 8A Schizophrenia 20.0 M e l l e r i 1 50 mg tds 20.0
M.C. F 89 Schizophrenia 32.0 M e l l e r i 1 50 mg tds 17-0
G.C. 8A Schi zophrenia 32.0 M e l l e r i 1 50 mg tds 15.0
E.B. F 67 Schizophrenia 32.0 M e l l e r i 1 50 mg tds 15.0
G.C. M 58 Schizophrenia 31.0 M e l l e r i 1 100 mg tds 10.0
J.B. M 61 Schizophrenia 15.0 Chlorpromazi ne 
100 mg tds
15.0
L.C. M k8 Schizophrenia 28.0 Chlorpromazi ne 
25 mg tds
18.0
B.C. M 28 Schi zophrenia 17.0 Chlorpromazi ne 
25 mg tds
17.0
F.B. M 59 Sch i zophreni a 15.0 Chlorpromazi ne 
75 mg tds
15.0
M.B. M 37 Sch i zophren i a 1 A. 0 Chlorpromazi ne 
100 mg tds
1 A. 0
A.A. M 78 Schizophrenia 37.0 Chlorpromaz i ne 
50 mg tds
17.0
M.C. M 58 Schizophrenia 27.0 Chiorpromazi ne 
200 mg tds
27.0
C.H. M 57 Schi zophren i a 32.0 Chlorpromazi ne 
75 mg tds
1.0
A. C. M 82 Schizophrenia 59.0 Chlorpromazi ne 
50 mg
A. 0
•
T a b le  showing t h e  s ex ,  age,  d i a g n o s i s ,  d u r a t i o n  o f  h o s p i t a l i s a t i o n
and t r e a t m e n t  and t y p e  o f  t r e a t m e n t  i n  p a t i e n t s  on t r i c y c l i c
drugs
Sex Age(yrs) Diagnos i s
Duration of  
hosp i t a l -  
i sat  ion 
(yrs)
Drug treatment
Duration of  
' t reatment  
(yrs)
R.P. M 79 Depression 8.0 Imipramine 10 mg tds 
Valium 2 mg tds
8.0
F.H. M 59 Depression , 14.0 imipramine 50 mg tds 1.0
A.K. M ; 59 Depress ion 0.5 Pentofran i l  50 mg tds 
Valium 10 mg tds
0 .5
R.S. F ; 63 Depress ion 10.0 A m i t r y p t i 1ine 50 mg tds 
Mogadon 10 mg nocte
0.5
J.H. F 2k Depress ion 0.3 Anaframi 1 50 mg tds 
Tryp t izo l  100 mg nocte 
Va 1 i um 5 nig tds
0.3
D.M. M 62 Depress ion 25.0 Tryptafen 25 mg tds 
Valium 10 mg nocte
6.0
A. A. M 59 Depression 0.2 Trypti  zol 25 mg tds 
Lentizol  50 mg nocte
0 .2
-  V  “
T a b l e  showing serum and RBC f o l a t e ,  u r i n a r y  g l u c a r i c  a c i d  FIGLU
and u r o c a n i c  a c i d ,  serum B] 2 , and d i e t a r y  i n t a k e  o f  f o l a t e
in  p a t i e n t s  w i t h o u t  d rug  t h e r a p y .
Serum 
f o l a t e  
(ng/ml)
RBC Folate  
(ng/ml 
e ry th ro ­
cytes) .
Glucaric  
acid 
(ymoles/  
. . 24 . hrs)
FIGLU 
(mg/ 
9 hrs)
Urocanic
acid
(mg/
9 hrs)
B12
(pg/ml)
Fo la te  
i ntake  
(yg/day)
J.M. 4.4 114 18.2 5.3 1.2 480 61
E.R. 3 .8 109 13.4 12.9 13.2 400 38
E.B. 5.3 116 6.2 8.2 1.4 428 61
D.S. 3.8 141 26.8 8 .5 2.3 408 46
E.H. 4.  6 132 5 .9 2.1 0.1 248 20
D.W. 10. 4 138 10.2 0.4 0.2 180 41
J.D. 5.6 139 5 .3 9 .0 1.6 388 43
A .T . . 7.1 122 8 .9 15.6 None 240 53
L.S. 4 .0 123 8.2 5.2 None 288 42
C.W. 5.4 93 2.2 13.5 3.9 388 72
T.H. 4.0 99 3.6 0.8 5.2 500 75
C.S. 5 .8 178 4 .8 3.2 None 296 66
G.S. 5.8 148 2 .6 0.4 0.3 468 57
R.W. 5.8 134 10.4 1.7 1.4 508 76
J.W. .. 3 .4  . . . . 191 ......... . . . 12.4 . . . . 1 9 . 6 . . 3 .4 400 71
. . . . .  Ji
T a b le  show ing serum and RBC f o l a t e ,  u r i n a r y  g l u c a r i c  a c i d ,  FIGLU
and u r o c a n i c  a c i d ,  serum B ^ ,  and d i e t a r y  i n t a k e  o f  f o l a t e
in  p a t i e n t s  t r e a t e d  w i t h  a n t i c o n v u l s a n t  d r u g s .
Serum
f o l a t e
(ng/ml)
RBC Folate  
(ng/ml 
e ry th ro ­
cytes .. . .
G1ucaric 
acid 
(ymoles/  
. .24  hrs)
FIGLU 
(mg/ 
9 hrs)
Urocan i c 
acid 
(mg/
9 hrs)
B12
(pg/rnl)
Folate
intake
(yg/day)
J .T . 2 .8 93 134.4 10.4 9 .3 388 49
C.H. 4 .4 99 16.6 26.5 19.8 468 48
F. 1. 3.2 80 - - - 400 35
R.D. 3 .3 74 45.5 21.2 16.8 328 32
A.B. 3.4 71 30.4 35.4 14.0 348 81
J.B. 3.4 133 60.1 30.6 18.9 188 96
D.P. 2 .6 70 141.3 16.5 18.7 120 54
C.M. 3.8 104 41.2 11.8 7.0 460 28
A.A. 2 .8 111 224.4 30.0 19.3 460 39
E.T. 4.1 99 122.0 4 .6 1.9 500 38
W.F. 2 .4 146 51.2 14.0 8.5 272 32
G.M. 2 .7 64 103.9 13.6 4 .6 468 40
A.L. 3.0 72 89.6 14.8 2 .7 268 47
W.M. 2.8 117 37.1 47.3 11.2 420 63
L.A. 3.2 133 208.0 26.8 11.5 388 64
J.D. 3.0 81 - - - 248 35
T a b le  showing  serum and RBC f o l a t e ,  u r i n a r y  g l u c a r i c  a c i d ,  FIGLU
and u r o c a n i c  a c i d ,  serum B ^ ,  and d i e t a r y  i n t a k e  o f  f o l a t e
in  p a t i e n t s  t r e a t e d  w i t h  p h e n o t h i a z i n e  d r u g s .
Serum
f o l a t e
(ng/ml)
RBC Folate  
(ng/ml 
ery th ro ­
cytes)
G1ucar i c 
acid 
(ymoles/  
.24 h r s ) .
FIGLU
(mg/
9 hrs)
Urocan i c 
acid  
(mg/
B12
(pg/ml)
Folate
intake
(yg/day)
C.H. 4 .8 134 15.5 16.3 7.3 420 34
B.D. 4.1 76 11.4 14.4 7 .6 468 29
M.C. 3.3 62 12.1 19.4 5.7 - 25
G.C. 5.1 151 21.6 15.1 6 .8 268 35-
E.B. 3.8 140 17.4 20.7 9.6 420 23
G.C. 3,3 94 28.1 10.0 4.1 248 45
J.B. 7.1 77 58.1 23.7 10.2 180 47
L.C. 5.6 119 20.4 8 .7 5.4 460 46
B.C. 4 .7 115 10.8 8.3 1.6 460 37
F.B. 2 .4 80 22.8 23.3 12.7 260 49
R.B. 6 .4 127 60.3 19.6 20.7 460 48
A.A. 2 .6 76 17.6 29.2 9 .2 360 41
M.C. 5 .5 133 21.8 15.7 24.3 224 65
C.H. 3.7 89 80.0 12.2 4.3 420 87
A.C. 4.3 115 21.6 10.7 2.0 408 90
Table showing serum and RBC f o l a t e ,  u r inary  g lu c a r ic  a c id ,  FIGLU 
and urocanic ac id ,  serum and d ie ta r y  intake o f  f o l a t e
in indiv idual  pa t ien ts  t rea ted  wi th  t r i c y c l i c  drugs.
Serum 
f o l a t e  
(ng/ml)
RBC Folate  
(ng/ml 
e ry th ro -  
. . cytes) . . .
Glucar ic  
acid 
(ymoles/
. . .24 hrs).
FIGLU
(mg/
9 hrs)
Urocan i c 
acid 
(mg/
. 9 hrs)
B12
(pg/ml)
Folate  
i ntake  
(yg/day)
R.P. 4.1 98 45.4 22.6 10.7 328 46
F.H. 3.6 124 33*6 7*5 1.3 368 34
A.K. 6 .4 152 68.4 4.1 8.1 420 38
R.S. 5 .2 98 14.4 6 .2 2.1 468 27
J.H. 3.1 151 24.2 17.3 4 .4 428 23
D.M. 6 .4 125 16.8 11.9 4 .6 280 35
A.A. 4 .0 117 24.6 3.6 0.4 480 50
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Appendix Four
THE PROTOCOL USED IN THE EVALUATION OF SKELETAL OSSIFICATION 
AND ORGANOGENESIS OF RAT FOETUS
j
Experiment
Control or test no. Dose
Rat No.
No. foetuses
No. resorption sites
No. Corpora lutea
Foetus No. Weight Sex External examination Fixative
Experiment 
Control or test 
Eat Eoo
Foetus No.
Head
Palate
Nasal ! 
Cavaties
Olfactory) 
lobes
Eyes
Brain
Thorax
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